Document:

EX-4.9

 Exhibit 4.9 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH
(I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 DATED 1 June 2022 

GSK PLC 
 and 

PFIZER INC. 
 and 

HALEON PLC 
 and 

GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (NO.2) LIMITED 

and 
 GLAXOSMITHKLINE CONSUMER
HEALTHCARE HOLDINGS LIMITED 
 and 

ANACOR PHARMACEUTICALS, INC. 

and 
 PF CONSUMER HEALTHCARE
HOLDINGS LLC 
  
  

SEPARATION CO-OPERATION AND 

IMPLEMENTATION AGREEMENT 
  

 
 Slaughter and
May 
 One Bunhill Row 
 London
EC1Y 8YY 
 (SRN/TGXF) 

Exhibits and schedules have been omitted pursuant to the Instructions as to Exhibits in Form 20-F and
will be furnished on a supplemental basis to the Securities and Exchange Commission upon request. 

 CONTENTS 
  

							
	 	  	Page	 
			
	1.	  	Interpretation	  	 	6	 
			
	2.	  	Co-operation and Implementation	  	 	33	 
			
	3.	  	Separation Process and Termination	  	 	39	 
			
	4.	  	Dividends	  	 	40	 
			
	5.	  	Circular, Prospectus and Compliance and Reporting Obligations	  	 	45	 
			
	6.	  	Amendments to Cosmos SAPA and NEBA	  	 	46	 
			
	7.	  	Termination at Admission of Cosmos SHA and Cosmos SCA; Continuing Cosmos SHA Provisions; and Other Post-Completion Matters	  	 	47	 
			
	8.	  	Tax Covenant	  	 	47	 
			
	9.	  	Settlement of Outstanding Cross-Group Amounts	  	 	47	 
			
	10.	  	Post-Separation Committee	  	 	48	 
			
	11.	  	Exclusion of Liability	  	 	48	 
			
	12.	  	[Reserved]	  	 	49	 
			
	13.	  	Employees	  	 	49	 
			
	14.	  	[Reserved]	  	 	49	 
			
	15.	  	Restrictive Covenants	  	 	49	 
			
	16.	  	Confidentiality	  	 	50	 
			
	17.	  	Announcements	  	 	51	 
			
	18.	  	Warranties	  	 	52	 
			
	19.	  	Costs and Expenses	  	 	52	 
			
	20.	  	Payments	  	 	53	 
			
	21.	  	Recharge to Haleon	  	 	53	 
			
	22.	  	Notices	  	 	53	 
			
	23.	  	Entire Agreement	  	 	55	 

					
			
	24.	  	Contracts (Rights of Third Parties) Act 1999	  	56
			
	25.	  	Assignment	  	57
			
	26.	  	Remedies and Waivers	  	57
			
	27.	  	Variation	  	58
			
	28.	  	Further Assurance	  	58
			
	29.	  	No Partnership or Agency	  	58
			
	30.	  	Invalidity	  	58
			
	31.	  	Continuing Effect	  	59
			
	32.	  	Counterparts	  	59
			
	33.	  	Language	  	59
			
	34.	  	Governing Law and Jurisdiction	  	59
			
	35.	  	Agent for Service	  	60

 SCHEDULES AND ATTACHMENTS 
  

					
	 Schedule 1 Provisions on Claims under the Dividend Indemnities
	  	 	67	
		
	 Schedule 2 Continuing Cosmos SHA Provisions and Post-Completion Matters
	  	 	71	
		
	 Part A (Continuing Cosmos SHA Provisions)
	  	 	71	
		
	 Part B (Other post-Completion Matters)
	  	 	84	
		
	 Schedule 3 Allocation of Costs and Expenses
	  	 	88	

 AGREED FORM DOCUMENTS 

Pfizer Relationship Agreement 

Orderly Marketing Agreement 

Registration Rights Agreement 

Sponsors’ Agreements 

Lock-up Deed 
 Demerger Agreement

 GSK Exchange Agreement 

Pfizer Exchange Agreement 
 SLP
Exchange Agreement 
 Cosmos SAPA Amendment Agreement 

Tax Covenant 
 ATFA 

Transitional Services Agreement 

GSK Manufacturing and Supply Agreement 

Consumer Manufacturing and Supply Agreement 

GSK Quality Agreement 
 Consumer
Quality Agreement 
 Shared Brands Licences Agreement 

Shared Brands Committee Agreement 

Corporate Brand Licence Agreement 

Co-Existence Agreement 
 Long Term
Access Agreement 
 Pharmacovigilance Agreement 

NEBA Amendment Agreement 

Argentina NEBA 
 Brazil ATFA 

Deed of Termination 
 Regulatory
Information Access and Service Agreement 

 This Agreement is made as a deed on 1 June 2022. 

BETWEEN: 
  

	1.	 GSK PLC, a public limited company incorporated in England with number 03888792, having its registered
office at 980 Great West Road, Brentford, Middlesex, TW8 9GS (“GSK”); 

  

	2.	 PFIZER INC., a corporation incorporated under the laws of Delaware whose registered office is at 235
East 42nd Street, New York, New York 10017 (“Pfizer”); 

  

	3.	 HALEON PLC, a public limited company incorporated in England with number 13691224, having its
registered office at 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS (“Haleon”); 

  

	4.	 GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (NO.2) LIMITED, a private limited company incorporated
under the laws of England under registered number 11961650 whose registered office is at 980 Great West Road, Brentford, Middlesex TW8 9GS (“JVCo”); 

 

	5.	 GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS LIMITED, a private limited company incorporated under
the laws of England under registered number 08998608 whose registered office is at 980 Great West Road, Brentford, Middlesex TW8 9GS (“GSKCHHL”); 

 

	    	 ANACOR PHARMACEUTICALS, INC., a corporation incorporated under the laws of Delaware whose registered
office is at 235 East 42nd Street, New York, New York 10017 (“Anacor”); and 

  

	6.	 PF CONSUMER HEALTHCARE HOLDINGS LLC, a limited liability company incorporated under the laws of
Delaware whose registered office is at 235 East 42nd Street, New York, New York 10017 (“PFCHHL”). 

 WHEREAS: 

 

	(A)	 GSK intends to demerge approximately 80.1% of its interest in the Consumer Healthcare Business, by way of an
indirect dividend demerger, for the purpose of benefiting both the Consumer Healthcare Business and the GSK Business. GSK also intends that, subsequent to such demerger, Haleon, as the holder of the Consumer Healthcare Business, shall be listed on
the London Stock Exchange as a separate and independently managed group. 

  

	(B)	 Haleon is a company that is not part of the GSK Group or the Pfizer Group. GSKCHHL is (and will be,
immediately prior to the Demerger) a subsidiary of GSK with 100% of its A Shares and B Shares held by GSK and 100% of its C Shares held by the SLPs (which A Shares, B Shares and C Shares comprise all ownership interests of whatever nature in
GSKCHHL). GSKCHHL is (and will be immediately following the Demerger and the Share Exchanges) the registered holder of 100% of the issued ordinary A shares and 100% of the issued preference shares in JVCo, which is the current parent company of the
Consumer Healthcare Group. 

  

	(C)	 GSK and Haleon have conditionally agreed on the terms of the Demerger Agreement pursuant to which GSK will
transfer to Haleon the Relevant GSKCHHL Shares (being all of the A Shares, representing in excess of 80% of the entire issued ordinary share capital of GSKCHHL which comprises A Shares, B Shares and C Shares) in consideration for

  
 4 

	 	 
which Haleon will allot and issue, credited as fully paid up, the Haleon Demerger Shares to the Qualifying GSK Shareholders, in satisfaction of the Demerger Dividend to be declared on the GSK
Shares pursuant to the Demerger Resolution. 

  

	(D)	 Separately, pursuant to: (i) the GSK Exchange Agreement, GSK has agreed to transfer GSK’s entire
shareholding of B Shares to Haleon in exchange for Haleon issuing the GSK Haleon Exchange Shares to GSK; (ii) the Pfizer Exchange Agreement, Anacor and Pfizer have agreed that the Pfizer Group PFCHHL Transferor shall transfer the PFCHHL Interests
(being all of the common interests in PFCHHL (which comprise all ownership interests of whatever nature in PFCHHL) and which shall be held by Anacor until the commencement of the PFCHHL Transfer and by Pfizer following completion of the PFCHHL
Transfer until completion of the Pfizer Share Exchange) to Haleon in exchange for Haleon issuing the Pfizer Haleon Exchange Shares (comprising new Haleon Ordinary Shares and the Haleon NVPS) to the Pfizer Group PFCHHL Transferor and the Depositary
and, following which, the Pfizer Group PFCHHL Transferor will sell the Haleon NVPS immediately upon receipt of such Haleon NVPS pursuant to a binding commitment made prior to its transfer of the PFCHHL Interests to Haleon; and (iii) the SLP Exchange
Agreement, each SLP has agreed to transfer its entire shareholding of C Shares to Haleon in exchange for Haleon issuing the applicable portion of the SLP Haleon Exchange Shares to each such SLP. 

 

	(E)	 As a result of the Demerger Completion and the completion of the Share Exchanges: (i) (A) the Pfizer Group
PFCHHL Transferor and the Depositary (with respect to the Haleon Ordinary Shares held on behalf of the Pfizer Group PFCHHL Transferor) will hold, in aggregate, 32% of the issued Haleon Ordinary Shares (rounded to the nearest whole ordinary share)
and 100% of the issued preference shares in Haleon, it being understood that any Haleon Ordinary Shares issued to the Depositary pursuant to the Pfizer Exchange Agreement will be held by the Depositary on behalf of the Pfizer Group PFCHHL Transferor
in connection with and under the establishment of the Haleon ADR Programme, (B) the Qualifying GSK Shareholders will hold at least approximately 54.47% of the issued ordinary shares of Haleon, (C) GSK will hold up to approximately 6.03% of the
issued ordinary shares of Haleon (and with the issued ordinary shares comprised in (B) and (C) together representing 60.5% of the issued ordinary shares of Haleon (rounded to the nearest whole ordinary share)), and (D) the SLPs will collectively
hold 7.5% of the issued ordinary shares of Haleon (rounded to the nearest whole ordinary share); (ii) Haleon will hold 100% of the issued ordinary shares and common interests, respectively, in each of GSKCHHL and PFCHHL; and (iii) (1) GSKCHHL will
hold 100% of the issued ordinary A shares and 100% of the issued preference shares in JVCo and (2) PFCHHL will hold 100% of the issued ordinary B shares in JVCo. 

 

	(F)	 It is also intended that, prior to commencement of the Demerger Completion Steps, the relevant Parties will
have taken all necessary actions so that each of the following actions shall have occurred: (i) JVCo will declare and pay the Final Quarterly Dividend, the Final Sweep Dividend and, separately, the
Pre-Separation Dividend to GSKCHHL and PFCHHL in accordance with the Cosmos SHA and the Treasury Side Letter; (ii) GSKCHHL will declare and pay the Pre-Separation
GSKCHHL Onward Dividend to GSK in respect of the A Shares and the B Shares; (iii) GSKCHHL will declare and pay the Final Sweep GSKCHHL Onward Dividend to GSK in respect of the A Shares and the B Shares and to the SLPs in respect of the C
Shares; (iv) GSKCHHL will declare and pay the Final Quarterly GSKCHHL Onward Dividend to GSK in respect of the A Shares and the B Shares and (if and only to the extent the SLPs are entitled to receive such dividend under the GSKCHHL Articles of
Association) to the SLPs in respect of the C Shares; and (v) PFCHHL will declare and pay or otherwise effect the Pre-Separation PFCHHL Onward Dividend, the Final Quarterly PFCHHL Onward Dividend and the
Final Sweep PFCHHL Onward Dividend to Anacor or, if completion of the PFCHHL Transfer has occurred prior to such time, Pfizer.  

 

	(G)	 It is further noted that Haleon redeemed the Redeemable Shares on 11 April 2022. 

  
 5 

	(H)	 In connection with the proposed listing of Haleon, and prior to the Demerger, it is also intended that:
(i) the Prospectus and Circular shall be published and posted; (ii) the GSK General Meeting shall take place to, among other things, approve the Demerger and the relevant parts of the Separation Transaction as a Class 1 transaction
for the purposes of Chapter 10 of the Listing Rules and approve certain transactions related to the Demerger and the Separation Transaction as related party transactions for the purposes of Chapter 11 of the Listing Rules; (iii) the Haleon ADR
Programme shall be established to come into effect on or around the time of Admission; and (iv) following payment by JVCo of the dividends referred to in recital (F)(i) above, the ATB Re-organisation
shall be completed. 

  

	(I)	 Following the Demerger Completion and the completion of the Share Exchanges, it is intended that Admission
shall occur, subsequent to which GSK shall implement the GSK Share Consolidation. 

  

	(J)	 The Parties have, to date, been co-operating in relation to the
proposed listing of Haleon, the Demerger and the Share Exchanges within the framework of the Cosmos SHA and the Cosmos SCA. With publication of the Circular and the Prospectus expected shortly, the Parties now wish to enter into this Agreement as
they have agreed to take certain additional steps and implement certain additional arrangements to effect completion of, or which otherwise relate to, the Separation Transaction. Accordingly, this Agreement, which is a deed, records their respective
obligations relating to such matters and certain terms on which relations between the Parties shall be governed following Completion. 

  

	(K)	 For U.S. federal income tax purposes, GSK and Haleon intend that the Demerger, together with certain related
transactions, qualify as a reorganization under Sections 368(a)(1)(D) and 355 of the Internal Revenue Code of 1986, as amended (the “Code”), and this Agreement, together with the Demerger Agreement, constitute a “plan of
reorganization” for the purposes of Section 368 of the Code. 

 THIS DEED PROVIDES as follows: 

 

	1.	 INTERPRETATION 

 

	1.1	 In this Agreement and the Schedules: 

 

					
	       
	 	 “Admission”
	  	 means, unless otherwise expressly set forth herein, admission of the Haleon Admission Shares to the premium listing segment
of the Official List of the FCA and to trading on the London Stock Exchange’s main market for listed securities;

			
		 	 “Affected Party”
	  	 has the meaning given to that term in paragraph 1.2 of Part B (Other post-Completion Matters) of Schedule
2 (Continuing Cosmos SHA Provisions and Post-Completion Matters);

  
 6 

					
	       
	 	 “Affiliate”
	  	 means, in relation to any person (the “relevant person”) at any time during the period for which the
determination of affiliation is being made:
  

(i) any person Controlled (directly or indirectly) by the relevant person;

 

(ii)  any person Controlling (directly or indirectly) the relevant person; and

 

(iii)  any person under common Control (directly or indirectly) with the relevant
person,
  
 provided that (x) Pfizer and GSK (and any
members of their respective Groups) shall not be deemed to be an “Affiliate” of any members of the Consumer Healthcare Group, and any members of the Consumer Healthcare Group shall not be deemed to be an “Affiliate” of Pfizer or
GSK (or any members of their respective Groups), as of or following Completion, (y) any Delayed Business shall not constitute an “Affiliate” of JVCo unless, and until, the relevant completion date for the transfer of such Delayed
Business under the Cosmos SAPA and (z) any Deferred Closing Business shall not constitute an “Affiliate” of JVCo unless, and until, the relevant completion date for the transfer of such Deferred Closing Business under the
NEBA;

			
		 	 “Agreed Form”
	  	 means, in relation to any document, that document in a form agreed by the parties thereto and initialled for identification
purposes by or on behalf of each of the parties thereto, and, to the extent their agreement is required pursuant to the terms of the Cosmos SAPA, Cosmos SHA or any other agreements between members of the GSK Group, members of the Haleon Group
and/or members of the Pfizer Group, agreed by each of GSK, Haleon and Pfizer (whether or not parties thereto);

			
		 	 “Agreed Rate”
	  	 has the meaning given to that term in clause 20.1;

			
		 	 “Ancillary Agreements”
	  	 means the Listing Ancillary Agreements and the Separation Ancillary Agreements;

			
		 	 “Argentina NEBA”
	  	 means the letter agreement relating to the retention, operation and transfer of the manufacturing site located in Buenos
Aires, Argentina entered into or to be entered into between GSK and JVCo on or around the date of this Agreement;

  
 7 

					
	       
	 	 “A Shares”
	  	 means the A ordinary shares of £1.00 each in the share capital of GSKCHHL all of which are fully paid and held as at
the date of this Agreement by GSK;

			
		 	 “ATB Re-organisation”
	  	 means all of (i) the distribution in specie of the ordinary shares of GSKCHH3 by JVCo to GSKCHHL only, (ii) the
distribution of £53.125m by JVCo to GSKCHHL only, and (iii) the conversion of a portion of A shares in the share capital of JVCo held by GSKCHHL (of equivalent value to the distribution mentioned at (i)) into preference shares in the
share capital of JVCo in a manner consistent with the SCA Side Letter;

			
		 	 “ATFA”
	  	 means the asset transfer framework agreement between GSK, GSKCHHL and JVCo entered into on or around the date of this
Agreement;

			
		 	 “Brazil ATFA”
	  	 means the asset transfer framework agreement relating to the transfer of the manufacturing site located in
Jacarepaguá, Brazil entered into or to be entered into between GSK, GSKCHHL and JVCo on or around the date of this Agreement;

			
		 	 “B Shares”
	  	 means the B ordinary shares of £1.00 each in the share capital of GSKCHHL all of which are fully paid and held as at
the date of this Agreement by GSK;

			
		 	 “Business Day”
	  	 means a day (other than a Saturday or Sunday) on which banks are open for general business in London, UK;

			
		 	 “Circular”
	  	 means the circular to be dated with the Posting Date and to be sent to the shareholders of GSK in connection with the
Demerger, including a notice of general meeting of GSK, substantially in the Agreed Form;

			
		 	 “Co-Existence Agreement”
	  	 means the co-existence agreement in respect of certain trade marks and domain names
of the GSK Group and Consumer Healthcare Group entered into or to be entered into between Glaxo Group Limited, SmithKline Beecham Limited and Haleon on or around the date of this Agreement;

			
		 	 “Completion”
	  	 means completion of the final step in the Separation Transaction;

  
 8 

					
	       
	 	 “Connected Persons”
	  	 means, in relation to a Party, any member of its Group and any officer, employee, agent, adviser or representative of that
Party or any member of its Group, in each case, from time to time;

			
		 	 “Consumer Healthcare Business”
	  	 means the consumer healthcare business which, as at the date of Demerger Completion is operated within the JVCo Group and
any other asset or business of the consumer healthcare business that, as at the date of Demerger Completion, is contemplated to be operated within the Haleon Group after Separation Completion pursuant to the ATFA, the Argentina NEBA and/or the
Brazil ATFA;

			
		 	 “Consumer Healthcare Group”
	  	 means:
  

(i) prior to Demerger Completion, the JVCo Group; and

 

(ii)  from Demerger Completion, the Haleon Group;

			
		 	“Consumer Healthcare Group Companies”	  	 means any member of the Consumer Healthcare Group from time to time, and “Consumer Healthcare Group
Company” shall be construed accordingly;

			
		 	 “Consumer Healthcare Product”
	  	 means, in respect of any jurisdiction, any oral care, nutritional care, skin care, medicine or other cosmetic or healthcare
product or device of any kind, in each case, for the treatment of, or use by, human beings which is available without, or both with and without, a prescription, but excluding any such product or device that is subject to the same regulatory
classification and/or regulatory treatment (including in relation to advertising) as a product or device that is available only with a prescription;

			
		 	“Consumer Manufacturing and Supply Agreement”	  	 means the manufacturing and supply agreement entered into or to be entered into between GlaxoSmithKline Consumer Trading
Services Limited as supplier and GlaxoSmithKline Trading Services Limited as purchaser on or around the date of this Agreement;

			
		 	 “Consumer Quality Agreement”
	  	 means the quality agreement to be entered into between GlaxoSmithKline Consumer Trading Services Limited and
GlaxoSmithKline Trading Services Limited in respect of the Consumer Manufacturing and Supply Agreement;

  
 9 

			
	 “Control”
	  	 means, in relation to a person, the ability of another person to ensure that the activities and business of the first
mentioned person are conducted in accordance with the wishes of that other person (whether by exercise of contractual rights, ownership of shares or otherwise), and a person shall be deemed to have Control of a body corporate if that person has the
contractual right to procure that the activities and business of that body corporate are conducted in accordance with that person’s wishes or if that person possesses the majority of the issued share capital or the voting rights in that body
corporate or the right to receive the majority of the income of that body corporate on any distribution by it of all of its income or the majority of its assets on a winding up (and “Controlled” and “Controlling”
shall be construed accordingly);

		
	 “Corporate Brand Licence Agreement”
	  	 means the brand licence agreement in respect of corporate marks entered into or to be entered into between certain
licensors, certain licensees and certain registered proprietors on or around the date of this Agreement;

		
	 “Cosmos Agreements”
	  	 has the meaning given to that term in clause 23.1;

		
	 “Cosmos Closing”
	  	 has the meaning given to the term “Closing” in the Cosmos SAPA;

		
	 “Cosmos Completion Date”
	  	 means 31 July 2019;

		
	 “Cosmos SAPA”
	  	 means the stock and asset purchase agreement entered into among Pfizer, GSK, GSKCHHL and JVCo dated 19 December 2018,
as amended from time to time including on 31 July 2019 and by the Cosmos SAPA Amendment Agreement;

		
	 “Cosmos SAPA Amendment Agreement”
	  	 means the amendment agreement to the Cosmos SAPA entered into or to be entered into in the Agreed Form among Pfizer, GSK,
GSKCHHL and JVCo on or around the date of this Agreement;

		
	 “Cosmos SCA”
	  	 means the structuring considerations agreement entered into among GSKCHHL, Pfizer, PFCHHL, GSK and JVCo dated 31 July
2019, as amended or supplemented from time to time;

  
 10 

			
	 “Cosmos SHA”
	  	 means the shareholders’ agreement in relation to JVCo entered into among GSKCHHL, Pfizer, PFCHHL, GSK and JVCo dated
31 July 2019, as amended or supplemented from time to time;

		
	 “Costs”
	  	 means charges and reasonable costs (including legal costs) and expenses (other than, subject to the below, Tax), which are
properly incurred and of an out-of-pocket nature, together with any amounts in respect of VAT comprised in such charges, costs and expenses but only to the extent not
recoverable;

		
	 “C Shares”
	  	 means the C ordinary shares of £1.00 each in the share capital of GSKCHHL, which shares rank pari passu with
the A Shares and the B Shares except that they carry no right to any Pre-Separation GSKCHHL Onward Dividend and carry no voting rights, all of which are fully paid and held as at the date of this Agreement by
the SLPs;

		
	 “CTA 2010”
	  	 means the UK Corporation Tax Act 2010;

		
	 “Deed of Termination”
	  	 means the global deed of termination relating to certain services provided by GSK or members of the GSK Group to Haleon or
members of the Consumer Healthcare Group entered into or to be entered into between GSK and Haleon on or around the date of this Agreement;

		
	 “Deferred Closing Business”
	  	 has the meaning given to that term in the NEBA;

		
	 “Delayed Business”
	  	 has the meaning given to that term in the Cosmos SAPA;

		
	 “Demerger”
	  	 means, unless otherwise expressly set forth herein, the proposed demerger of approximately 80.1% of GSK’s interest in
the Consumer Healthcare Business pursuant to the Demerger Agreement and the Demerger Dividend;

		
	 “Demerger Agreement”
	  	 means the demerger agreement entered into or to be entered into in the Agreed Form between GSK and Haleon on or around the
date of this Agreement;

		
	 “Demerger Completion”
	  	 means the time and date when the Demerger Conditions Precedent have been fulfilled and the Demerger Completion Steps have
taken place;

		
	 “Demerger Completion Steps”
	  	 has the meaning given to the term “Completion Steps” in the Demerger Agreement;

  
 11 

			
	 “Demerger Conditions Precedent”
	  	 means the conditions set out in clause 2.1 (Conditions Precedent) of the Demerger Agreement;

		
	 “Demerger Dividend”
	  	 means the interim dividend, in specie, proposed to be declared by the GSK Board to effect the Demerger pursuant to the
authority granted to the GSK Board under the Demerger Resolution;

		
	 “Demerger Record Time”
	  	 means 6.00 p.m. on 15 July 2022, or such other time and/or date as the GSK Board may determine;

		
	 “Demerger Resolution”
	  	 means resolution 1 set out in the notice of general meeting of GSK included in the Circular;

		
	 “Depositary”
	  	 means JPMorgan Chase Bank N.A., as depositary for the Haleon ADSs;

		
	 “Disposal” or “Disposes”
	  	 means, in relation to any share in the capital of Haleon, any disposition of any right or interest in such share and
includes:
  

(i) any sale, assignment or transfer of any such share;

 

(ii)  creating or permitting to subsist any pledge, charge, mortgage, lien or other
security interest or encumbrance in respect of any such share;
  

(iii)  creating any trust or conferring any interest in respect of any such share;

 
 (iv) any
agreement, arrangement or understanding in respect of votes or the right to receive dividends in respect of any such share (other than this agreement);
  

(v)   the renunciation or assignment of any right to subscribe or receive any such
share or any legal or beneficial interest in any such share;
  

(vi) any agreement to do any of the above; and

 
 (vii) the
transmission of any such share by operation of Law,
  
 or
the holder of any such share (or any other member of its Group) entering into or agreeing to any arrangement whatsoever which has a similar economic effect to any such disposition;

  
 12 

			
	 “Dividend Indemnities”
	  	 means the indemnities given by Haleon to GSK and each member of the GSK Group and to Pfizer and each member of the Pfizer
Group which are contained in clause 4.11 (Dividends) and Schedule 1 (Provisions on Claims under the Dividend Indemnities);

		
	 “EMA”
	  	 means the European Medicines Agency, or any successor agency;

		
	 “Exchange Act”
	  	 means the U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder;

		
	 “Exchange Agreements”
	  	 means the GSK Exchange Agreement, the Pfizer Exchange Agreement and the SLP Exchange Agreement;

		
	 “FCA”
	  	 means the Financial Conduct Authority acting in its capacity as the competent authority under Part VI of
FSMA;

		
	 “FDA”
	  	 means the US Food and Drug Administration, or any successor agency;

		
	 “Final Quarterly Dividend”
	  	 means the final quarterly interim dividend to be paid by JVCo to GSKCHHL and PFCHHL prior to the Demerger on or around 30
June 2022;

		
	 “Final Quarterly GSKCHHL Onward Dividend”
	  	 means the dividend to be paid by GSKCHHL to GSK (as holder of the A Shares and B Shares) and (if and only to the extent the
SLPs are entitled to receive such dividend under the GSKCHHL Articles of Association) to the SLPs (as holders of the C Shares) in accordance with the GSKCHHL Articles of Association prior to the Demerger following any Final Quarterly Dividend and
comprising amounts received pursuant thereto;

		
	 “Final Quarterly Onward Dividends”
	  	 means the Final Quarterly GSKCHHL Onward Dividend and the Final Quarterly PFCHHL Onward Dividend and comprising amounts
received pursuant thereto;

		
	 “Final Quarterly PFCHHL Onward Dividend”
	  	 means one or more dividend(s), distribution(s), transfer(s) or other similar transaction(s) from PFCHHL to Anacor (or, if
completion of the PFCHHL Transfer has occurred prior to such dividend(s), distribution(s), transfer(s) or other similar transaction(s), Pfizer) prior to the Demerger following any Final Quarterly Dividend and comprising amounts received by PFCHHL
pursuant thereto;

  
 13 

			
	 “Final Sweep Dividend”
	  	 has the meaning given to that term in the Treasury Side Letter;

		
	 “Final Sweep GSKCHHL Onward Dividend”
	  	 means the dividend to be paid by GSKCHHL to GSK (as holder of the A Shares and B Shares) and to the SLPs (as holders of the
C Shares) in accordance with the GSKCHHL Articles of Association prior to the Demerger following the Final Sweep Dividend and comprising amounts received pursuant thereto;

		
	 “Final Sweep Onward Dividends”
	  	 means the Final Sweep GSKCHHL Onward Dividend and the Final Sweep PFCHHL Onward Dividend and comprising amounts received
pursuant thereto;

		
	 “Final Sweep PFCHHL Onward Dividend”
	  	 means one or more dividend(s), distribution(s), transfer(s) or other similar transaction(s) from PFCHHL to Anacor (or, if
completion of the PFCHHL Transfer has occurred prior to such dividend(s), distribution(s), transfer(s) or other similar transaction(s), Pfizer) prior to the Demerger following the Final Sweep Dividend and comprising amounts received by PFCHHL
pursuant thereto;

		
	 “FSMA”
	  	 means the Financial Services and Markets Act 2000;

		
	 “Governance Code”
	  	 means the then current version of the UK Corporate Governance Code published by the UK Financial Reporting Council or any
successor body;

		
	 “Governmental Entity”
	  	 means any supra national, national, state, municipal or local government (including any subdivision, court, administrative
agency or commission or other authority thereof) or any quasi-governmental or private body exercising any regulatory, taxing, importing or other governmental or quasi-governmental authority, including the European Union;

		
	 “Group”
	  	 means:
  

(i) in relation to GSK, the GSK Group;

 
 (ii)  in
relation to Pfizer and/or Anacor, the Pfizer Group;
  

(iii)  in relation to Haleon, the Haleon Group; and

 
 (iv) in
relation to JVCo, the JVCo Group;

		
	 “GSK Board”
	  	 means the board of directors of GSK and any duly authorised committee of that board, from time to time;

  
 14 

			
	 “GSK Business”
	  	 means the business operated within the GSK Group, which is described in the Circular and which, for the avoidance of doubt,
does not include the Consumer Healthcare Business;

		
	 “GSKCHHL Articles of Association”
	  	 means the articles of association adopted by GSKCHHL (as amended or replaced from time to time);

		
	 “GSKCHHL Onward Dividends”
	  	 means the Final Quarterly GSKCHHL Onward Dividend, the Pre-Separation GSKCHHL
Onward Dividend and the Final Sweep GSKCHHL Onward Dividend;

		
	 “GSKCHH3”
	  	 means GSK Consumer Healthcare Holdings (No. 3) Limited, a company incorporated in England with number 13401293, having its
registered office at 980 Great West Road, Brentford, Middlesex, TW8 9GS;

		
	 “GSK Consolidation Resolution”
	  	 means the relevant parts of resolution 1 relating to the proposed consolidation of the share capital of GSK as set out in
the notice of general meeting of GSK included in the Circular;

		
	 “GSK Exchange Agreement”
	  	 means the Agreed Form exchange agreement between GSK and Haleon setting out the terms of the GSK Share
Exchange;

		
	 “GSK General Meeting”
	  	 means the general meeting of GSK to approve, among other things:

 
 (i) the
Demerger and the relevant parts of the Separation Transaction as a Class 1 transaction for the purposes of Listing Rule 10;
  

(ii)  the relevant parts of the Separation Transaction and the associated and ancillary
agreements and arrangements relating thereto or to be entered into pursuant thereto for the purposes of Chapter 11 of the Listing Rules; and
  

(iii)  the GSK Share Consolidation;

		
	 “GSK Group”
	  	 means GSK and its subsidiaries and subsidiary undertakings from time to time, excluding Haleon and the Consumer Healthcare
Group Companies;

  
 15 

			
		
	 “GSK Group Companies”
	  	 means any member of the GSK Group from time to time, and “GSK Group Company” shall be construed
accordingly;

		
	 “GSK Haleon Exchange Shares”
	  	 means the Haleon Ordinary Shares to be allotted and issued, credited as fully paid up, in accordance with the GSK Exchange
Agreement, which immediately following completion of the Demerger and the Share Exchanges, represent up to approximately 6.03% of the issued Haleon Ordinary Shares;

		
	 “GSK Manufacturing and Supply Agreement”
	  	 means the manufacturing and supply agreement entered into or to be entered into between GlaxoSmithKline Trading Services
Limited as supplier and GlaxoSmithKline Consumer Trading Services Limited as purchaser on or around the date of this Agreement;

		
	 “GSK NEB Agreement”
	  	 means the net economic benefit agreement entered into between GSK, Pfizer and JVCo and dated 31 July 2019, as amended
or supplemented from time to time;

		
	 “GSK Pre-Separation Bonds Guarantee”
	  	 means the guarantee given by GSK in respect of the Pre-Separation
Bonds;

		
	 “GSK Quality Agreement”
	  	 means the quality agreement or to be entered into between GlaxoSmithKline Trading Services Limited and GlaxoSmithKline
Consumer Trading Services Limited in respect of the GSK Manufacturing and Supply Agreement;

		
	 “GSK Retained Shares”
	  	 means any Haleon Ordinary Shares (including Haleon ADSs and other securities convertible into shares) held by or on behalf
of any member of GSK’s Group in Haleon and any ultimate holding company thereof from time to time;

		
	 “GSK Share Consolidation”
	  	 means the consolidation of the share capital of GSK pursuant to and in accordance with the GSK Consolidation
Resolution;

		
	 “GSK Share Exchange”
	  	 means the transfer of GSK’s entire shareholding of B Shares to Haleon in exchange for Haleon issuing the GSK Haleon
Exchange Shares to GSK pursuant to and in accordance with the terms of the GSK Exchange Agreement;

  
 16 

			
	 “GSK Shareholders”
	  	 means holders of GSK Shares on the register of members of GSK from time to time;

		
	 “GSK Shares”
	  	 means ordinary shares in the capital of GSK having the rights set out in GSK’s articles of association from time to
time;

		
	 “Guarantee Fee Arrangements”
	  	 means the guarantee fee arrangements effected pursuant to:

 
 (i) the
guarantee fee agreement between Haleon (as guarantor) and GlaxoSmithKline Consumer Healthcare Holdings (US) LLC (as beneficiary) dated 25 May 2022; and
  

(ii)  the guarantee fee agreement between GSK (as guarantor) and GlaxoSmithKline Consumer
Healthcare Holdings (US) LLC (as beneficiary) dated 28 April 2022;

		
	 “Haleon Admission Shares”
	  	 means the Haleon Demerger Shares and the Haleon Exchange Shares (excluding the Haleon NVPS);

		
	 “Haleon ADR Programme”
	  	 means the American depositary receipt programme to be established for Haleon on or around Admission, as detailed in the
Steps Plan;

		
	 “Haleon ADSs”
	  	 means the American depositary shares each representing 2 Haleon Ordinary Shares to be admitted to listing and trading on
the NYSE pursuant to the establishment of the Haleon ADR Programme;

		
	 “Haleon Board”
	  	 means the board of directors of Haleon and any duly authorised committee of that board, from time to time;

		
	 “Haleon Committee Terms of Reference”
	  	 means the terms of reference for the following committees of the Haleon Board: audit and risk committee, remuneration
committee, nominations and governance committee and disclosure committee;

		
	 “Haleon Demerger Shares”
	  	 means the Haleon Ordinary Shares to be allotted and issued to the Qualifying GSK Shareholders as GSK shall direct, credited
as fully paid up, in accordance with the Demerger Agreement, together with (where the context so requires) any Haleon Ordinary Shares in issue prior to commencement of the Demerger Completion Steps;

  
 17 

			
	 “Haleon Exchange Shares”
	  	 means:
  

(i) the GSK Haleon Exchange Shares;

 

(ii)  the SLP Haleon Exchange Shares; and

 

(iii)  the Pfizer Haleon Exchange Shares,

 
 which, together, immediately following completion of the
Demerger and the Share Exchanges, represent up to approximately 45.53% of the issued Haleon Ordinary Shares (to the nearest whole Haleon Ordinary Share) and 100% of the issued preference shares of Haleon;

		
	 “Haleon Group”
	  	 means Haleon and its subsidiaries and subsidiary undertakings from time to time;

		
	 “Haleon NVPS”
	  	 means 25,000,000 unlisted redeemable non-voting preference shares of £[1.00]
each in the share capital of Haleon carrying the rights set out in Haleon’s articles of association (as reproduced in schedule 2 (Haleon NVPS Terms) to the Pfizer Exchange Agreement);

		
	 “Haleon Ordinary Shares”
	  	 means ordinary shares in the capital of Haleon having the rights set out in Haleon’s articles of association from time
to time;

		
	 “HMRC”
	  	 means HM Revenue & Customs;

		
	 “Indemnified Party”
	  	 has the meaning given to that term in Schedule 1 (Provisions on Claims under the Dividend
Indemnities);

		
	 “Indemnifying Party”
	  	 has the meaning given to that term in Schedule 1 (Provisions on Claims under the Dividend
Indemnities);

		
	 “India Condition”
	  	 has the meaning given to that term in the Demerger Agreement;

		
	 “Informing Party”
	  	 has the meaning given to that term in paragraph 1.2 of Part B (Other post-Completion Matters) of Schedule
2 (Continuing Cosmos SHA Provisions and Post-Completion Matters);

		
	 “Investigation”
	  	 has the meaning given to that term in paragraph 1.1 of Part B (Other post-Completion Matters) of Schedule
2 (Continuing Cosmos SHA Provisions and Post-Completion Matters);

		
	 “Japan Condition”
	  	 has the meaning given to that term in the Demerger Agreement;

		
	 “JVCo Board”
	  	 means the board of directors of JVCo and any duly authorised committee of that board, from time to time;

  
 18 

			
	 “JVCo Directors”
	  	 means the directors of JVCo from time to time;

		
	 “JVCo Group”
	  	 means JVCo and its subsidiaries and subsidiary undertakings from time to time;

		
	 “JVCo Shareholder Loan”
	  	 means any shareholder loan granted by GSK or any member of its wholly-owned Group or Pfizer or any member of its
wholly-owned Group (in each case as lender) to JVCo (or any member of the JVCo Group) (as borrower) pursuant to the provisions of clause 12.6 of the Cosmos SHA;

		
	 “Korea Condition”
	  	 has the meaning given to that term in the Demerger Agreement;

		
	 “Law”
	  	 means any statute, law, rule, regulation, ordinance, code or rule of common law issued, administered or enforced by any
Governmental Entity, or any judicial or administrative interpretation thereof, including the rules of any stock exchange or listing authority;

		
	 “Listing Ancillary Agreements”
	  	 means:
  

(i) the Pfizer Relationship Agreement;

 

(ii)  the Orderly Marketing Agreement;

 

(iii)  the Registration Rights Agreement;

 
 (iv) the
Sponsors’ Agreements; and
  

(v)   the Lock-up Deed,

 
 and any document, agreement or arrangement pursuant thereto
or in connection therewith;

		
	 “Listing Date”
	  	 has the meaning given to that term in the Treasury Side Letter;

		
	 “Listing Rules”
	  	 means the rules and regulations made by the FCA (acting in its capacity as the competent authority for the purposes of
FSMA) under FSMA, and contained in the publication of the same name, as amended from time to time (including any successor rules);

		
	 “Listing Transaction”
	  	 has the meaning given to that term in the Cosmos SHA;

  
 19 

			
	 “Lock-up Deed”
	  	 means the lock-up deed entered into or to be entered into in the Agreed Form
between GSK, Pfizer, the SLPs, Citigroup Global Markets Limited and Morgan Stanley & Co. International plc on or around the date of this Agreement;

		
	 “London Stock Exchange”
	  	 means London Stock Exchange plc;

		
	 “Long Term Access Agreement”
	  	 means the long term access agreement entered into or to be entered into between GSK and Haleon on or around the date of
this Agreement;

		
	 “Major Market”
	  	 means the United States of America, Canada, Japan, China, the United Kingdom, the European Union and France, Germany, Italy
and Spain individually;

		
	 “NEBA”
	  	 means the net economic benefit arrangements, comprising the GSK NEB Agreement and the Pfizer NEB Agreement as may be
amended and restated from time to time, including pursuant to the NEBA Amendment Agreement;

		
	 “NEBA Amendment Agreement”
	  	 means the amendment and restatement agreement with respect to the GSK NEB Agreement entered into or to be entered into
between GSK, JVCo and Pfizer on or around the date of this Agreement;

		
	 “New Haleon Articles of Association”
	  	 means the articles of association of Haleon in the Agreed Form to be adopted by Haleon with effect from or before
Admission;

		
	 “New JVCo Articles of Association”
	  	 means the articles of association of JVCo in the Agreed Form to be adopted by JVCo with effect from
Completion;

		
	 “Official List”
	  	 means the Official List maintained by the FCA pursuant to Part 6 of FSMA;

		
	 “Orderly Marketing Agreement”
	  	 means the orderly marketing agreement entered into or to be entered into in the Agreed Form between GSK, Pfizer and the
SLPs on or around the date of this Agreement;

		
	 “Party”
	  	 means a party to this Agreement;

		
	 “Percentage Interest”
	  	 means the respective percentage interests of each of GSKCHHL and PFCHHL in the issued ordinary shares of
JVCo;

  
 20 

			
	 “PFCHHL Interests”
	  	 means all of the common interests in the capital of PFCHHL in issue immediately prior to the completion of the Pfizer Share
Exchange, which comprise all ownership interests of whatever nature in PFCHHL and all of which are held by Anacor as at the date of this Agreement and all of which, from completion of the PFCHHL Transfer until the completion of the Pfizer Share
Exchange, shall be held by Pfizer;

		
	 “PFCHHL Onward Dividends”
	  	 means the Final Quarterly PFCHHL Onward Dividend, the Pre-Separation PFCHHL Onward
Dividend and the Final Sweep PFCHHL Onward Dividend;

		
	 “PFCHHL Transfer”
	  	 means the series of transactions pursuant to which the PFCHHL Interests will be transferred, distributed or otherwise
assigned from Anacor to Pfizer;

		
	 “Pfizer Exchange Agreement”
	  	 means the Agreed Form exchange agreement between Pfizer, Anacor and Haleon setting out the terms of the Pfizer Share
Exchange;

		
	 “Pfizer Group”
	  	 means Pfizer and its subsidiaries and subsidiary undertakings from time to time, excluding the Consumer Healthcare Group
Companies;

		
	 “Pfizer Group PFCHHL Transferor”
	  	 means Anacor or, if the PFCHHL Transfer has completed by the time of Demerger Completion, Pfizer;

		
	 “Pfizer Haleon Exchange Shares”
	  	 means the Haleon Ordinary Shares and the Haleon NVPS to be allotted and issued, credited as fully paid up, in accordance
with the Pfizer Exchange Agreement, which immediately following the Demerger Completion and the completion of the Share Exchanges, represent respectively 32% of the issued Haleon Ordinary Shares (rounded to the nearest whole Haleon Ordinary Share)
and 100% of the issued preference shares of Haleon;

		
	 “Pfizer NEB Agreement”
	  	 means the net economic benefit agreement entered into between Pfizer, GSK and JVCo and dated 31 July 2019, as amended
or supplemented from time to time;

		
	 “Pfizer Relationship Agreement”
	  	 means the relationship agreement entered into or to be entered into in the Agreed Form between Pfizer and Haleon on or
around the Posting Date;

		
	 “Pfizer Retained Shares”
	  	 means any Haleon Ordinary Shares (including Haleon ADSs and other securities convertible into shares) held by or on behalf
of any member of the Pfizer Group in Haleon and any ultimate holding company thereof from time to time;

  
 21 

			
	 “Pfizer Share Exchange”
	  	 means the transfer of the PFCHHL Interests from the Pfizer Group PFCHHL Transferor to Haleon in exchange for Haleon issuing
the Pfizer Haleon Exchange Shares to the Pfizer Group PFCHHL Transferor and the Depositary, pursuant to and in accordance with the terms of the Pfizer Exchange Agreement;

		
	 “Pharmaceutical Regulatory Authority”
	  	 means, with respect to any regulatory jurisdiction, any national, federal, supranational, regional, state, provincial or
local governmental or regulatory authority, agency, department, bureau, commission, council or other Governmental Entity, including the FDA and EMA, regulating or otherwise exercising authority with respect to pharmaceutical products in such
regulatory jurisdiction;

		
	 “Pharmacovigilance Agreement”
	  	 means the pharmacovigilance agreement entered into or to be entered into between
GlaxoSmithKline Services Unlimited and
GlaxoSmithKline Consumer Healthcare (Overseas) Limited on or around the date of this Agreement;

		
	 “Posting Date”
	  	 means the date of the Demerger Agreement (or such other date as may be determined by GSK and notified to Haleon and Pfizer
as the date for the issue and dispatch of the Circular and the publication of the Prospectus);

		
	 “Prescription Product”
	  	 means, in respect of any jurisdiction, any oral care, nutritional care, skin care, medicine or other cosmetic or healthcare
product or device of any kind, in each case, for the treatment of, or use by, human beings, which is (i) only available with a prescription or (ii) available without, or with and without, a prescription but is subject to the same
regulatory classification and/or regulatory treatment (including in relation to advertising) as a product or device that is only available with a prescription;

		
	 “Pre-Separation Bonds”
	  	 means the:
  

-  GBP 300,000,000 2.875 per cent Fixed Rate Notes due 29 October 2028
issued by GSK Consumer Healthcare Capital UK plc;
  

-  GBP 400,000,000 3.375 per cent Fixed Rate Notes due 29 October 2038
issued by GSK Consumer Healthcare Capital UK plc;
  

-  USD 1,750,000,000 3.125 per cent Fixed Rate Senior Notes due 2025 issued by
GSK Consumer Healthcare Capital UK plc;

  
 22 

			
		  	 -  EUR 850,000,000 1.250 per cent Fixed Rate Notes due
29 March 2026 issued by GSK Consumer Healthcare Capital NL B.V.;
  

-  EUR 750,000,000 1.750 per cent. Fixed Rate Notes due 29 March 2030
issued by GSK Consumer Healthcare Capital NL B.V.;
  

-  EUR 750,000,000 2.125 per cent Fixed Rate Senior Notes due 29 March 2034
issued by GSK Consumer Healthcare Capital NL B.V.;
  

-  USD 700,000,000 3.024 per cent Callable Fixed Rate Senior Notes due 2024
issued by GSK Consumer Healthcare Capital US LLC;
  

-  USD 300,000,000 Callable Floating Rate Senior Notes due 2024 issued by GSK
Consumer Healthcare Capital US LLC;
  

-  USD 2,000,000,000 3.375 per cent Fixed Rate Senior Notes due 2027 issued by
GSK Consumer Healthcare Capital US LLC;
  

-  USD 1,000,000,000 3.375 per cent Fixed Rate Senior Notes due 2029 issued by
GSK Consumer Healthcare Capital US LLC;
  

-  USD 2,000,000,000 3.625 per cent Fixed Rate Senior Notes due 2032 issued by
GSK Consumer Healthcare Capital US LLC; and
  

-  USD 1,000,000,000 4.000 per cent Fixed Rate Senior Notes due 2052 issued by
GSK Consumer Healthcare Capital US LLC;

		
	 “Pre-Separation Dividend”
	  	 means the dividend to be paid by JVCo to GSKCHHL and PFCHHL prior to the Demerger (as provided in clause 17.32(B) of the
Cosmos SHA and as otherwise agreed between the parties to the Cosmos SHA, including pursuant to the Treasury Side Letter);

		
	 “Pre-Separation GSKCHHL Onward Dividend”
	  	 means the dividend to be paid by GSKCHHL to GSK (as holder of the A Shares and B Shares) prior to the Demerger following
the Pre-Separation Dividend and comprising amounts received by GSKCHHL pursuant to the Pre-Separation Dividend;

  
 23 

			
	 “Pre-Separation Onward Dividends”
	  	 means the Pre-Separation GSKCHHL Onward Dividend and the Pre-Separation PFCHHL Onward Dividend and comprising amounts received pursuant thereto;

		
	 “Pre-Separation PFCHHL Onward Dividend”
	  	 means one or more dividend(s), distribution(s), transfer(s) or other similar transaction(s) from PFCHHL to Anacor (or, if
completion of the PFCHHL Transfer has occurred prior to such dividend(s), distribution(s), transfer(s) or other similar transaction(s), Pfizer) prior to the Demerger following the Pre-Separation Dividend and comprising amounts received by PFCHHL
pursuant thereto;

		
	 “Proceedings”
	  	 means any proceeding, suit or action arising out of or in connection with this Agreement or the negotiation, existence,
validity or enforceability of this Agreement, whether contractual or non-contractual;

		
	 “Prospectus”
	  	 means the prospectus relating to the Admission of the Haleon Admission Shares to be dated the Posting Date;

		
	 “Qualifying GSK Shareholders”
	  	 means the GSK Shareholders on the register of members of GSK at the Demerger Record Time;

		
	 “Redeemable Shares”
	  	 means the fully paid redeemable preference shares of £1.00 each in the share capital of Haleon (subscribed by Trexco
on or around the re-registration of Haleon as a public limited company);

		
	 “Registration Rights Agreement”
	  	 means the registration rights agreement between Haleon, Pfizer, GSK and each of the SLPs dated on or around the date of
this Agreement;

		
	 “Regulatory Conditions”
	  	 means, subject to clause 2.11 of this Agreement, the India Condition, the Japan Condition and the Korea
Condition;

		
	 “Regulatory Information Access and Service Agreement”
	  	 means the regulatory information access and service (linked products) agreement entered into or to be entered into between
GlaxoSmithKline Services Unlimited and GlaxoSmithKline Consumer Healthcare (Overseas) Unlimited on or around the date of this Agreement;

		
	 “Related Party Transactions Resolution”
	  	 means resolution 2 set out in the notice of general meeting of GSK included in the Circular;

		
	 “Relevant GSKCHHL Shares”
	  	 means all of the class A ordinary shares of £1.00 each in the capital of GSKCHHL in issue immediately prior to
Demerger Completion;

		
	 “SCA Side Letter”
	  	 means the letter agreement between GSKCHHL, Pfizer, PFCHHL, GSK and JVCo dated 22 November 2021;

		
	 “SEC”
	  	 means the U.S. Securities and Exchange Commission;

  
 24 

			
	 “Securities Act”
	  	 means the U.S. Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder;

		
	 “Separation Ancillary Agreements”
	  	 means the:
  

(i)  Demerger Agreement;

 

(ii)  Exchange Agreements;

 

(iii)   Cosmos SAPA Amendment Agreement;

 
 (iv) Tax
Covenant;
  

(v)   ATFA;

 

(vi) Transitional Services Agreement;

 

(vii)  GSK Manufacturing and Supply Agreement;

 

(viii)  Consumer Manufacturing and Supply Agreement;

 
 (ix) GSK
Quality Agreement;
  

(x)   Consumer Quality Agreement;

 
 (xi) Shared
Brands Licences Agreement;
  

(xii)  Shared Brands Committee Agreement;

 

(xiii)  Corporate Brand Licence Agreement;

 
 (xiv) Co-Existence Agreement;
  

(xv)   Long Term Access Agreement;

 

(xvi) Pharmacovigilance Agreement;

 
 (xvii) NEBA
Amendment Agreement;
  

(xviii)Argentina NEBA;

 
 (xix) Brazil
ATFA;
  

(xx)   Guarantee Fee Arrangements;

 
 (xxi) Deed of
Termination; and
  

(xxii) Regulatory Information Access and Service Agreement,

 
 and any document, agreement or arrangement pursuant thereto
or in connection therewith;

  
 25 

			
	 “Separation Transaction”
	  	 means the steps comprised in the Demerger, the Exchange Agreements, execution of the Separation Ancillary Agreements and
Admission, pursuant to which, among other things, Haleon will become a listed company holding the Consumer Healthcare Business;

		
	 “Service Document”
	  	 has the meaning given to that term in clause 35.5;

		
	 “Shared Brands Committee Agreement”
	  	 means the shared brands committee agreement entered into or to be entered into between GlaxoSmithKline Services Unlimited
and GlaxoSmithKline Consumer Healthcare (Overseas) Limited on or around the date of this Agreement;

		
	 “Shared Brands Licences Agreement”
	  	 means the deed of amendment and restatement to amend and restate certain shared brand licence agreements entered into or to
be entered into between certain licensors, certain licensees and certain registered proprietors on or around the date of this Agreement;

		
	 “Share Exchanges”
	  	 means the GSK Share Exchange, the Pfizer Share Exchange and the SLP Share Exchange;

		
	 “SLP Exchange Agreement”
	  	 means the Agreed Form exchange agreement between the SLPs and Haleon setting out the terms of the SLP Share
Exchange;

		
	 “SLP Haleon Exchange Shares”
	  	 means the Haleon Ordinary Shares to be allotted and issued, credited as fully paid up, in accordance with the SLP Exchange
Agreement, which immediately following completion of the Demerger and the Share Exchanges, represent 7.5% of the issued Haleon Ordinary Shares (rounded to the nearest whole Haleon Ordinary Share);

  
 26 

			
	 “SLPs”
	  	 means:
  

(i) GSK (No. 1) Scottish Limited Partnership, a private fund limited partnership registered in
Scotland with registration number SL035527 and whose principal place of business is at 50 Lothian Road, Festival Square, Edinburgh, EH3 9WJ;
  

(ii)  GSK (No. 2) Scottish Limited Partnership, a private fund limited partnership
registered in Scotland with registration number SL035526 and whose principal place of business is at 50 Lothian Road, Festival Square, Edinburgh, EH3 9WJ; and
  

(iii)  GSK (No. 3) Scottish Limited Partnership, a private fund limited partnership
registered in Scotland with registration number SL035525 and whose principal place of business is at 50 Lothian Road, Festival Square, Edinburgh, EH3 9WJ,
  

being the Scottish limited partnerships that will each receive shares in Haleon pursuant to the SLP Exchange Agreement, and
“SLP” shall be construed accordingly;

		
	 “SLP Share Exchange”
	  	 means the transfer of each SLP’s entire shareholding of C Shares to Haleon in exchange for Haleon issuing the
applicable portion of the SLP Haleon Exchange Shares to each such SLP, pursuant to and in accordance with the terms of the SLP Exchange Agreement;

		
	 “Sponsors”
	  	 means:
  

(i) Citigroup Global Markets Limited, a company incorporated in England and Wales with
registered number 01763297 whose registered office is Citigroup Centre, Canada Square, Canary Wharf, London E14 5LB;
  

(ii)  Goldman Sachs International, a company incorporated in England and Wales with
registered number 02263951 whose registered office is Plumtree Court, 25 Shoe Lane, London, EC4A 4AU; and
  

(iii)  Merrill Lynch International, a company incorporated in England and Wales with
registered number 02312079 whose registered office is 2 King Edward Street, London, EC1A 1HQ;

  
 27 

			
	 “Sponsors’ Agreements”
	  	 means:
  

(i) the sponsors’ agreement between Haleon, JVCo and each of the Sponsors dated on or
around the date of this Agreement; and
  

(ii)  the sponsors’ agreement between GSK and each of the Sponsors dated on or around
the date of this Agreement;

		
	 “Steps Plan”
	  	 means the demerger steps plan prepared by Slaughter and May summarising the proposals in relation to the Separation
Transaction, and initialled for identification purposes by or on behalf of each of GSK, Pfizer and Haleon;

		
	 “Sterling” and “£”
	  	 means the lawful currency of the United Kingdom;

		
	 “subsidiary undertaking”
	  	 means a subsidiary undertaking as defined in section 1162 Companies Act 2006 (and a company shall be treated, for the
purposes only of the membership requirement contained in subsections 1162(2)(b) and (d) respectively, as a member of another company even if its shares in that other company are registered in the name of (A) another person (or its nominee)
whether by way of security or in connection with the taking of security or (B) its nominee);

		
	 “Sweep Amount”
	  	 has the meaning given to that term in the Treasury Side Letter;

		
	 “Switch Exclusivity Period”
	  	 has the meaning given to that term in paragraph 2.5 of Part A of Schedule 2 (Continuing Cosmos SHA
Provisions and Post-Completion Matters);

		
	 “Switch Milestone”
	  	 has the meaning given to that term in paragraph 2.2 of Part A of Schedule 2 (Continuing Cosmos SHA
Provisions and Post-Completion Matters);

		
	 “Switch Party”
	  	 has the meaning given to that term in paragraph 2.2 of Part A of Schedule 2 (Continuing Cosmos SHA
Provisions and Post-Completion Matters);

  
 28 

			
	 “Switch Product”
	  	 means, in respect of any jurisdiction, any Prescription Product (including any specific doses and/or indications of a
Prescription Product) that is proposed by the relevant Switch Party to switch to being a Consumer Healthcare Product, excluding:
  

(i) where the Switch Party is a member of the GSK Group: Imitrex and Ventolin and all products
sold under such brand names or variations or derivations (including translations) thereof; and
  

(ii)  where the Switch Party is a member of the Pfizer Group: Viagra, Celebrex and Chantix
and all products sold under such brand names or variations or derivations (including translations) thereof;

		
	 “Tax”
	  	 means all taxes, and all levies, duties, imposts, charges and withholdings in the nature of tax, including taxes on gross
or net income, profits or gains and taxes on receipts, sales, use, employment, payroll, land, stamp, transfer, occupation, franchise, value added, wealth and personal property, together with all penalties, charges, additions to tax, and interest
relating to any of them, and regardless of whether any such amounts are chargeable or attributable directly or primarily to any other person or are recoverable from any other person;

		
	 “Tax Authority”
	  	 means any taxing, revenue or other authority competent to impose any liability to, or to assess or collect, any Tax,
including, without limitation, HMRC and the Internal Revenue Service;

		
	 “Tax Covenant”
	  	 means the deed of tax covenant relating to the Separation Transaction, entered into or to be entered into in the Agreed
Form between GSK, Haleon, GSKCHHL, Pfizer and JVCo on or around the date of this Agreement;

		
	 “Third Party”
	  	 means a person who:
  

(i) is not a member of the GSK Group or the Pfizer Group;

 
 (ii)  is
not connected with GSK or Pfizer; and
  

(iii)  is not a member of the Consumer Healthcare Group;

  
 29 

			
	 “Transaction Documents”
	  	 means this Agreement and the Ancillary Agreements;

		
	 “Transitional Services

Agreement”
	  	 means the transitional services agreement entered into or to be entered into between GlaxoSmithKline Services Unlimited,
GlaxoSmithKline LLC, GlaxoSmithKline Consumer Healthcare (Overseas) Limited and GlaxoSmithKline Consumer Healthcare Holdings (US) LLC on or around the date of this Agreement;

		
	 “Treasury Side Letter”
	  	 means the letter agreement between GSKCHHL, Pfizer, PFCHHL, GSK and JVCo dated 4 November 2021 pursuant to which the
parties thereto have agreed the interpretation, and confirmed the application, of certain provisions of the Cosmos SHA;

		
	 “Trexco”
	  	 means Trexco Limited, a company incorporated in England with number 00461588, having its registered office at 2 Lambs
Passage, London, EC1Y 8BB;

		
	 “VAT”
	  	 means:
  

(i) any value added tax imposed by VATA and legislation and regulations supplemental
thereto;
  

(ii)  to the extent not included in paragraph (i) above, any Tax imposed in
compliance with the council directive of 28 November 2006 on the common system of value added tax (EC Directive 2006/112); and
  

(iii)  any other Tax of a similar nature to the Taxes referred to in paragraph
(i) or paragraph (ii) above, whether imposed in the UK or a member state of the EU in substitution for, or levied in addition to, the Taxes referred to in paragraph (i) or paragraph (ii) above or imposed
elsewhere;

		
	 “VATA”
	  	 means the Value Added Tax Act 1994; and

		
	 “Working Hours”
	  	 means 9.30 a.m. to 5.30 p.m. (local time) on a Business Day.

  
 30 

	1.2	 In this Agreement, unless otherwise specified: 

 

	 	(A)	 references to clauses, sub clauses, paragraphs, sub paragraphs, and Schedules are to clauses, sub clauses,
paragraphs, sub paragraphs of, and Schedules to, this Agreement; 

  

	 	(B)	 use of any gender includes the other genders and (unless the context otherwise requires) the singular shall
include the plural and vice versa; 

  

	 	(C)	 references to a “company” shall be construed so as to include any corporation or other body
corporate, wherever and however incorporated or established; 

  

	 	(D)	 references to a “person” shall be construed so as to include any individual, firm, company,
corporation, body corporate, government, state or agency of a state, local or municipal authority or government body or any joint venture, association or partnership (whether or not having separate legal personality); 

 

	 	(E)	 references to a “holding company” or a “subsidiary” shall be construed as
a holding company or subsidiary (as the case may be) as defined in section 1159 of the Companies Act 2006; 

  

	 	(F)	 references to a “body corporate” shall be construed as a body corporate as defined in
section 1173 of the Companies Act 2006; 

  

	 	(G)	 references to a “parent undertaking” shall be construed as a parent undertaking as defined
in section 1162 of the Companies Act 2006; 

  

	 	(H)	 references to a “party” shall be construed so as to include a reference to that
party’s successors and permitted assigns; 

  

	 	(I)	 a reference to any statute or statutory provision or other regulation shall be construed as a reference to
the same as it may have been, or may from time to time be, amended, modified or re-enacted and shall include any subordinate legislation made from time to time under that statute or statutory provision, except
to the extent that any amendment or modification made after the date of this Agreement would increase or alter the liability of any Party under this Agreement; 

 

	 	(J)	 references to “include” and “including” shall be deemed to be followed by
the words “without limitation”; 

  

	 	(K)	 any reference to a “day” (including within the phrase “Business Day”)
shall mean a period of 24 hours running from midnight to midnight; 

  

	 	(L)	 references to times are to London time (unless otherwise stated); 

 

	 	(M)	 reference to “liabilities”, “costs” and/or “expenses”
incurred by a person shall not include any amount in respect of VAT or any Tax of a similar nature included in such liabilities, costs and/or expenses for which that person or any other member of its Group is entitled to credit or repayment from any
Tax Authority; 

  
 31 

	 	(N)	 references to “indemnify” any person against any circumstance shall include indemnifying
and keeping such person harmless from all actions, claims and proceedings from time to time made against such person and all loss, damage, payments, costs or expenses suffered, made or incurred by such person as a consequence of that circumstance
and, unless otherwise specified, any indemnity given in this Agreement shall be deemed to have been given on an after-Tax basis; 

 

	 	(O)	 any indemnity or obligation to pay (the “Payment Obligation”) being given or assumed on an
“after-Tax basis” or expressed to be “calculated on an after-Tax basis” means that the amount payable pursuant to such Payment
Obligation (the “Payment”) shall be calculated in such a manner as will ensure that, after taking into account: 

  

	 	(i)	 any Tax required to be deducted or withheld from the Payment; 

 

	 	(ii)	 the amount and timing of any additional Tax which becomes (or would, but for the use of any credit or other
relief which would otherwise have been available to reduce the Tax liabilities of any member of the Pfizer Group, the Consumer Healthcare Group or the GSK Group, as the case may be, have become) payable as a result of the Payment’s being
subject to Tax; and 

  

	 	(iii)	 the amount and timing of any Tax benefit which is obtained, to the extent that such Tax benefit is
attributable to the matter giving rise to the Payment Obligation, 

 the recipient of the Payment is in the
same position as that in which it would have been if the matter giving rise to the Payment Obligation had not occurred (or, in the case of a Payment Obligation arising by reference to a matter affecting a person other than the recipient of the
Payment, the recipient of the Payment and that other person are, taken together, in the same position as that in which they would have been had the matter giving rise to the Payment Obligation not occurred), provided that the amount of the Payment
shall not exceed that which it would have been if it had been regarded for all Tax purposes as received solely by the recipient and not any other person; 
  

	 	(P)	 references to a “liability to Tax” or “Tax payable” (and equivalent terms)
include circumstances where Tax would be (or become) payable but for the use of a Relief (as such term is defined in the Tax Covenant); 

  

	 	(Q)	 a reference to any other document referred to in this Agreement is a reference to that other document as
amended, varied, novated or supplemented (other than in breach of the provisions of this Agreement or that other document) at any time; 

  

	 	(R)	 a reference to any English legal term for any action, remedy, method of judicial proceeding, legal document,
legal status, court, official or any legal concept or thing shall in respect of any jurisdiction other than England be treated as a reference to any analogous term in that jurisdiction; and 

  
 32 

	 	(S)	 the rule known as the ejusdem generis rule shall not apply and accordingly: 

 

	 	(i)	 general words introduced by the word “other” shall not be given a restrictive meaning by reason of
the fact that they are preceded by words indicating a particular class of acts, matters or things; and 

  

	 	(ii)	 general words shall not be given a restrictive meaning by reason of the fact that they are followed by
particular examples intended to be embraced by the general words. 

  

	1.3	 In this Agreement, unless otherwise specified: 

 

	 	(A)	 all headings and titles are inserted for convenience only and are to be ignored in the interpretation of
this Agreement; and 

  

	 	(B)	 the Schedules form part of this Agreement and shall have the same force and effect as if expressly set out
in the body of this Agreement, and any reference to this Agreement shall include the Schedules. 

  

	1.4	 In this Agreement, references to members of Pfizer Group’s or members of GSK Group’s holdings of
Haleon Ordinary Shares shall include: (i) Haleon Ordinary Shares held directly in the form of shares; (ii) Haleon Ordinary Shares held by one or more nominees on behalf of members of the Pfizer Group or GSK Group (as applicable); and (iii) Haleon
Ordinary Shares held indirectly as a result of a holding of Haleon ADSs. 

  

	2.	 CO-OPERATION AND IMPLEMENTATION 

Co-operation and implementation 

 

	2.1	 From the date of this Agreement and without prejudice to the generality of the obligations of the Parties
pursuant to the Cosmos SHA in relation to achieving Admission, each Party hereby agrees and undertakes: 

  

	 	(A)	 to the extent that any Ancillary Agreement has not been executed and delivered as at the date of this
Agreement, to procure that it or any member of its Group that is proposed to be party to such Ancillary Agreement shall execute and deliver such Ancillary Agreement in the Agreed Form when reasonably requested by GSK to do so and, in any event at or
before Completion; 

  

	 	(B)	 to perform any and all of its obligations pursuant to any Ancillary Agreement to which it is party;

  

	 	(C)	 to procure the due performance of any and all obligations of the members of its Group (and to exercise such
rights and powers as it has to procure the performance of obligations of any other person) pursuant to any Ancillary Agreement to which such members of its Group are party; 

 

	 	(D)	 to ensure that it and members of its Group shall do all such acts and things (and co-operate with the other Parties and their Groups) as may reasonably be necessary for the purpose of consummating successfully the Separation Transaction as a Listing Transaction for the purposes of and in
accordance with the Cosmos SHA and this Agreement, including (without limitation): 

  

	 	(i)	 procuring the production, approval and publication of the Prospectus, including (without limitation):

  

	 	(a)	 procuring that any person who will be a director of Haleon following Admission and who was nominated as such
by such Party provides all necessary information relating to themselves and takes responsibility as required by applicable Law for the Prospectus (and delivering all necessary or customary consents regarding the publication of the same);

  
 33 

	 	(b)	 providing all information required by or in relation to such Party or any member of its Group that is
required by Law for the Prospectus; and 

  

	 	(c)	 giving any undertaking, representation or comfort letter (and procuring that members of its Group give any
undertakings, representations or comfort letters) required under the Sponsors’ Agreements or otherwise by any sponsors or financial advisers or accountants to Haleon appointed for the purposes of Admission, provided that such undertaking,
representation or comfort letter is on customary and reasonable terms; 

  

	 	(ii)	 taking all reasonable steps to ensure that the Demerger is an exempt distribution (as defined in section
1075 CTA 2010); 

  

	 	(iii)	 the Pfizer Group PFCHHL Transferor exchanging its shares in the capital of PFCHHL for the issuance of the
Pfizer Haleon Exchange Shares to the Pfizer Group PFCHHL Transferor and the Depositary pursuant to and in accordance with the Pfizer Exchange Agreement; 

  

	 	(iv)	 GSK exchanging its entire shareholding of B Shares for the GSK Haleon Exchange Shares pursuant to and in
accordance with the GSK Exchange Agreement; and 

  

	 	(v)	 GSK and the relevant members of its Group procuring and exercising all such rights as it or they have to
procure that each SLP exchanges its entire shareholding of C Shares for the SLP Haleon Exchange Shares pursuant to and in accordance with, and otherwise complies with its obligations under, the SLP Exchange Agreement; 

  
 34 

	 	(E)	 to use all reasonable endeavours to procure that (and procure that the members of its Group shall procure
that) any necessary Third Party (including, without limitation, sponsors and accountants) execute such documents and do all such acts or things as may be reasonably required for the purpose of giving each party to a Transaction Document the full
benefit of the relevant provisions of such Transaction Document, in each case, subject to the terms of the Cosmos Agreements; 

  

	 	(F)	 to use all reasonable endeavours to procure the successful establishment of the Haleon ADR Programme in
accordance with the Steps Plan; and 

  

	 	(G)	 to use all reasonable endeavours to procure, after payment by JVCo of the Final Quarterly Dividend, the
Final Sweep Dividend and the Pre-Separation Dividend, the completion of the ATB Re-organisation. 

Delivery of listing documentation 
  

	2.2	 Each Party agrees, undertakes and confirms that, without prejudice to the generality of the obligations of
the Parties pursuant to the Cosmos SHA, and subject in all respects to the Cosmos SHA, it shall, and shall procure that relevant members of its Group shall: 

  

	 	(A)	 provide any and all information and assistance reasonably required by GSK and/or Haleon to consummate
successfully the Separation Transaction as a Listing Transaction for the purposes of and in accordance with the Cosmos SHA; and 

  

	 	(B)	 execute, deliver and approve (as required) all documents required to consummate successfully the Separation
Transaction as a Listing Transaction for the purposes of and in accordance with the Cosmos SHA, including (without limitation), the Prospectus, the Circular and the Listing Ancillary Agreements, in each case subject to any approval and/or
consultation rights it may have in the Cosmos SHA with respect to such documents. 

 Ancillary Agreements 

 

	2.3	 The Parties hereby agree and acknowledge that: 

 

	 	(A)	 the Ancillary Agreements are in Agreed Form; 

 

	 	(B)	 GSK, as controller of the process to effect the Separation Transaction in accordance with the Cosmos SHA,
may request amendments to the Ancillary Agreements and may request any of the Parties and/or any members of any of their Groups to enter into other agreements in connection with the Separation Transaction, in each case, to the extent permitted by,
and subject in all respects to, the Cosmos SAPA, Cosmos SHA or any other agreements between members of the GSK Group, members of the Haleon Group and/or members of the Pfizer Group in relation to the same; and 

  
 35 

	 	(C)	 (i) the Ancillary Agreements and (ii) any other agreements that GSK may request from any of the Parties
and/or any members of any of their Groups to enter into in connection with the Separation Transaction, in each case to the extent their agreement is required pursuant to the terms of the Cosmos SAPA, Cosmos SHA or any other agreements between
members of the GSK Group, members of the Haleon Group and/or members of the Pfizer Group, as agreed by each of Haleon and Pfizer (whether or not parties thereto), shall be executed and delivered by the parties thereto, subject in all respects to the
Cosmos SHA and such other agreements; it being understood and agreed that nothing in this clause 2.3 shall expand the rights or obligations of any of the parties to the Cosmos SHA or any such other agreements, and nothing in this clause
2.3 shall require any party to enter into any agreement or any amendment to any agreement except to the extent that such party is required to enter into such agreement or amendment pursuant to the terms of the Cosmos SAPA, Cosmos SHA or any
other relevant agreement to which such party is bound. 

 Confirmations and further assurance 

 

	2.4	 The Parties agree and acknowledge that they shall comply in all respects with the Cosmos SHA and shall
procure such compliance by the members of their respective Groups. For the avoidance of doubt, the Parties agree and acknowledge that this Agreement is without prejudice to GSK’s and Pfizer’s rights under the Cosmos SHA, the Cosmos SCA,
the SCA Side Letter, the Treasury Side Letter and the obligations of Pfizer, GSK and the members of the Pfizer Group and the GSK Group pursuant to the terms of the Cosmos SHA, the Cosmos SCA, the SCA Side Letter, and the Treasury Side Letter;
provided that, notwithstanding anything to the contrary in this Agreement or the Cosmos SHA, the Cosmos SCA or the Treasury Side Letter, (1) the issuance to the Pfizer Group PFCHHL Transferor of the Haleon NVPS pursuant to the Pfizer Share
Exchange and the sale or disposition of the Haleon NVPS by the Pfizer Group PFCHHL Transferor immediately thereafter and (2) the distribution referred to in limb (ii) of the definition of ATB
Re-organisation shall be expressly permitted for all purposes hereunder and thereunder. Notwithstanding anything to the contrary in this Agreement or the other Transaction Documents, the Parties agree and
acknowledge that, in connection with the Separation Transaction: 

  

	 	(A)	 any reference in the GSK Exchange Agreement or the other Transaction Documents to the issuance to GSK of GSK
Haleon Exchange Shares shall, at the sole discretion of GSK (upon written notice to Haleon no fewer than five (5) days prior to the date of Demerger Completion), be read to include an issuance of a portion of such GSK Haleon Exchange Shares (as
applicable) to a nominee of GSK’s choice to hold such portion of such GSK Haleon Exchange Shares on behalf of GSK; 

  

	 	(B)	 any reference in the Pfizer Exchange Agreement or the other Transaction Documents to the issuance to the
Pfizer Group PFCHHL Transferor of Pfizer Haleon Exchange Shares (including the Haleon NVPS) shall, at the sole discretion of the Pfizer Group PFCHHL Transferor (upon written notice to GSK and Haleon no fewer than five (5) days prior to the date of
Demerger Completion), be read to include an issuance of a portion of such Pfizer Haleon Exchange Shares (as applicable) to a nominee of the Pfizer Group PFCHHL Transferor’s choice to hold such portion of such Pfizer Haleon Exchange Shares on
behalf of the Pfizer Group PFCHHL Transferor; and 

  

	 	(C)	 any reference in the SLP Exchange Agreement or the other Transaction Documents to the issuance to the SLPs
of SLP Haleon Exchange Shares shall, at the sole discretion of the relevant SLP or GSK (upon written notice to Haleon no fewer than five (5) days prior to the date of Demerger Completion), be read to include an issuance of a portion of such SLP
Haleon Exchange Shares (as applicable) to a nominee of the relevant SLP’s or GSK’s choice to hold such portion of such SLP Haleon Exchange Shares on behalf of the relevant SLP. 

 

	2.5	 The Parties hereby confirm in all respects and for all purposes under the Cosmos SHA and Cosmos SCA that
they approve, consent and agree to the form, terms, contents, performance and implementation and/or activation of the following agreements, instruments, arrangements and actions in the Agreed Form, and that, as applicable, all obligations to consult
with any other entity have been fully discharged in respect of the same: 

  

	 	(A)	 the Demerger Agreement; 

 

	 	(B)	 the Exchange Agreements; 

 

	 	(C)	 the Ancillary Agreements; 

 

	 	(D)	 the Sponsors’ Agreements; 

 

	 	(E)	 the Lock-up Deed entry into which the Parties acknowledge discharges
the obligations of the relevant parties under clause 17.34(E) of the Cosmos SHA; 

  
 36 

	 	(F)	 the Pfizer Relationship Agreement, entry into which the Parties acknowledge discharges the obligations of
the relevant parties under clause 17.34(C)(i) of the Cosmos SHA (it being acknowledged that, taking into account the extent of GSK’s prospective interest in Haleon, there will be no relationship agreement between GSK and Haleon);

  

	 	(G)	 the Registration Rights Agreement, entry into which the Parties acknowledge discharges the obligations of
the relevant parties to enter into a registration rights agreement under clause 18.2 of the Cosmos SHA; 

  

	 	(H)	 the appointment of Deloitte LLP as auditor to Haleon; 

 

	 	(I)	 the appointment of the Sponsors as Haleon’s sponsors; 

 

	 	(J)	 the appointment of Slaughter and May as UK legal counsel to Haleon in relation to Admission and the
Separation Transaction; 

  

	 	(K)	 the appointment of Freshfields Bruckhaus Deringer LLP and Sullivan & Cromwell LLP as independent
legal counsel to Haleon in relation to Admission and the Separation Transaction; 

  

	 	(L)	 all actions undertaken to implement the Steps Plan and the matters set out therein, including (without
limitation) the ATB Re-organisation; 

  

	 	(M)	 all actions required for Haleon to obtain directors’ and officers’ liability insurance effective
as of Admission in accordance with the Cosmos SHA; 

  

	 	(N)	 all actions taken to terminate or replace existing powers of attorney and bank mandates within the Consumer
Healthcare Group; 

  

	 	(O)	 the following governance arrangements of Haleon: 

 

	 	(i)	 the registered name of Haleon; 

 

	 	(ii)	 the composition of its board of directors and management as detailed in the Prospectus, subject to and
without limiting the rights of Pfizer set forth in clause 18.1 of the Cosmos SHA (and, following Admission, paragraph 3 of Part A of Schedule 2 (Continuing Cosmos SHA Provisions and Post-Completion Matters)) and the Pfizer
Relationship Agreement; 

  

	 	(iii)	 arrangements regarding its governance committees and committees and
sub-committees of its board of directors as detailed in the Prospectus and the form of the Haleon Committee Terms of Reference; 

  
 37 

	 	(iv)	 the summary of its remuneration policy as detailed in the Prospectus; and 

 

	 	(v)	 its corporate policies and procedures as approved by the Haleon Board prior to the date of this Agreement,
including (without limitation) its anti-bribery and corruption policy as adopted on 23 May 2022 and its code of promotion as adopted on 23 May 2022; 

  

	 	(P)	 adoption by Haleon of the New Haleon Articles of Association in the Agreed Form; 

 

	 	(Q)	 adoption by JVCo of the New JVCo Articles of Association in the Agreed Form; 

 

	 	(R)	 Haleon’s dividend policy as detailed in the Prospectus; 

 

	 	(S)	 the establishment or incurrence of borrowings or other financing arrangements in accordance with and
pursuant to the Treasury Side Letter; 

  

	 	(T)	 Haleon effecting any reduction of capital after Admission; and 

 

	 	(U)	 25 February 2023 being, as at the date of this Agreement, the current date of expiry of the GSK
Separation Execution Period (as defined in the Cosmos SHA) for the purposes of the Cosmos SHA, subject to any extensions to such GSK Separation Execution Period for the purposes of the Cosmos SHA in accordance with and pursuant to clause 17.13 of
the Cosmos SHA. 

  

	2.6	 The Parties: 

  

	 	(A)	 hereby agree and acknowledge that implementation of the proposed governance arrangements of Haleon at
Admission specified in clause 2.5(O), is expected to result in: 

  

	 	(i)	 at least half of the Haleon Board, excluding the chair, being
non-executive directors whom the Haleon Board considers to be independent; and 

  

	 	(ii)	 the appointment of a chair of the Haleon Board who the Haleon Board considers to be independent on
appointment 

 (with independence tested in each case against the circumstances set out in provision 10 of
the Governance Code) (it being understood no continuing director, officer or employee of either GSK or Pfizer or any member of their respective Groups shall be considered independent and it being further understood, agreed and acknowledged that
Haleon shall not appoint any continuing director, officer or employee of the GSK Group to the Haleon Board); and 
  

	 	(B)	 hereby agree and undertake not to vary such governance arrangements prior to Admission in any way that will
or may result in Haleon not complying in all material respects with the recommendations of the Governance Code, 

provided that if supervening natural events (such as death, incapacity or disability) mean that a particular individual or
individuals otherwise expected at the Posting Date to be or become a member of the Haleon Board will not be part of the Haleon Board, and as a result the foregoing outcomes will not be achieved, such matter shall, if not reasonably capable of being
addressed reasonably promptly prior to Admission, be a matter for the 

  
 38 

 
Haleon Board to address in the normal course and reasonably promptly; provided further that nothing in this clause 2.6 shall prejudice Pfizer’s rights pursuant to the Relationship
Agreement or paragraph 3 of Part A of Schedule 2 (Continuing Cosmos SHA Provisions and Post-Completion Matters). 
  

	2.7	 Without prejudice to the appointments to the Haleon Board as set out in the current draft Prospectus and/or
pursuant to the Pfizer Relationship Agreement, GSK and Pfizer agree and undertake: 

  

	 	(A)	 to procure the resignation of their respective nominee directors who are not continuing as directors of
Haleon as of Admission from the boards of directors of all Consumer Healthcare Group Companies, such resignations to take effect from Admission; and 

  

	 	(B)	 to procure that their respective Groups provide all reasonable assistance and use all reasonable endeavours
to procure the resignation of such nominee directors as referred to in clause 2.7(A), 

 and the
Parties agree to procure that each relevant Consumer Healthcare Group Company shall confirm, on customary terms and in customary form, that it does not have any claim or right of action whatsoever outstanding against any resigning nominee director
as referred to in clause 2.7(A) and that, to the extent such claim or right of action exists or may exist, the relevant Consumer Healthcare Group Company waives such claim and releases the relevant resigning nominee director from any
liability that such resigning nominee director has or might have in respect thereof. 
  

	2.8	 For the avoidance of doubt: 

 

	 	(A)	 the proposed appointments to the Haleon Board as set out in the current draft Prospectus and/or pursuant to
the Pfizer Relationship Agreement, are prospective appointments; and 

  

	 	(B)	 such appointments shall only be effective from Admission. 

 

	2.9	 GSK and Pfizer agree and undertake that they shall each (and shall procure that the relevant members of
their respective Groups and their respective employees and employees of relevant members of their respective Groups shall) deliver any requisite consent, including (without limitation) approval of the special resolution of Haleon’s shareholders
required pursuant to section 641(1)(b) of the Companies Act 2006 and a form of consent qua creditor, in any reasonable and customary form requested by Haleon in connection with any reduction of capital to be effected by Haleon after Admission such
that the same, including (without limitation) the special resolution of Haleon’s shareholders required pursuant to section 641(1)(b) of the Companies Act 2006, can be presented to the court that will be requested to approve such reduction of
capital. 

  

	2.10	 Anacor and Pfizer agree and undertake that, if completion of the PFCHHL Transfer has not occurred prior to
Demerger Completion, then Anacor and Pfizer shall ensure that the PFCHHL Transfer shall not occur prior to Completion of the Pfizer Share Exchange. 

  

	2.11	 In the event that any Party identifies a need to obtain or complete a mandatory regulatory notification,
consent or clearance process, in each case, as required by applicable Law, in order to permit the implementation of the Separation Transaction and any related corporate restructuring steps (including, for the avoidance of doubt, the PFCHHL Transfer
or the Shares Exchanges), the Parties hereby agree that they shall discuss such matter in good faith and with expedition, and if GSK and Pfizer agree, acting reasonably and in good faith in reaching such determination, that such notification,
consent and/or clearance is required to be obtained or completed in order to permit the implementation of the Separation Transaction and any related corporate restructuring steps (including, for the avoidance of doubt, the PFCHHL Transfer or the
Shares Exchanges) in compliance with applicable Law, the Parties agree to co-operate in good faith and with expedition, to obtain or complete such regulatory notification, consent or clearance process and enter into, and procure that relevant
members of their respective Groups enter into, one or more amendments to this Agreement (and any other agreements entered into or to be entered into by them and any member of their respective Groups in connection with the Separation Transaction) as
is reasonably necessary in connection with such regulatory notification, consent and/or clearance process, and (including, for the avoidance of doubt, by expanding the Demerger Conditions Precedent and the Regulatory Conditions to include such
regulatory notification, consent and/or clearance process). 

  

	3.	 SEPARATION PROCESS AND TERMINATION 

 

	3.1	 The Parties agree and acknowledge that, as and to the extent provided in clause 17.29 of the Cosmos SHA, GSK
and GSKCHHL shall (except as specifically set forth in clause 17.29 of the Cosmos SHA): 

  

	 	(A)	 have absolute discretion from time to time as to the structure and process of the Separation Transaction;
and 

  
 39 

	 	(B)	 without limitation and in their absolute discretion (save as to the extent that the Cosmos SCA provides
otherwise) be entitled to (and, where specifically noted therein, shall be required to) take any step or action set out in clauses 17.29(A) to 17.29(K) (inclusive) of the Cosmos SHA. 

 

	3.2	 Notwithstanding any other provision of any Transaction Document (but subject to the Cosmos SHA), the Parties
hereby agree and acknowledge that GSK shall have the right in its absolute discretion to abandon the Separation Transaction by providing notice of the same in writing to the other Parties at any time prior to Demerger Completion, and upon GSK
providing such notice this Agreement shall automatically terminate. 

  

	3.3	 The Parties hereby agree and acknowledge that, in the event that this Agreement is terminated pursuant to
clause 3.1: 

  

	 	(A)	 GSK, JVCo and each member of their respective Groups shall have no liability to Pfizer, PFCHHL or any member
of their respective Groups, in each case in connection with such termination and in each case save to the extent the Cosmos SCA provides otherwise; 

  

	 	(B)	 without prejudice to clause 17.34(G) of the Cosmos SHA, Pfizer and PFCHHL shall not (and shall procure that
no member of their respective Groups shall) seek to obtain any financial compensation or other remedy from GSK, JVCo or any member of their respective Groups, 

in each case of clauses (A) and (B) in connection with such termination and in each case save to the extent the Cosmos SCA
provides otherwise; 
  

	 	(C)	 this Agreement shall be of no further force or effect; and 

 

	 	(D)	 for the avoidance of doubt, the Cosmos SHA shall continue in full force and effect. 

 

	3.4	 Save as provided in clause 3.1, no Party shall have the right to rescind or unilaterally terminate
this Agreement, whether before or after Completion. 

  

	4.	 DIVIDENDS 

  

	4.1	 Each Party shall take all actions that it is able to take and shall procure, so far as it is able to do so
(and shall procure that the members of its Group shall procure, so far as they are able to do so), that all actions able to be taken are taken so that, prior to commencement of the Demerger Completion Steps: 

 

	 	(A)	 JVCo shall declare and pay the Final Quarterly Dividend to GSKCHHL and PFCHHL; 

 

	 	(B)	 GSKCHHL shall declare and pay the Final Quarterly GSKCHHL Onward Dividend to GSK (as holder of the A Shares
and the B Shares) and (if and only to the extent the SLPs are entitled to receive such dividend under the GSKCHHL Articles of Association) to the SLPs (as holders of the C Shares); 

  
 40 

	 	(C)	 PFCHHL shall declare and pay or otherwise effect the Final Quarterly PFCHHL Onward Dividend to Pfizer or
Anacor, as applicable; 

 and each Party shall take all actions that it is able to take and shall procure,
so far as it is able to do so (and shall procure that the members of its Group shall procure, so far as they are able to do so), that all actions able to be taken are taken so that, prior to commencement of the Demerger Completion Steps and
following satisfaction of the Regulatory Conditions: 
  

	 	(D)	 JVCo shall, at a time notified by GSK reasonably in advance of proposed payment (which time shall be agreed
between GSK and Pfizer in accordance with the Treasury Side Letter), declare and pay a final pre-Demerger interim dividend to GSKCHHL and PFCHHL in proportion to their respective Percentage Interests in JVCo
as at the relevant record date in respect of the period to and including 15 July 2022 comprising the Final Sweep Dividend which, as provided in the Treasury Side Letter, shall be calculated by reference to a good faith estimate of what the Sweep
Amount will be as at the Listing Date, such estimate being made in accordance with the Treasury Side Letter; 

  

	 	(E)	 GSKCHHL shall declare and pay a final pre-Demerger interim dividend
to GSK (as holder of the A Shares and the B Shares) and (if any, only to the extent the SLPs are entitled to receive such dividend under the GSKCHHL Articles of Association) to the SLPs (as the holders of the C Shares) in accordance with the GSKCHHL
Articles of Association comprising amounts received by GSKCHHL pursuant to (D) above and constituting the Final Sweep GSKCHHL Onward Dividend; 

  

	 	(F)	 PFCHHL shall declare and pay or otherwise effect a final
pre-Demerger interim dividend to Pfizer or Anacor, as applicable, comprising amounts received by it pursuant to (D) above and constituting the Final Sweep PFCHHL Onward Dividend;

  

	 	(G)	 consistent with the provisions of clause 4.4, following repayment of any outstanding Shareholder
Loans under clause 17.32(A) of the Cosmos SHA, JVCo shall, at a time notified by GSK reasonably in advance of proposed payment (which time shall be agreed between GSK and Pfizer in accordance with the Treasury Side Letter and shall be reasonably in
advance of the commencement of the Demerger Completion Steps to allow sufficient time for the payments described in (H) and (I) below to be made prior to the commencement of the Demerger Completion Steps), declare and pay the Pre-Separation Dividend to GSKCHHL and PFCHHL in proportion to their respective Percentage Interests in JVCo; 

  

	 	(H)	 consistent with the provisions of clause 4.4, GSKCHHL shall declare and pay the Pre-Separation GSKCHHL Onward Dividend (comprising amounts received by it pursuant to (G) above) to GSK in respect of the A Shares and the B Shares and the Parties hereby agree and acknowledge that,
subject to (G) above, it is GSK’s responsibility to ensure that the Pre-Separation GSKCHHL Onward Dividend is declared and paid prior to the commencement of the Demerger Completion Steps;

  

	 	(I)	 consistent with the provisions of clause 4.4, PFCHHL shall declare and pay or otherwise effect the Pre-Separation PFCHHL Onward Dividend (comprising amounts received by it pursuant to (G) above) to Pfizer or Anacor, as applicable, and the Parties hereby agree and acknowledge that, subject to
(G) above, it is Pfizer’s responsibility to ensure that the Pre-Separation PFCHHL Onward Dividend is declared and paid or otherwise effected prior to the commencement of the Demerger Completion
Steps; 

  
 41 

	 	(J)	 GSKCHHL shall declare and pay to GSK (as holder of the A Shares and the B Shares) and (if and only to the
extent that the SLPs are entitled to receive such dividend under the GSKCHHL Articles of Association) to the SLPs a dividend comprising amounts received by GSKCHHL as dividends paid by JVCo and which are directly referable to dividends received by
GSKCHHL from JVCo since Cosmos Closing (if any and other than amounts received by GSKCHHL pursuant to (A), (D) and/or (G) above); and 

 

	 	(K)	 PFCHHL shall declare and pay or otherwise effect to Pfizer or Anacor, as applicable, a dividend comprising
amounts received by PFCHHL as dividends paid by JVCo and which are directly referable to dividends received by PFCHHL from JVCo since Cosmos Closing (if any and other than amounts received by PFCHHL pursuant to (A), (D) and/or
(G) above). 

  

	4.2	 For the avoidance of doubt, the payment of the Final Sweep Dividend shall be paid separately from the Pre-Separation Dividend and no amount of cash taken into account in calculating the amount of the Pre-Separation Dividend shall also be taken into account in calculating the
amount of the Final Sweep Dividend. 

  

	4.3	 For the avoidance of doubt, the Parties agree and acknowledge that: 

 

	 	(A)	 it is Pfizer’s responsibility to ensure that the PFCHHL Onward Dividends are declared and paid or
otherwise effected prior to the commencement of the Demerger Completion Steps and promptly and as soon as possible after receipt by PFCHHL of the later of: (i) the relevant portion of the Pre-Separation
Dividend; and (ii) the relevant portion of the Final Sweep Dividend; provided that, notwithstanding anything to the contrary herein or in any Transaction Document, Pfizer may, in its sole discretion, cause the PFCHHL Onward Dividends to be paid
following the completion of the PFCHHL Transfer but, in all events, prior to completion of the Pfizer Share Exchange; and 

  

	 	(B)	 it is GSK’s responsibility to ensure that the GSKCHHL Onward Dividends are declared and paid prior to
the commencement of the Demerger Completion Steps and promptly and as soon as possible after receipt by GSKCHHL of the later of: (i) the relevant portion of the Pre-Separation Dividend; and (ii) the
relevant portion of the Final Sweep Dividend. 

  

	4.4	 The Parties further agree to co-operate and take all necessary
actions so that the Final Sweep Dividend and the Pre-Separation Dividend shall be paid by JVCo following satisfaction of the Regulatory Conditions and the passing of the Demerger Resolution and the Related
Party Transactions Resolution by GSK Shareholders at the GSK General Meeting and in any event by 23:59 PM on the day immediately prior to the day specified in the Steps Plan for Demerger Completion. The Parties hereby agree and acknowledge that, on
the basis set out in the immediately preceding sentence, there is sufficient time for payment or completion of the PFCHHL Onward Dividends and the GSKCHHL Onward Dividends ahead of Demerger Completion and completion of the Share Exchanges.

  
 42 

	4.5	 [Subject to the Pre-Separation Dividend and the Final Sweep Dividend
having been paid by JVCo in accordance with the timing specified in clause 4.4, Demerger Completion shall occur pursuant to and at the time and date specified in the Demerger Agreement and completion of each Share Exchange shall occur
pursuant to and at the time and date specified in the applicable Exchange Agreement. In the event that the Pre-Separation Dividend and/or the Final Sweep Dividend have not been paid by JVCo in accordance with
the timing specified in clause 4.4: 

  

	 	(A)	 the Parties agree that they shall co-operate to procure the payment
of the Pre-Separation Dividend and/or the Final Sweep Dividend (as applicable) by JVCo as soon as possible after such time; 

 

	 	(B)	 Pfizer agrees that it shall procure the payment or completion of the PFCHHL Onward Dividends as soon as
possible following payment of the relevant portion of the Pre-Separation Dividend and/or the Final Sweep Dividend (as applicable) to PFCHHL pursuant to clause 4.5(A); 

 

	 	(C)	 GSK agrees that it shall procure the payment of the GSKCHHL Onward Dividends as soon as possible following
payment of the relevant portion of the Pre-Separation Dividend and/or the Final Sweep Dividend (as applicable) to GSKCHHL pursuant to clause 4.5(A); 

 

	 	(D)	 provided that the PFCHHL Onward Dividends and the GSKCHHL Onward Dividends have been paid or effected before
23:59 PM on the date specified in the Steps Plan for Demerger Completion, then, notwithstanding any failure to pay the Pre-Separation Dividend and/or the Final Sweep Dividend in accordance with the timing
specified in clause 4.4, Demerger Completion, completion of the Share Exchanges and Admission shall occur in accordance with the relevant times and dates specified in the Steps Plan; and 

 

	 	(E)	 if any of the PFCHHL Onward Dividends and/or the GSKCHHL Onward Dividends are not paid or effected by PFCHHL
and/or GSKCHHL (as applicable) prior to 23:59 PM on the date specified in the Steps Plan for Demerger Completion, then the Parties agree that: 

  

	 	(i)	 the dates specified in the Steps Plan for Demerger Completion, completion of the Share Exchanges and
Admission shall each be delayed by one calendar week; 

  

	 	(ii)	 the Parties shall make necessary amendments to the Demerger Agreement, each of the Exchange Agreements and
any other Transaction Documents to reflect the same; 

  

	 	(iii)	 Pfizer shall take all reasonably necessary actions to prepare for and procure the payment or completion of
the PFCHHL Onward Dividends in accordance with the timing detailed in clause 4.3(A); 

  

	 	(iv)	 GSK shall take all reasonably necessary actions to prepare for and procure the payment of the GSKCHHL Onward
Dividends in accordance with the timing detailed in clause 4.3(B); and 

  

	 	(v)	 notwithstanding anything in this Agreement or the Demerger Agreement to the contrary, and without limiting
the obligations of Haleon pursuant to the Dividend Indemnities, the Parties expressly agree that Haleon shall hold any portions of the PFCHHL Onward Dividends and/or the GSKCHHL Onward Dividends, as applicable, that are not paid or otherwise
effected by PFCHHL or GSKCHHL prior to such time, due to a settlement failure or otherwise, on trust for the Pfizer Group or the GSK Group, as applicable, and shall cooperate with the Pfizer Group or the GSK Group, as applicable, to take all
reasonably necessary actions to establish alternative arrangements for, and to procure, the payment of such amounts to designees of the Pfizer Group or the GSK Group, as applicable, as soon as reasonably practicable. 

 

	4.6	 JVCo shall only be required to declare and/or pay dividend(s) in accordance with this clause 4
to the extent that: 

  

	 	(A)	 it has sufficient distributable reserves and, without limiting the obligations of any Party under the Cosmos
SHA, the Treasury Side Letter and/or this Agreement, the JVCo Board resolves to do so; 

  

	 	(B)	 there are no amounts outstanding (in respect of interest, principal or otherwise) under any JVCo Shareholder
Loan(s); and 

  
 43 

	 	(C)	 there are no outstanding special dividends in respect of payment obligations pursuant to clause 10.1 of the
Cosmos SHA which have been declared or become payable. 

  

	4.7	 Except where dividends are to be paid in a currency other than Sterling in accordance with the terms of the
Cosmos SAPA, dividends shall be paid in Sterling. The Final Quarterly Dividend shall be paid on or around 30 June 2022. The Final Sweep Dividend and Pre-Separation Dividend shall be paid to GSKCHHL and PFCHHL
on the same day (and are expected to be paid on 13 July 2022). All dividends shall be paid or settled by inter-bank transfer, by other electronic means for same day value directly to an account with a bank or other financial institution (or other
organisations operating deposit accounts) as notified in writing by GSKCHHL or PFCHHL (as applicable) to JVCo, or by settling existing intercompany debt balances. For dividends being paid by inter-bank transfer or by other electronic means then, in
the absence of any notification required pursuant to the immediately preceding sentence, JVCo shall hold the amount of the relevant dividend on trust for GSKCHHL or PFCHHL (as applicable). 

 

	4.8	 The Parties shall, subject to and in accordance with the Cosmos SHA and the Treasury Side Letter:

  

	 	(A)	 cooperate and take such steps as are reasonably required in connection with distributable reserves planning
for JVCo and its Group to enable the payment of the Final Quarterly Dividend, the Final Sweep Dividend and the Pre-Separation Dividend; and 

 

	 	(B)	 cooperate in good faith to determine the timing of all dividends and payments contemplated by this
clause 4 so as to ensure, so far as they are each able to do so, that each such dividend and payment is paid and made prior to the commencement of the Demerger Completion Steps. 

 

	4.9	 JVCo shall, so far as it is legally able to do so, procure that (and GSKCHHL and PFCHHL shall, so far as
they are legally able to do so, exercise their rights in relation to JVCo and under this Agreement and the Cosmos SHA to procure that) all resolutions for the declaration or payment of dividends or other payments consistent with this
clause 4 are duly passed by the relevant members of the JVCo Group and the JVCo Board (as applicable). 

  

	4.10	 In the event that any of: 

 

	 	(A)	 the Final Quarterly Dividend; 

 

	 	(B)	 the Final Sweep Dividend; 

 

	 	(C)	 the Pre-Separation Dividend; 

 

	 	(D)	 the other dividends paid by JVCo since Cosmos Closing; 

 

	 	(E)	 the Final Quarterly Onward Dividends; 

 

	 	(F)	 the Final Sweep Onward Dividends; 

  
 44 

	 	(G)	 the Pre-Separation Onward Dividends; and 

 

	 	(H)	 the dividends distributions or transfers paid by GSKCHHL and/or PFCHHL since Cosmos Closing to the extent
directly referable to dividends received by GSKCHHL and/or PFCHHL (as applicable) from JVCo since Cosmos Closing, 

are in any respect defective or are susceptible to legal challenge, Haleon agrees and undertakes to take or procure all
possible steps, (including, without limitation, distributable reserves planning and management; rectification and ratification steps; and procuring that none of JVCo, GSKCHHL or PFCHHL or any other member of Haleon’s Group take steps to seek
recovery of prior distributions, transfers or dividend payments) such that any amounts received by any member of the GSK Group or any member of the Pfizer Group pursuant to any of the dividends, distributions or transfers listed at
(A) to (H) of this clause 4.10 can be retained by the relevant member(s) of the GSK Group or the Pfizer Group (as applicable), provided that nothing in this clause 4.10 shall require any Party to take any action that
is or would be unlawful. 
  

	4.11	 Haleon shall indemnify GSK, each member of the GSK Group, Pfizer and each member of the Pfizer Group from
and against any and all liabilities and Costs arising before, on, or after Completion in respect of: 

  

	 	(A)	 any defect in, or any actual or potential claim, proceeding, suit or action brought (notwithstanding
clause 4.10 above) by any member of the Haleon Group that arises out of or in connection with any of the dividends, distributions or transfers listed at clause 4.10(A) to (H) (inclusive); and 

 

	 	(B)	 any failure by Haleon to take all possible steps required pursuant to clause 4.10 to ensure that any
amounts received by any member of the GSK Group or any member of the Pfizer Group pursuant to any of the dividends, distributions or transfers listed at clause 4.10(A) to (H) (inclusive) can be retained by the relevant member(s) of the
GSK Group and/or the Pfizer Group (as applicable). 

  

	5.	 CIRCULAR, PROSPECTUS AND COMPLIANCE AND REPORTING OBLIGATIONS 

 

	5.1	 Without prejudice to the Sponsors’ Agreements and without prejudice to the generality of the
obligations of the Parties pursuant to the Cosmos SHA, each of the Parties undertakes to each of the other Parties that if, at any time after the date hereof and before the commencement of dealings in Haleon Admission Shares, it comes to its notice
that: 

  

	 	(A)	 any statement contained in the Circular or the Prospectus has become or been discovered to be untrue,
incorrect or misleading in any material respect; 

  

	 	(B)	 it has been discovered that either the Circular or the Prospectus does not contain a statement that it
should contain in order to comply with any applicable Law or the rules of any relevant regulatory authority and that omission is or may be material; 

  

	 	(C)	 there has been a significant change affecting any matter contained in the Circular or the Prospectus which
would have been required to be disclosed in any such document had it occurred before the Posting Date; or 

  
 45 

	 	(D)	 a significant new matter has arisen, the inclusion of information in respect of which would have been
required in the Circular or in the Prospectus had it arisen before the Posting Date, 

 then that Party
shall immediately notify each of the other Parties of the same in writing. 
  

	5.2	 Each of the Parties undertakes: 

 

	 	(A)	 to procure that, prior to Completion, except as required by Law, the FCA or the London Stock Exchange, and
without prejudice to any rights of termination pursuant to any of the Transaction Documents, no action will be taken by it which is inconsistent with: 

  

	 	(i)	 the provisions of this Agreement or any of the other Transaction Documents; or 

 

	 	(ii)	 completion of the Separation Transaction; 

 

	 	(B)	 that it shall comply with applicable legal and regulatory requirements in relation to the Demerger, the
Separation Transaction, the Circular and the Prospectus and the matters and transactions contemplated thereby and by the Transaction Documents; and 

  

	 	(C)	 to notify and consult with the other Parties before taking any action as a consequence of any matter
referred to in clause 5.1, except to the extent that such undertaking to notify and consult with the other Parties inhibits any Party from complying with any of its fiduciary obligations or applicable Law. In the case of Haleon, such action
may include the publication of a supplementary prospectus in accordance with section 87G of FSMA. For the avoidance of doubt, the Parties hereby agree and acknowledge that in the event that any notification is made pursuant to clause 5.1, GSK
(with respect to the Circular) and GSK and Haleon (with respect to the Prospectus) shall determine any additional actions to be taken in connection with such notification, in the case of the Prospectus in consultation with Pfizer, in all cases in
accordance with applicable Law and subject to the terms of the Cosmos SHA. 

  

	5.3	 The Parties agree and undertake to provide all information, updates, notices and similar as required
pursuant to and in accordance with the terms of the Sponsors’ Agreements. 

  

	6.	 AMENDMENTS TO COSMOS SAPA AND NEBA 

 

	6.1	 Each of Pfizer, GSK, GSKCHHL and JVCo hereby agrees and confirms that: 

 

	 	(A)	 the Cosmos SAPA Amendment Agreement is in Agreed Form; and 

 

	 	(B)	 it shall execute and deliver the Cosmos SAPA Amendment Agreement on or prior to the Demerger.

  
 46 

	6.2	 Each of GSK, JVCo and Pfizer hereby agrees and confirms that: 

 

	 	(A)	 the NEBA Amendment Agreement is in Agreed Form; and 

 

	 	(B)	 it shall execute and deliver the NEBA Amendment Agreement on or prior to the Demerger.

  

	7.	 TERMINATION AT ADMISSION OF COSMOS SHA; CONTINUING COSMOS SHA PROVISIONS; AND OTHER POST-COMPLETION
MATTERS 

  

	7.1	 The Parties agree and acknowledge that: 

 

	 	(A)	 the Cosmos SHA shall terminate with effect from Admission, without prejudice to any rights or liabilities
arising under the Cosmos SHA prior to such termination; 

  

	 	(B)	 notwithstanding clause 28.1 of the Cosmos SHA, the provisions of clauses 9, 14, 17.34(C), 17.34(E), 18,
23.7, 26, 27, 28, 30, 33, 36 and 46 of the Cosmos SHA and those provisions of the Cosmos SHA that are expressly stated to continue after termination of the Cosmos SHA shall not continue after termination of the Cosmos SHA and, instead, clause
7.1(C) and Schedule 2 (Continuing Cosmos SHA Provisions and Post-Completion Matters) of this Agreement shall apply; and 

  

	 	(C)	 Schedule 2 (Continuing Cosmos SHA Provisions and Post-Completion Matters) shall apply with effect
from Admission. 

  

	7.2	 Each Party warrants and confirms (for itself and on behalf of its Group) that, as of the date hereof, it is
not aware of any breach of the Cosmos SHA by any party thereto. 

  

	8.	 TAX COVENANT 

Each of GSK, Haleon, GSKCHHL, Pfizer and JVCo hereby agrees and confirms that: 

 

	 	(A)	 the Tax Covenant is in Agreed Form; and 

 

	 	(B)	 it shall execute and deliver the Tax Covenant on or prior to the Demerger, to be effective as at the time of
the Demerger. 

  

	9.	 SETTLEMENT OF OUTSTANDING CROSS-GROUP AMOUNTS 

Any amounts outstanding at Completion between: (i) any member of the GSK Group and any member of the Consumer Healthcare
Group; and/or (ii) any member of the Pfizer Group and any member of the Consumer Healthcare Group shall, to the extent not already settled (unless otherwise agreed by the Parties) be settled by payment to the relevant creditor or payee entity
in the normal course following Completion in accordance with this Agreement, the Demerger Agreement or any other arrangements in effect as at the date of this Agreement, and each Party hereby agrees and undertakes to procure compliance by the
members of its Group with the provisions of this clause 9. 

  
 47 

	10.	 POST-SEPARATION COMMITTEE 

 

	10.1	 Without prejudice to clause 34 (Governing Law and Jurisdiction), and, for the avoidance of
doubt, without prejudice to any consent or decision-making rights which any Party (or any member of any Party’s Group) may have pursuant to the Cosmos Agreements or any of the Transaction Documents, GSK, Pfizer and Haleon shall establish a
post-separation committee to review and assist in the implementation of this Agreement and the Demerger Agreement after Completion, to consider any additional issues arising from the implementation of the Demerger or from the separation of
operations and businesses inherent in the Separation Transaction, and to act as a forum for any disputes which may arise between members of the GSK Group, the Pfizer Group or the Consumer Healthcare Group in relation to the same (the
“Post-Separation Committee”). 

  

	10.2	 The Post-Separation Committee shall meet from time to time as agreed by GSK, Pfizer and Haleon and shall
determine its own remit and procedures. 

  

	10.3	 The members of the Post-Separation Committee shall be such members of senior management or other
representatives of each of GSK, Pfizer and Haleon as they may respectively nominate. The members of the Post-Separation Committee shall be entitled to invite such other persons as they may determine to attend particular meetings of the
Post-Separation Committee. 

  

	11.	 EXCLUSION OF LIABILITY 

 

	11.1	 Without prejudice to the Cosmos SAPA and subject to clause 11.2, the Parties agree and acknowledge that,
except in the case of fraud or serious misconduct, no member of the GSK Group or the Pfizer Group (and none of their officers, employees, agents, consultants, advisers or representatives) shall have any liability or responsibility to any member of
the Consumer Healthcare Group by virtue or reason of its ownership interest in the JVCo Group, or participation in the management or conduct of the JVCo Group’s business in the period from Cosmos Closing to Completion, including as a result of:

  

	 	(A)	 decisions made by the JVCo Board (or any committee of such board), including those in which JVCo Directors
nominated by GSK and/or Pfizer have or may have participated; and/or 

  

	 	(B)	 actions taken by GSK, members of the GSK Group, Pfizer and/or members of the Pfizer Group in their capacity
as shareholders of the JVCo Group, 

 and Haleon and JVCo confirm for themselves and each of their
respective Groups that, except in the case of fraud or serious misconduct, they shall not bring any claim or commence any proceedings against any of GSK, any member of the GSK Group, Pfizer or any member of the Pfizer Group (or any officer,
employee, agent, consultant, adviser or representative of the foregoing) in respect of such matters. 

  
 48 

	11.2	 For the avoidance of doubt, the Parties agree and acknowledge that clause 11.1 does not exclude any
liability of any Party or any member of any Party’s Group in respect of any breach of any agreement between: 

  

	 	(A)	 any member of the GSK Group and any member of the Pfizer Group or the Consumer Healthcare Group; or

  

	 	(B)	 any member of the Pfizer Group and any member of the GSK Group or the Consumer Healthcare Group.

  

	12.	 [RESERVED] 

 

	13.	 EMPLOYEES 

  

	13.1	 Each Party, for itself and on behalf of each member of its Group, hereby waives, and undertakes that it
shall not bring any action or commence proceedings in respect of any claim which arises as a consequence of or by reference to any action or omission prior to Completion that it may have against any employee (or any former employee) of any member of
any other Party’s Group which relates: 

  

	 	(A)	 to that person’s involvement in, or work on or in connection with, the Separation Transaction; or

  

	 	(B)	 actions or omissions of that person in the course of such employment or other role which relate(s) to the
business, operations or affairs of any other Group, 

 provided that the foregoing shall not apply:
(i) insofar as any such claim relates to allegations of fraud or serious misconduct on the part of such person; (ii) where such person has brought a claim against the relevant Party (or a member of the relevant Party’s Group) or the
trustees or managers of a retirement or other compensation or benefits scheme of that Party (or of a member of that Party’s Group); or (iii) to any claims pursuant to any separate agreement entered into with any person. 

 

	13.2	 For the avoidance of doubt, nothing in this clause 13 shall affect the rights that any Party or any
member of any Party’s Group has against employees, consultants or agents of members of its own Group. 

  

	14.	 [RESERVED] 

 

	15.	 RESTRICTIVE COVENANTS 

 

	15.1	 For a period of [***] following Completion, Haleon shall not, and shall procure that each of the Consumer
Healthcare Group Companies shall not, without the prior written consent of GSK, directly or indirectly solicit, endeavour to entice away or offer to employ a [***] who is employed by any GSK Group Company at Completion other than any employee who
responds to a recruitment advertisement published generally and not specifically directed at such persons. 

  

	15.2	 For a period of [***] following Completion, GSK shall not, and shall procure that each of the GSK Group
Companies shall not without the prior written consent of Haleon, directly or indirectly solicit, endeavour to entice away or offer to employ a [***] who is employed by any Consumer Healthcare Group Company at Completion, other than any employee who
responds to a recruitment advertisement published generally and not specifically directed at such persons. 

  
 49 

	16.	 CONFIDENTIALITY 

 

	16.1	 Subject to clause 17.3, each Party shall treat as confidential all information obtained as a
precursor to or as a result of negotiating or entering into or performing this Agreement or which relates to: 

  

	 	(A)	 the provisions of this Agreement; 

 

	 	(B)	 the negotiations relating to this Agreement; or 

 

	 	(C)	 the subject matter of this Agreement. 

 

	16.2	 Each Party shall: 

 

	 	(A)	 not disclose any such confidential information to any person other than: 

 

	 	(i)	 in the case of Pfizer, a director of Haleon nominated by Pfizer; 

 

	 	(ii)	 any of its directors or employees who need to know such information in order to discharge their duties; and

  

	 	(iii)	 other members of its Group (and/or, in the case of GSK: (a) the trustee of the GSK Pension Scheme;
(b) the trustee of the GSK Pension Fund; (c) the trustee of the SmithKline Beecham Pension Plan; and/or (d) the trustee of the SmithKline Beecham Senior Executive Pension Plan); 

 

	 	(B)	 not use any such confidential information other than for the purpose of: 

 

	 	(i)	 in the case of Haleon, conducting the Consumer Healthcare Business; 

 

	 	(ii)	 in the case of Pfizer, GSK or any member of their respective Groups, managing or monitoring its investment
in Haleon; and 

  

	 	(iii)	 in connection with the performance of its obligations and the exercise of its rights under this Agreement;
and 

  

	 	(C)	 procure that any person to whom any such confidential information is disclosed by it complies with the
restrictions contained in this clause 16 as if such person were a party to this Agreement. 

  

	16.3	 Notwithstanding the other provisions of this clause 16, any Party may disclose any such confidential
information: 

  

	 	(A)	 if and to the extent required by Law or for the purpose of any judicial or arbitral proceedings;

  

	 	(B)	 if and to the extent required by any securities exchange or regulatory or Tax or other Governmental Entity
to which that Party or a member of its Group is subject or submits, wherever situated, including (amongst other bodies) the FCA, London Stock Exchange, Panel on Takeovers and Mergers, HMRC, the SEC or the New York Stock Exchange, whether or not the
requirement for information has the force of Law; 

  
 50 

	 	(C)	 to a Tax Authority in connection with the disclosing Party’s (or a member of its Group’s) Tax
affairs; 

  

	 	(D)	 to its advisers, auditors, actual or proposed debt financiers and bankers, provided they have a duty to keep
such information confidential; 

  

	 	(E)	 to the extent the information has come into the public domain through no fault of that Party;

  

	 	(F)	 to the extent the Party (or Parties) to which such information relates has (or have) given prior written
consent to the disclosure; 

  

	 	(G)	 to the extent expressly permitted by this Agreement or to the extent it is expressly permitted to do so
pursuant to any Transaction Document; 

  

	 	(H)	 if and to the extent required in connection with any regulatory consent or clearance process required by
applicable Law; or 

  

	 	(I)	 if it was in the possession of a Party or any of its advisers (in either case as evidenced by written
records) without any obligation of secrecy prior to it being received or held. 

  

	16.4	 Any Party disclosing information pursuant to clauses 16.3(A) or clause 16.3(B) shall (to the
extent permitted by Law) take all such steps as may be reasonable and practicable in the circumstances to agree the contents, form and timing of such disclosure with the Party (or Parties) to whom such information relates before making such
disclosure. 

  

	16.5	 The restrictions contained in this clause 16 shall continue to apply to each Party without limit in
time. 

  

	16.6	 Notwithstanding the foregoing in this clause 16, to the extent that the Cosmos SAPA, the Cosmos SHA
or any other Transaction Document or any other contract pursuant to which any Party or any member of its Group is bound provides that certain information shall be maintained confidential on a basis that is more protective of such information or for
a longer period of time than provided for in this clause 16, then the applicable provisions contained in the Cosmos SAPA, the Cosmos SHA or such other Transaction Document or contract shall control with respect thereto but only to the extent
such provision is more protective or runs for a longer period of time. 

  

	17.	 ANNOUNCEMENTS 

 

	17.1	 Subject to clause 17.2, no announcement or other publication concerning the transactions contemplated
by the Transaction Documents or any ancillary matter shall be made by any Party or member of its Group without the prior written approval of the other Parties, such approval not to be unreasonably withheld or delayed. 

  
 51 

	17.2	 Notwithstanding clause 17.1, any Party or member of its Group may, whenever practicable and
permissible after consultation with the other Parties and subject to the requirements of the Sponsors’ Agreements, make an announcement concerning this Agreement, the Transaction Documents, the Separation Transaction or the Consumer Healthcare
Business, if and to the extent required by: 

  

	 	(A)	 Law or for the purposes of any judicial or arbitral proceedings; or 

 

	 	(B)	 any securities exchange or regulatory or Governmental Entity to which that Party is subject or submits,
wherever situated, including (amongst other bodies) the FCA, London Stock Exchange, Panel on Takeovers and Mergers, HMRC, the SEC or the New York Stock Exchange, whether or not the requirement has the force of Law. 

 

	17.3	 For the avoidance of doubt, nothing in this Agreement shall prohibit any Party or any member of its
respective Group from making any disclosure or public statements regarding its intentions with respect to the Haleon Ordinary Shares, Haleon ADSs in respect thereof or Haleon NVPS that it holds in Haleon. 

 

	17.4	 The restrictions contained in this clause 17 shall continue to apply to each Party without limit in
time unless otherwise agreed between the Parties. 

  

	18.	 WARRANTIES 

Each of the Parties warrants and undertakes to each other as at the date of this Agreement that: 

 

	 	(A)	 it is validly existing and is a company duly incorporated and registered under the Law of its jurisdiction
of incorporation; 

  

	 	(B)	 it has the legal right and full power and authority to enter into and perform this Agreement, which will
constitute valid and binding obligations on it in accordance with its terms; and 

  

	 	(C)	 except as referred to in this Agreement, (including, for the avoidance of doubt, the filings, notices and
approvals associated with the Regulatory Conditions), it: 

  

	 	(i)	 is not required to make any announcement, consultation, notice, report or filing; and 

 

	 	(ii)	 does not require any consent, approval, registration, authorisation or permit, 

in each case with or from any Governmental Entity in connection with the performance of this Agreement. 

 

	19.	 COSTS AND EXPENSES 

 

	19.1	 The Parties hereby agree, notwithstanding the terms of the Cosmos SHA (including, without limitation, clause
17.34(G) thereof), to the allocation of certain costs and expenses in connection with the Separation Transaction (i) as specified in Schedule 3 (Allocation of Costs and Expenses) or (ii) which constitute matters that are the subject of
any indemnity pursuant to the Tax Covenant, and that the Party identified as responsible in Schedule 3 (Allocation of Costs and Expenses) or pursuant to the Tax Covenant, as applicable, shall pay such costs and expenses and that such
allocation as specified in Schedule 3 (Allocation of Costs and Expenses) or pursuant to the Tax Covenant shall apply in priority to the terms of the Cosmos SHA (including as restated in Schedule 2 (Continuing Cosmos SHA
Provisions and Post-Completion Matters) of this Agreement). 

  
 52 

	19.2	 The Parties hereby agree that: 

 

	 	(A)	 in respect of costs and expenses in connection with the Separation Transaction that are not allocated
pursuant to the operation of clause 19.1 and Schedule 3 (Allocation of Costs and Expenses) or the Tax Covenant, the provisions of paragraph 6 of Part A of Schedule 2 (Continuing Cosmos SHA Provisions and
Post-Completion Matters) shall apply to allocate such costs and expenses; and 

  

	 	(B)	 where clause 19.2(A) applies, the Party identified as responsible pursuant to the application of
paragraph 6 of Part A of Schedule 2 (Continuing Cosmos SHA Provisions and Post-Completion Matters) shall pay such costs and expenses. 

  

	19.3	 Except as otherwise provided for in this Agreement or any Transaction Document, each Party shall pay its own
costs and expenses in relation to the negotiation, preparation, execution and carrying into effect of this Agreement and the other Transaction Documents (and any other document entered into pursuant to this Agreement or any such document).

  

	20.	 PAYMENTS 

  

	20.1	 Payments due to be made under this Agreement shall, if not paid within thirty (30) days of the due date, and
except to the extent the liability giving rise to the payment compensates the recipient for late payment by virtue of its extending to interest and penalties, carry interest at a rate of (i) two (2) per cent. above the base lending rate from time to
time of the Bank of England, or (ii) if such base lending rate is less than zero, at two (2) per cent. (the “Agreed Rate”) for the period from the date falling thirty (30) days after the due date to the date of actual payment.

  

	20.2	 Payments due to be made under this Agreement shall be free and clear of all deductions, withholdings, set-offs, or counterclaims whatsoever, except as may be required by Law. If any deductions or withholdings are required by Law, the paying party shall be obliged to pay such sum as will, after such deduction,
withholdings, set-off or counter-claim has been made, leave the receiving party with the same amount as it would have been entitled to receive in the absence of any such requirement to make such deduction or
withholding. 

  

	21.	 RECHARGE TO HALEON 

Subject to Admission having occurred, JVCo shall, following Completion, charge to Haleon an amount equal to all costs and
expenses incurred by JVCo in connection with Admission to the extent not otherwise reimbursed pursuant to the Transaction Documents, together with an amount in respect of VAT on the relevant amount where applicable. 

 

	22.	 NOTICES 

  

	22.1	 A notice under this Agreement shall only be effective if it is in writing.
E-mail is permitted. Any notice validly served on one member of any Party’s Group in accordance with this clause 22 shall be deemed to have been served on each member of such Party’s Group.

  
 53 

	22.2	 Notices under this Agreement shall be sent to a Party at its address and for the attention of the
individuals set out below: 

  

			
	GSK	  	
		
	Address:	  	
	E-mail address:	  	
	For the attention of:	  	
		
	Pfizer	  	
		
	Address:	  	
	E-mail address:	  	
	For the attention of:	  	
		
	Haleon	  	
		
	Address:	  	
	E-mail address:	  	
	For the attention of:	  	
		
	JVCo	  	
		
	Address:	  	
	E-mail address:	  	
	For the attention of:	  	
		
	GSKCHHL	  	
		
	Address:	  	
	E-mail address:	  	
	For the attention of:	  	
		
	PFCHHL	  	
		
	Address:	  	
	E-mail address:	  	
	For the attention of:	  	

 provided that a Party may change its notice details on giving notice to the other Parties of
the change in accordance with this clause 22. That notice shall only be effective on the date falling five (5) clear Business Days after the notification has been received or such later date as may be specified in the notice. 

  
 54 

	22.3	 Any notice given under this Agreement shall be deemed to have been duly given as follows:

  

	 	(A)	 if delivered personally, on delivery; 

 

	 	(B)	 if sent by first class inland post, two (2) clear Business Days after the date of posting;

  

	 	(C)	 if sent by airmail, six (6) clear Business Days after the date of posting; and 

 

	 	(D)	 if sent by e-mail, when despatched. 

 

	22.4	 Any notice given under this Agreement outside Working Hours in the place to which it is addressed shall be
deemed not to have been given until the start of the next period of Working Hours in such place. 

  

	22.5	 A notice under or in connection with this Agreement shall not be invalid by reason of any mistake or
typographical error or if the contents are incomplete, provided it should have been reasonably clear to the recipient what the correct or missing particulars should have been. 

 

	22.6	 The provisions of this clause 22 shall not apply in relation to the service of Service Documents.

  

	23.	 ENTIRE AGREEMENT 

 

	23.1	 This Agreement, any other Transaction Document and any other agreement or document entered into by each of
the Parties in connection with any such document, including the Cosmos SHA, the Cosmos SAPA and the other agreements and documents entered into in connection therewith (together, the “Cosmos Agreements”), together constitute the
whole and only agreement between the Parties relating to the subject matter of this Agreement, any other Transaction Document and any other agreement or document entered into by each of the Parties in connection with any such document.

  

	23.2	 All terms of the Cosmos Agreements shall remain unchanged and in full force and effect and nothing in this
Agreement or in any of the Transaction Documents shall amend, limit or otherwise modify the parties’ respective rights and obligations under the Cosmos Agreements, in each case except as, and only to the extent, expressly provided in this
Agreement or in any of the Transaction Documents. 

  

	23.3	 [Reserved] 

  

	23.4	 Each Party acknowledges that in entering into this Agreement, any other Transaction Document and any other
agreement or document entered into by each of the Parties in connection with any such document, it is not relying upon any pre contractual statement which is not set out in this Agreement, any other Transaction Document, any Cosmos Agreement or any
other agreement or document entered into by each of the Parties in connection with any such document. 

  
 55 

	23.5	 Except in the case of fraud, no Party shall have any right of action against any other Party (or their
respective Connected Persons) arising out of or in connection with any pre contractual statement except to the extent that it is repeated in this Agreement or in a Transaction Document or any Cosmos Agreement or in any other agreement or document
entered into by each of the Parties in connection with any such document. 

  

	23.6	 Except in the case of fraud and for any liability in respect of a breach of this Agreement or any
Transaction Document or any Cosmos Agreement, no Party (nor any of its Connected Persons) shall owe any duty of care or have any liability in tort or otherwise to any other Party (or its Connected Persons) in relation to Haleon, JVCo or the Consumer
Healthcare Business. 

  

	23.7	 For the purposes of this clause 23, “pre contractual statement” means any draft,
agreement, undertaking, representation, warranty, promise, assurance or arrangement of any nature whatsoever, whether or not in writing, relating to the subject matter of this Agreement or any other Transaction Document or in any other agreement or
document entered into in connection with any such document (as the case may be) made or given by any person at any time prior to the date of this Agreement or any other Transaction Document, except for those contained in any Transaction Document or
any Cosmos Agreement. 

  

	23.8	 Each Party agrees to the terms of this clause 23 on its own behalf and as agent for each of its
Connected Persons. The provisions of this clause 23 shall not limit, supersede or otherwise affect any limitation of damages or remedies provisions that are expressly set forth in any Transaction Document or any Cosmos Agreement.

  

	24.	 CONTRACTS (RIGHTS OF THIRD PARTIES) ACT 1999 

 

	24.1	 The Parties agree that: 

 

	 	(A)	 certain provisions of this Agreement confer a benefit on members of the Parties’ respective Groups,
their respective Connected Persons and such other third parties (each a “Relevant Third Party”) and, subject to the remaining provisions of this clause 24, are intended to be enforceable by each of the Relevant Third Parties
by virtue of the Contracts (Rights of Third Parties) Act 1999, provided that the Party in the same Group as (or with the relevant connection to) the Relevant Third Party shall have the sole conduct of any action to enforce such right on behalf of
such Relevant Third Party; and 

  

	 	(B)	 notwithstanding the provisions of clause 24.1(A), this Agreement may be rescinded or varied in any
way and at any time by the Parties to this Agreement without the consent of any Relevant Third Party. 

  

	24.2	 Save as set out in clause 24.1(A), a person who is not a Party shall have no right under the
Contracts (Rights of Third Parties) Act 1999 or any other statutory provision to enforce any of its terms. 

  
 56 

	25.	 ASSIGNMENT 

No Party shall, without the prior written consent of the other Parties: 

 

	 	(A)	 assign or purport to assign all or any part of the benefit of, or its rights or benefits under, this
Agreement (together with any causes of action arising in connection with any of them); 

  

	 	(B)	 make a declaration of trust in respect of or enter into any arrangement whereby it agrees to hold in trust
for any other person all or any part of the benefit of, or its rights or benefits under, this Agreement; 

  

	 	(C)	 sub-contract or enter into any arrangement whereby another person is
to perform any or all of its obligations under this Agreement; 

  

	 	(D)	 transfer or charge any of its rights or obligations under this Agreement; or 

 

	 	(E)	 grant, declare, create or dispose of any right or interest in, in whole or in part, this Agreement,

 and any purported assignment in contravention of this clause 25 shall be null and void ab
initio. 
  

	26.	 REMEDIES AND WAIVERS 

 

	26.1	 No delay or omission by any Party in exercising any right, power or remedy provided by Law or under this
Agreement shall: 

  

	 	(A)	 affect that right, power or remedy; or 

 

	 	(B)	 operate as a waiver or variation of it. 

 

	26.2	 The single or partial exercise of any right, power or remedy provided by Law or under this Agreement shall
not preclude any other or further exercise of it or the exercise of any other right, power or remedy. 

  

	26.3	 The rights and remedies of each Party under, or pursuant to, this Agreement are cumulative, may be exercised
as often as such Party considers appropriate and are in addition to its rights and remedies under general Law. 

  

	26.4	 Notwithstanding any express remedies provided under this Agreement and without prejudice to any other right
or remedy which any Party may have, each Party acknowledges and agrees that damages alone would not be an adequate remedy for any breach by it of the provisions of this Agreement, so that in the event of a breach or anticipated breach of such
provisions, the remedies of injunction, an order for specific performance and/or other equitable remedies would be available. Furthermore, each Party acknowledges and agrees that it will not raise any objection to the application by or on behalf of
another Party or any member of its Group for any such remedies. 

  
 57 

	27.	 VARIATION 

  

	27.1	 No variation of this Agreement shall be valid unless it is in writing and duly executed by or on behalf of
all the Parties to it. 

  

	27.2	 If this Agreement is varied: 

 

	 	(A)	 the variation shall not constitute a general waiver of any provisions of this Agreement;

  

	 	(B)	 the variation shall not affect any rights, obligations or liabilities under this Agreement that have already
accrued up to the date of variation; and 

  

	 	(C)	 the rights and obligations of the Parties under this Agreement shall remain in full force and effect, except
as, and only to the extent that, they are so varied. 

  

	28.	 FURTHER ASSURANCE 

Each Party shall (and shall use reasonable endeavours to procure that any relevant Third Party shall) at its own cost, from
time to time on request, do all acts and/or execute all documents in a form reasonably satisfactory to any other Party which that other Party may reasonably consider necessary for giving full effect to this Agreement and securing to that other Party
the full benefit of the rights, powers and remedies conferred upon that other Party in this Agreement, in each case subject to the terms and conditions set forth in this Agreement. 

 

	29.	 NO PARTNERSHIP OR AGENCY 

Nothing in this Agreement (or in any other Transaction Document or any other arrangements contemplated hereby or therein) shall
constitute a partnership between the Parties or any of them or make the agent of any other Party for any purpose. No party has any authority or power to bind, to contract in the name of, or to create a liability for another party in any way or for
any purpose save as specifically set out in this Agreement. 
  

	30.	 INVALIDITY 

 

	30.1	 If at any time any provision (or part of any provision) of this Agreement is or becomes illegal, invalid or
unenforceable in any respect under the Law of any jurisdiction, that shall not affect or impair: 

  

	 	(A)	 the legality, validity or enforceability in that jurisdiction of any other (or the remainder of a) provision
of this Agreement; or 

  

	 	(B)	 the legality, validity or enforceability under the Law of any other jurisdiction of that or any other
provision of this Agreement. 

  

	30.2	 Each of the provisions of this Agreement is severable. 

  
 58 

	30.3	 If and to the extent that any provision of this Agreement: 

 

	 	(A)	 is held to be, or becomes, invalid or unenforceable under the Law of any jurisdiction; but

  

	 	(B)	 would be valid, binding and enforceable if some part of the provision were deleted or amended,

 then the provision shall apply with the minimum modifications necessary to make it valid, binding and
enforceable. All other provisions of this Agreement shall remain in force. 
  

	31.	 CONTINUING EFFECT 

Each provision of this Agreement shall continue in full force and effect after Completion, unless such provision has been fully
performed on or before Completion. 
  

	32.	 COUNTERPARTS 

 

	32.1	 This Agreement may be executed in any number of counterparts, and by the Parties on separate counterparts,
but shall not be effective until each Party has executed at least one counterpart. Each counterpart shall constitute an original of this Agreement, but all the counterparts shall together constitute but one and the same instrument.

  

	32.2	 Delivery of a counterpart of this Agreement by e-mail attachment
shall be an effective mode of delivery. 

  

	33.	 LANGUAGE 

Each notice or communication under or in connection with this Agreement shall be in English. 

 

	34.	 GOVERNING LAW AND JURISDICTION 

 

	34.1	 This Agreement is to be governed by and construed in accordance with English law. Any matter, claim or
dispute arising out of or in connection with this Agreement, whether contractual or non-contractual, is to be governed by and determined in accordance with English law. 

 

	34.2	 The courts of England are to have exclusive jurisdiction to settle any dispute arising out of or in
connection with this Agreement. Any Proceedings shall be brought only in the courts of England. 

  

	34.3	 Each Party waives (and agrees not to raise) any objection, on the ground of forum non conveniens or
on any other ground, to the taking of Proceedings in the courts of England. Each Party also agrees that a judgment against it in Proceedings brought in England shall be conclusive and binding upon it and may be enforced in any other jurisdiction.

  

	34.4	 Each Party irrevocably submits and agrees to submit to the jurisdiction of the courts of England.

  
 59 

	35.	 AGENT FOR SERVICE 

 

	35.1	 Each of Pfizer, Anacor and PFCHHL irrevocably appoints Pfizer Limited, c/o UK Legal Department, Pfizer Ltd
(IPC 3-1), Walton Oaks, Dorking Road, Tadworth, Surrey KT20 7NS, to be its agent for the receipt of Service Documents. Each such Party agrees that any Service Document may be effectively served on it in
connection with Proceedings in England and Wales by service on its agent effected in any manner permitted by the Civil Procedure Rules. 

  

	35.2	 If the agent at any time ceases for any reason to act as such, Pfizer, Anacor and PFCHHL shall each appoint
a replacement agent having an address for service in England or Wales and shall notify the other Parties of the name and address of the replacement agent. Failing such appointment and notification, JVCo shall be entitled by notice to Pfizer to
appoint a replacement agent to act on behalf of Pfizer, Anacor and PFCHHL, provided that Pfizer shall be entitled, by notice to JVCo, to replace that agent with a replacement agent having an address for service in England or Wales. The provisions of
this clause 35 applying to service on an agent apply equally to service on a replacement agent. 

  

	35.3	 A copy of any Service Document served on an agent appointed in accordance with clauses 35.1 or
35.2 shall be sent by post to Pfizer, Anacor or PFCHHL (as applicable). Failure or delay in so doing shall not prejudice the effectiveness of service of the Service Document. 

 

	35.4	 Without prejudice to clauses 35.1 to 35.3, any Party without an address for service in England
or Wales shall appoint, and keep appointed at all times, an agent for service with an address for service in England or Wales and shall notify the other Parties of the name and address of its appointed agent for service. Failing such appointment and
notification, JVCo shall be entitled by notice to such Party to appoint an agent to act on behalf of such Party, provided that such Party shall be entitled, by notice to the other Parties, to replace that agent with a replacement agent having an
address for service in England or Wales. Such Party agrees that any Service Document may be effectively served on it in connection with Proceedings in England and Wales by service on its agent effected in any manner permitted by the Civil Procedure
Rules. 

  

	35.5	 “Service Document” means a claim form, application notice, order, judgment or other
document relating to any Proceedings. 

  
 60 

 IN WITNESS of which this document has been executed as a deed on the date which appears on page 1 above.

  

					
	 SIGNED as a DEED by 

DAVID REDFERN as
 attorney
for GSK PLC in
 the presence of: 
	  	 )
	  	 /s/ David
Redfern                                

	  	 )
	  	 (Signature of attorney)

	  	 )
	  	 DAVID REDFERN as attorney for

GSK PLC

	  	 )

  

			
	 Witness’s signature:
	 	/s/ Diane Hewett
		
	 Name (print):
	 	Diane Hewett
		
	 Occupation:
	 	Homemaker
		
	 Address:
	 	 

 [Separation Co-operation and Implementation Agreement - signature page] 

  
 61 

					
	Executed as a deed by	  	 )
	  	 /s/ Deborah Baron
                            

	PFIZER INC.	  	 )
	  	(Authorised signatory)
	acting by DEBORAH BARON	  	 )
	  	
	who, in accordance with the laws of the	  	 )
	  	
	territory in which PFIZER INC. is	  	 )
	  	
	incorporated, is acting under the	  	 )
	  	
	authority of 	  	 )
	  	
	PFIZER INC.	  	 )
	  	

  
 [Separation
Co-operation and Implementation Agreement - signature page] 

  
 62 

					
	 SIGNED as a DEED by 

AMANDA MELLOR as
 attorney
for HALEON PLC in
 the presence of: 
	  	 )
	  	 /s/ Amanda
Mellor                                        

	  	 )
	  	 (Signature of attorney)

	  	 )
	  	 AMANDA MELLOR as attorney for

HALEON PLC

	  	 )

  

			
	 Witness’s signature:
	 	/s/ Bridget Creegan
		
	 Name (print):
	 	Bridget Creegan
		
	 Occupation:
	 	Chartered Company Secretary
		
	 Address:
	 	 

  

  
 [Separation
Co-operation and Implementation Agreement - signature page] 

  
 63 

					
	 Executed as a deed by
	  	 )
	  	 /s/ David
Redfern                        

	GLAXOSMITHKLINE CONSUMER HEALTHCARE	  	 )
	  	 Director

	 HOLDINGS (NO.2) LIMITED
	  	 )
	  	
	 acting by DAVID REDFERN a director
	  	 )
	  	
	 in the presence of:
	  	 )
	  	

  

			
	 Witness’s signature:
	 	/s/ Diane Hewett
		
	 Name (print):
	 	Diane Hewett
		
	 Occupation:
	 	Homemaker
		
	 Address:
	 	 

  

  
 [Separation
Co-operation and Implementation Agreement - signature page] 

  
 64 

					
	 SIGNED as a DEED by
	 	)	  	/s/ David Redfern                        
	DAVID REDFERN as attorney for	 	)	  	 (Signature of attorney)

	GLAXOSMITHKLINE CONSUMER HEALTHCARE	 	)	  	 DAVID REDFERN as attorney for

	HOLDINGS LIMITED 	 	)	  	 GLAXOSMITHKLINE CONSUMER HEALTHCARE

	 in the presence of:
	 	)	  	HOLDINGS LIMITED

  

			
	 Witness’s signature:
	 	/s/ Diane Hewett
		
	 Name (print):
	 	Diane Hewett
		
	 Occupation:
	 	Homemaker
		
	 Address:
	 	 

 [Separation Co-operation and Implementation Agreement - signature page] 

  
 65 

					
	 EXECUTED as a DEED by
	  	 )
	  	 /s/ Andrew J.
Muratore                        

	 ANACOR PHARMACEUTICALS, INC. 
	  	 )
	  	(Authorised signatory)
	 acting by ANDREW J. MURATORE
	  	 )
	  	
	 who, in accordance with the laws of the
	  	 )
	  	
	 territory in which ANACOR PHARMACEUTICALS, INC. 
	  	 )
	  	
	 is incorporated, is acting under the
	  	 )
	  	
	 authority of ANACOR PHARMACEUTICALS, INC.
	  	 )
	  	

 [Separation Co-operation and Implementation Agreement - signature page] 

  
 66 

					
	 Executed as a deed by
	  	 )
	  	 /s/ Andrew J.
Muratore                        

	 PF CONSUMER HEALTHCARE
	  	 )
	  	(Authorised signatory)
	 HOLDINGS LLC
	  	 )
	  	
	 acting by ANDREW J. MURATORE
	  	 )
	  	
	 who, in accordance with the laws of the
	  	 )
	  	
	 territory in which PF CONSUMER
	  	 )
	  	
	 HEALTHCARE HOLDINGS LLC is
	  	 )
	  	
	 incorporated, is acting under the
	  	 )
	  	
	 authority of PF CONSUMER HEALTHCARE
	  	 )
	  	
	 HOLDINGS LLC
	  	 )
	  	
		  	 )
	  	
		  	 )
	  	

 [Separation Co-operation and Implementation Agreement - signature page] 

  
 67EX-4.10

 Exhibit 4.10 

DATED 1 June 2022 
 GSK
PLC 
 and 
 HALEON PLC

  
  

EXCHANGE AGREEMENT 
  

 
 Slaughter and
May 
 One Bunhill Row 
 London
EC1Y 8YY 
 (SRN/TGXF) 
 Exhibits and schedules
have been omitted pursuant to the Instructions as to Exhibits in Form 20-F and will be furnished on a supplemental basis to the Securities and Exchange Commission upon request. 

 CONTENTS 
  

							
	 	 	 	  	Page	 
	 1.
	 	 Interpretation
	  	 	5	 
			
	 2.
	 	 Condition Precedent
	  	 	25	 
			
	 3.
	 	 Termination
	  	 	26	 
			
	 4.
	 	 Transfer and Issue of Shares
	  	 	27	 
			
	 5.
	 	 Completion Obligations
	  	 	28	 
			
	 6.
	 	 Tax
	  	 	29	 
			
	 7.
	 	 GSK Exchange Indemnities and SLP Exchange Indemnities
	  	 	30	 
			
	 8.
	 	 Confidentiality
	  	 	31	 
			
	 9.
	 	 Announcements
	  	 	33	 
			
	 10.
	 	 Warranties
	  	 	33	 
			
	 11.
	 	 Costs and Expenses
	  	 	34	 
			
	 12.
	 	 Payments
	  	 	35	 
			
	 13.
	 	 Further Assurance
	  	 	35	 
			
	 14.
	 	 Notices
	  	 	36	 
			
	 15.
	 	 Entire Agreement
	  	 	37	 
			
	 16.
	 	 Contracts (Rights of Third Parties) Act 1999
	  	 	38	 
			
	 17.
	 	 Assignment
	  	 	38	 
			
	 18.
	 	 Remedies and Waivers
	  	 	39	 
			
	 19.
	 	 Variation
	  	 	39	 
			
	 20.
	 	 No partnership or agency
	  	 	40	 
			
	 21.
	 	 Invalidity
	  	 	40	 
			
	 22.
	 	 Continuing effect
	  	 	40	 
			
	 23.
	 	 Counterparts
	  	 	40	 
			
	 24.
	 	 Language
	  	 	41	 
			
	 25.
	 	 Governing Law and Jurisdiction
	  	 	41	 

 SCHEDULES 
  

					
	 Schedule 1 Provisions on Claims under the GSK Exchange Indemnities and the SLP Exchange
Indemnities
	  	 	45	 

 This Agreement is made as a deed on 1 June 2022. 

BETWEEN: 
  

	1.	 GSK PLC, a public limited company incorporated in England with number 03888792, having its registered
office at 980 Great West Road, Brentford, Middlesex, TW8 9GS (“GSK”); and 

  

	2.	 HALEON PLC, a public limited company incorporated in England with number 13691224, having its
registered office at 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS (“Haleon”). 

 WHEREAS:

  

	(A)	 GSK intends to demerge approximately 80.1% of its interest in the Consumer Healthcare Business, by way of an
indirect dividend demerger, for the purpose of benefiting both the Consumer Healthcare Business and the GSK Business. GSK also intends that, subsequent to such demerger, Haleon, as the holder of the Consumer Healthcare Business, shall be listed on
the London Stock Exchange as a separate and independently managed group. 

  

	(B)	 Haleon is a company that is not part of the GSK Group or the Pfizer Group. GSKCHHL is a subsidiary of GSK
with 100% of its A Shares and B Shares held by GSK and 100% of its C Shares held by the SLPs (which comprise all ownership interests of whatever nature in GSKCHHL). GSKCHHL is (and will be immediately following the Demerger Completion and the
completion of the Share Exchanges) the registered holder of 100% of the issued ordinary A shares and 100% of the issued preference shares in JVCo, which is the current parent company of the Consumer Healthcare Group. PFCHHL is, at the date of this
Agreement, a subsidiary of Anacor, with 100% of its common interests (which comprise all ownership interests of whatever nature in PFCHHL) held by Anacor. Pfizer and Anacor intend to effect the PFCHHL Transfer as soon as possible following
satisfaction of the final Regulatory Condition. Following completion of the PFCHHL Transfer, 100% of the common interests of PFCHHL will be held by Pfizer until completion of the Pfizer Share Exchange. PFCHHL is (and will be immediately following
the Demerger Completion and the completion of the Share Exchanges) the registered holder of 100% of the issued ordinary B shares in JVCo. 

  

	(C)	 GSK and Haleon have conditionally agreed on the terms of the Demerger Agreement pursuant to which GSK will
transfer to Haleon the Relevant GSKCHHL Shares (being all of the A Shares, representing in excess of 80% of the entire issued ordinary share capital of GSKCHHL, which comprises A Shares, B Shares and C Shares) in consideration for which Haleon will
allot and issue, credited as fully paid up, the Haleon Demerger Shares to the Qualifying GSK Shareholders, in satisfaction of the Demerger Dividend to be declared on the GSK Shares pursuant to the Demerger Resolution. 

 

	(D)	 Separately, pursuant to: (i) this Agreement, GSK shall agree to transfer GSK’s entire shareholding
of B Shares to Haleon in exchange for Haleon issuing the GSK Haleon Exchange Shares to GSK; (ii) the Pfizer Exchange Agreement, Anacor and Pfizer have agreed that the Pfizer Group PFCHHL Transferor shall transfer the PFCHHL Interests (being all
of the common interests in PFCHHL (which comprise all ownership interests of whatever nature in PFCHHL) and which shall be held by Anacor until the commencement of the PFCHHL Transfer and by Pfizer following completion of the PFCHHL Transfer until
completion of the Pfizer Share Exchange) to Haleon in exchange for Haleon issuing the Pfizer Haleon Exchange Shares (comprising new Haleon Ordinary Shares and the Haleon NVPS) to the Pfizer Group PFCHHL Transferor and the Depositary and, following
which, the Pfizer Group PFCHHL Transferor will sell the Haleon NVPS immediately upon receipt of such Haleon NVPS pursuant to a binding commitment made prior to its transfer of the PFCHHL Interests to Haleon; and (iii) the SLP Exchange
Agreement, each SLP has agreed to transfer its entire shareholding of C Shares to Haleon in exchange for Haleon issuing the 

  
 3 

	 	 
applicable portion of the SLP Haleon Exchange Shares to each such SLP. For U.S. federal income tax purposes, it is intended that the transfer of GSK’s entire shareholding of B Shares to
Haleon in exchange for Haleon issuing the GSK Haleon Exchange Shares to GSK pursuant to this Agreement constitute a taxable exchange under Section 1001 of the Internal Revenue Code of 1986, as amended. 

 

	(E)	 As a result of the Demerger Completion and the completion of the Share Exchanges: (i) (A) the Pfizer
Group PFCHHL Transferor and the Depositary (with respect to the Haleon Ordinary Shares held on behalf of the Pfizer Group PFCHHL Transferor) will hold, in aggregate, 32% of the issued Haleon Ordinary Shares (rounded to the nearest whole ordinary
share) and 100% of the issued preference shares in Haleon, it being understood that any Haleon Ordinary Shares issued to the Depositary pursuant to the Pfizer Exchange Agreement will be held by the Depositary on behalf of the Pfizer Group PFCHHL
Transferor in connection with and under the establishment of the Haleon ADR Programme (B) the Qualifying GSK Shareholders will hold at least approximately 54.47% of the issued ordinary shares of Haleon, (C) GSK will hold up to
approximately 6.03% of the issued ordinary shares of Haleon (and with the issued ordinary shares comprised in (B) and (C) together representing 60.5% of the issued ordinary shares of Haleon (rounded to the nearest whole ordinary share)) and
(D) the SLPs will collectively hold 7.5% of the issued ordinary shares of Haleon (rounded to the nearest whole ordinary share); (ii) Haleon will hold 100% of the issued ordinary shares and common interests, respectively, in each of GSKCHHL and
PFCHHL; and (iii) (1) GSKCHHL will hold 100% of the issued ordinary A shares and 100% of the issued preference shares in JVCo and (2) PFCHHL will hold 100% of the issued ordinary B shares in JVCo. 

 

	(F)	 It is also intended that, prior to commencement of the Demerger Completion Steps, the relevant Parties will
have taken all necessary actions so that each of the following actions shall have occurred: (i) JVCo will declare and pay the Final Quarterly Dividend, the Final Sweep Dividend and, separately, the
Pre-Separation Dividend to GSKCHHL and PFCHHL in accordance with the Cosmos SHA and the Treasury Side Letter; (ii) GSKCHHL will declare and pay the Pre-Separation
GSKCHHL Onward Dividend to GSK in respect of the A Shares and the B Shares; (iii) GSKCHHL will declare and pay the Final Sweep GSKCHHL Onward Dividend to GSK in respect of the A Shares and the B Shares and to the SLPs in respect of the C
Shares; (iv) GSKCHHL will declare and pay the Final Quarterly GSKCHHL Onward Dividend to GSK in respect of the A Shares and the B Shares and (if and only to the extent the SLPs are entitled to receive such dividend under the GSKCHHL Articles of
Association) to the SLPs in respect of the C Shares; and (v) PFCHHL will declare and pay or otherwise effect the Pre-Separation PFCHHL Onward Dividend, the Final Quarterly PFCHHL Onward Dividend and the
Final Sweep PFCHHL Onward Dividend to Anacor or, if completion of the PFCHHL Transfer has occurred prior to such time, Pfizer. 

  

	(G)	 It is further noted that Haleon redeemed the Redeemable Shares on 11 April 2022. 

 

	(H)	 In connection with the proposed listing of Haleon and prior to the Demerger, it is also intended that:
(i) the Prospectus and Circular shall be published and posted; (ii) the GSK General Meeting shall take place to, among other things, approve the Demerger and the relevant parts of the Separation Transaction as a Class 1 transaction
for the purposes of Chapter 10 of the Listing Rules and approve certain transactions related to the Demerger and the Separation Transaction as related party transactions for the purposes of Chapter 11 of the Listing Rules; (iii) the Haleon ADR
Programme shall be established to come into effect on or around the time of Admission; and (iv) following payment by JVCo of the dividends referred to in recital (F)(i) above, the ATB Re-organisation
shall be completed. 

  
 4 

	(I)	 Following the Demerger Completion and the completion of the Share Exchanges, it is also intended that
Admission shall occur, subsequent to which GSK shall implement the GSK Share Consolidation. 

  

	(J)	 This Agreement, which is a deed, sets out the terms on which the GSK Share Exchange shall be effected and
certain terms on which relations between GSK and Haleon will be governed following Completion. 

 THIS DEED
PROVIDES as follows: 
  

	1.	 INTERPRETATION 

 

	1.1	 In this Agreement and the Schedules: 

 

					
	       
	 	 “Admission”
	  	 means admission of the Haleon Admission Shares to the premium listing segment of the Official List of the FCA and to
trading on the London Stock Exchange’s main market for listed securities;

			
		 	 “Agreed Rate”
	  	 has the meaning given to it in clause 12.1;

			
		 	 “Anacor”
	  	 means Anacor Pharmaceuticals, Inc., a corporation incorporated under the laws of Delaware whose registered office is at 235
East 42nd Street, New York, New York 10017;

			
		 	 “Ancillary Agreements”
	  	 means the Listing Ancillary Agreements and the Separation Ancillary Agreements;

			
		 	 “Argentina NEBA”
	  	 means the letter agreement relating to the retention, operation and transfer of the manufacturing site located in Buenos
Aires, Argentina entered into or to be entered into between GSK and JVCo on or around the date of the SCIA;

			
		 	 “A Shares”
	  	 means the A ordinary shares of £1.00 each in the share capital of GSKCHHL, all of which are fully paid and held as at
the date of this Agreement by GSK and which, together with the B Shares and the C Shares, comprise all ownership interests of whatever nature in GSKCHHL;

			
		 	 “ATB Re-organisation”
	  	 means all of (i) the distribution in specie of the ordinary shares of GSKCHH3 by JVCo to GSKCHHL only, (ii) the
distribution of £53.125m by JVCo to GSKCHHL only, and (iii) the conversion of a portion of A shares in the share capital of JVCo held by GSKCHHL (of equivalent value to the distribution mentioned at (i)) into preference shares in the
share capital of JVCo in a manner consistent with the SCA Side Letter;

  
 5 

					
	       
	 	 “ATFA”
	  	 means the asset transfer framework agreement between GSK, GSKCHHL and JVCo entered into on or around the date of the
SCIA;

			
		 	 “Brazil ATFA”
	  	 means the asset transfer framework agreement relating to the transfer of the manufacturing site located in
Jacarepaguá, Brazil entered into or to be entered into between GSK, GSKCHHL and JVCo on or around the date of the SCIA;

			
		 	 “B Shares”
	  	 means the B ordinary shares of £1.00 each in the share capital of GSKCHHL, all of which are fully paid and held as at
the date of this Agreement by GSK and which, together with the A Shares and the C Shares, comprise all ownership interests of whatever nature in GSKCHHL;

			
		 	 “Business Day”
	  	 means a day (other than a Saturday or Sunday) on which banks are open for general business in London, UK;

			
		 	 “Circular”
	  	 means the circular to be dated with the Posting Date and to be sent to the shareholders of GSK in connection with the
Demerger, including a notice of general meeting of GSK;

			
		 	 “Co-Existence Agreement”
	  	 means the co-existence agreement in respect of certain trade marks and domain names
of the GSK Group and Consumer Healthcare Group entered into or to be entered into between Glaxo Group Limited, SmithKline Beecham Limited and Haleon on or around the date of the SCIA;

			
		 	 “Completion”
	  	 means the time and date of completion of the GSK Share Exchange pursuant to and in accordance with this
Agreement;

			
		 	 “Condition Precedent”
	  	 means the condition set out in clause 2.1 (Condition Precedent);

			
		 	 “Connected Persons”
	  	 means, in relation to a Party, any member of its Group and any officer, employee, agent, adviser or representative of that
Party or any member of its Group, in each case, from time to time;

			
		 	 “Consumer Healthcare Business”
	  	 means the consumer healthcare business which, as at the date of Demerger Completion is operated within the JVCo Group and
any other asset or business of the consumer healthcare business that, as at the date of Demerger Completion, is contemplated to be operated within the Haleon Group after Separation Completion pursuant to the ATFA, the Argentina NEBA and/or the
Brazil ATFA;

  
 6 

					
	       
	 	“Consumer Healthcare Group”	  	 means:
  

(i) prior to Demerger Completion, the JVCo Group; and

 

(ii)  from Demerger Completion, the Haleon Group;

			
		 	“Consumer Healthcare Group Companies”	  	 means any member of the Consumer Healthcare Group from time to time, and “Consumer Healthcare Group
Company” shall be construed accordingly;

			
		 	“Consumer Manufacturing and Supply Agreement”	  	 means the manufacturing and supply agreement entered into or to be entered into between GlaxoSmithKline Consumer Trading
Services Limited as supplier and GlaxoSmithKline Trading Services Limited as purchaser on or around the date of the SCIA;

			
		 	“Consumer Quality Agreement”	  	 means the quality agreement to be entered into between GlaxoSmithKline Consumer Trading Services Limited and
GlaxoSmithKline Trading Services Limited in respect of the Consumer Manufacturing and Supply Agreement;

			
		 	“Corporate Brand Licence Agreement”	  	 means the brand licence agreement in respect of corporate marks entered into or to be entered into between certain
licensors, certain licensees and certain registered proprietors on or around the date of the SCIA;

			
		 	“Cosmos SAPA”	  	 means the stock and asset purchase agreement entered into among Pfizer, GSK, GSKCHHL and JVCo dated 19 December 2018,
as amended from time to time including on 31 July 2019 and by the Cosmos SAPA Amendment Agreement;

			
		 	“Cosmos SAPA Amendment Agreement”	  	 means the amendment agreement to the Cosmos SAPA entered into or to be entered into among Pfizer, GSK, GSKCHHL and JVCo on
or around the date of the SCIA;

			
		 	“Cosmos SCA”	  	 means the structuring considerations agreement entered into among GSKCHHL, Pfizer, PFCHHL, GSK and JVCo dated 31 July
2019, as amended or supplemented from time to time;

  
 7 

					
	       
	 	 “Cosmos SHA”
	  	 means the shareholders’ agreement in relation to JVCo entered into among GSKCHHL, Pfizer, PFCHHL, GSK and JVCo dated
31 July 2019, as amended or supplemented from time to time;

			
		 	 “Costs”
	  	 means charges and reasonable and documented costs (including legal costs) and expenses (other than, subject to the below,
Tax), which are properly incurred and of an out-of-pocket nature, together with any amounts in respect of VAT comprised in such charges, costs and expenses but only to
the extent not recoverable;

			
		 	 “C Shares”
	  	 means the C ordinary shares of £1.00 each in the share capital of GSKCHHL, which shares rank pari passu with
the A Shares and the B Shares except that they carry no right to any Pre-Separation GSKCHHL Onward Dividend and carry no voting rights, all of which are fully paid and held as at the date of this Agreement by
the SLPs and which, together with the A Shares and the B Shares, comprise all ownership interests of whatever nature in GSKCHHL;

			
		 	 “Deed of Termination”
	  	 means the global deed of termination relating to certain services provided by GSK or members of the GSK Group to Haleon or
members of the Consumer Healthcare Group entered into or to be entered into between GSK and Haleon on or around the date of the SCIA;

			
		 	 “Demerger”
	  	 means the proposed demerger of approximately 80.1% of GSK’s interest in the Consumer Healthcare Business pursuant to
the Demerger Agreement and the Demerger Dividend;

			
		 	 “Demerger Agreement”
	  	 means the demerger agreement entered into or to be entered into between Haleon and GSK on or around the date of the
SCIA;

			
		 	 “Demerger Completion”
	  	 means the time and date when the Demerger Conditions Precedent have been fulfilled and the Demerger Completion Steps have
taken place;

			
		 	 “Demerger Completion Steps”
	  	 has the meaning given to the term “Completion Steps” in the Demerger Agreement;

  
 8 

					
	       
	 	“Demerger Conditions Precedent”	  	 means the conditions set out in clause 2.1 (Conditions Precedent) of the Demerger Agreement;

			
		 	“Demerger Dividend”	  	 means the interim dividend, in specie, proposed to be declared by the GSK Board to effect the Demerger pursuant to the
authority granted to the GSK Board under the Demerger Resolution;

			
		 	“Demerger Record Time”	  	 means 6.00 p.m. on 15 July 2022, or such other time and/or date as the GSK Board may determine;

			
		 	“Demerger Resolution”	  	 means resolution 1 set out in the notice of general meeting of GSK included in the Circular;

			
		 	“Depositary”	  	 means JPMorgan Chase Bank N.A., as depositary for the Haleon ADSs;

			
		 	“Excess GSK Shares”	  	 means any GSK Shares in issue at the Demerger Record Time in excess of (X) ((X) being the number of GSK Shares in issue
at the Latest Practicable Date);

			
		 	“Exchange Agreements”	  	 means this Agreement, the Pfizer Exchange Agreement and the SLP Exchange Agreement;

			
		 	“FCA”	  	 means the Financial Conduct Authority acting in its capacity as the competent authority under Part VI of
FSMA;

			
		 	“Final Quarterly Dividend”	  	 means the final quarterly interim dividend to be paid by JVCo to GSKCHHL and PFCHHL prior to the Demerger on or around
30 June 2022;

			
		 	“Final Quarterly GSKCHHL Onward Dividend”	  	 means the dividend to be paid by GSKCHHL to GSK (as holder of the A Shares and B Shares) and (if and only to the extent
the SLPs are entitled to receive such dividend under the GSKCHHL Articles of Association) to the SLPs (as holders of the C Shares) in accordance with the GSKCHHL Articles of Association prior to the Demerger following any Final Quarterly Dividend
and comprising amounts received pursuant thereto;

			
		 	“Final Quarterly PFCHHL Onward Dividend”	  	 means one or more dividend(s), distribution(s), transfer(s) or other similar transaction(s) from PFCHHL to Anacor (or,
if completion of the PFCHHL Transfer has occurred prior to such dividend(s), distribution(s), transfer(s)or other similar transaction(s), Pfizer) prior to the Demerger following any Final Quarterly Dividend and comprising amounts received by PFCHHL
pursuant thereto;

			
		 	“Final Sweep Dividend”	  	 has the meaning given to that term in the Treasury Side Letter;

  
 9 

					
	       
	 	“Final Sweep GSKCHHL Onward Dividend”	  	 means the dividend to be paid by GSKCHHL to GSK (as holder of the A Shares and B Shares) and to the SLPs (as holders of the
C Shares) in accordance with the GSKCHHL Articles of Association prior to the Demerger following the Final Sweep Dividend and comprising amounts received pursuant thereto;

			
		 	“Final Sweep PFCHHL Onward Dividend”	  	 means one or more dividend(s), distribution(s), transfer(s) or other similar transaction(s) from PFCHHL to Anacor (or, if
completion of the PFCHHL Transfer has occurred prior to such dividend(s), distribution(s), transfer(s)or other similar transaction(s), Pfizer) prior to the Demerger following the Final Sweep Dividend and comprising amounts received by PFCHHL
pursuant thereto;

			
		 	“FSMA”	  	 means the Financial Services and Markets Act 2000;

			
		 	“Governmental Entity”	  	 means any supra national, national, state, municipal or local government (including any subdivision, court, administrative
agency or commission or other authority thereof) or any quasi-governmental or private body exercising any regulatory, taxing, importing or other governmental or quasi-governmental authority, including the European Union;

			
		 	“Group”	  	 means, as applicable:
  

(i) in relation to GSK, the GSK Group;

 
 (ii)  in
relation to Pfizer and/or Anacor, the Pfizer Group;
  

(iii)  in relation to Haleon, the Consumer Healthcare Group; and

 
 (iv) in
relation to JVCo, the JVCo Group;

			
		 	“GSK Board”	  	 means the board of directors of GSK and any duly authorised committee of that board, from time to time;

			
		 	“GSK Business”	  	 means the business operated within the GSK Group, which is described in the Circular and which, for the avoidance of doubt,
does not include the Consumer Healthcare Business;

			
		 	“GSKCHHL”	  	 means GlaxoSmithKline Consumer Healthcare Holdings Limited, a company incorporated in England with number 08998608, having
its registered office at 980 Great West Road, Brentford, Middlesex, TW8 9GS;

  
 10 

					
	       
	 	“GSKCHHL Articles of Association”	  	 means the articles of association adopted by GSKCHHL (as amended or replaced from time to time);

			
		 	 “GSKCHHL Board”
	  	 means the board of directors of GSKCHHL and any duly authorised committee of that board, from time to time;

			
		 	 “GSKCHH3”
	  	 means GSK Consumer Healthcare Holdings (No. 3) Limited, a company incorporated in England with number 13401293, having its
registered office at 980 Great West Road, Brentford, Middlesex, TW8 9GS;

			
		 	 “GSK Consolidation Resolution”
	  	 means the relevant parts of resolution 1 relating to the proposed consolidation of the share capital of GSK as set out in
the notice of general meeting of GSK included in the Circular;

			
		 	 “GSK Exchange Indemnities”
	  	 means the indemnities given by GSK which are set out in clause 7.1 (GSK Exchange Indemnities and SLP Exchange
Indemnities);

			
		 	 “GSK General Meeting”
	  	 means the general meeting of GSK to approve, among other things:

 
 (i) the
Demerger and the relevant parts of the Separation Transaction as a Class 1 transaction for the purposes of Listing Rule 10;
  

(ii)  the relevant parts of the Separation Transaction and the associated and ancillary
agreements and arrangements relating thereto or to be entered into pursuant thereto for the purposes of Chapter 11 of the Listing Rules; and
  

(iii)  the GSK Share Consolidation;

			
		 	 “GSK Group”
	  	 means GSK and its subsidiaries and subsidiary undertakings from time to time, excluding Haleon and the Consumer Healthcare
Group Companies;

			
		 	“GSK Group Companies”	  	 means any member of the GSK Group from time to time, and “GSK Group Company” shall be construed
accordingly;

  
 11 

					
		 	 “GSK Haleon Exchange Shares”
	  	 means the Haleon Ordinary Shares to be allotted and issued, credited as fully paid up, in accordance with this
Agreement;

			
	       
	 	“GSK Manufacturing and Supply Agreement”	  	 means the manufacturing and supply agreement entered into or to be entered into between GlaxoSmithKline Trading Services
Limited as supplier and GlaxoSmithKline Consumer Trading Services Limited as purchaser on or around the date of the SCIA;

			
		 	 “GSK NEB Agreement”
	  	 means the net economic benefit agreement entered into between GSK, Pfizer and JVCo and dated 31 July 2019, as amended
or supplemented from time to time;

			
		 	 “GSK Quality Agreement”
	  	 means the quality agreement to be entered into between GlaxoSmithKline Trading Services Limited and GlaxoSmithKline
Consumer Trading Services Limited in respect of the GSK Manufacturing and Supply Agreement ;

			
		 	 “GSK Share Consolidation”
	  	 means the consolidation of the share capital of GSK pursuant to and in accordance with the GSK Consolidation
Resolution;

			
		 	 “GSK Share Exchange”
	  	 means the transfer of GSK’s entire shareholding of B Shares to Haleon in exchange for Haleon issuing the GSK Haleon
Exchange Shares to GSK pursuant to and in accordance with the terms of this Agreement;

			
		 	 “GSK Shareholders”
	  	 means holders of the GSK Shares on the register of members of GSK from time to time;

			
		 	 “GSK Shares”
	  	 means ordinary shares in the capital of GSK having the rights set out in GSK’s articles of association from time to
time;

			
	       
	 	 “Guarantee Fee Arrangements”
	  	 means the guarantee fee arrangements effected pursuant to:

 
 (i) the
guarantee fee agreement between Haleon (as guarantor) and GlaxoSmithKline Consumer Healthcare Holdings (US) LLC (as beneficiary) dated 25 May 2022; and
  

(ii)  the guarantee fee agreement between GSK (as guarantor) and GlaxoSmithKline Consumer
Healthcare Holdings (US) LLC (as beneficiary) dated 28 April 2022;

  
 12 

					
	       
	 	 “Haleon Admission Shares”
	  	 means the Haleon Demerger Shares and the Haleon Exchange Shares (excluding the Haleon NVPS);

			
		 	 “Haleon ADR Programme”
	  	 means the American depositary receipt programme to be established for Haleon on or around Admission, as detailed in the
Steps Plan;

			
		 	 “Haleon ADSs”
	  	 means the American depositary shares each representing 2 Haleon Ordinary Shares to be

admitted to listing and trading on the NYSE pursuant to the establishment of the Haleon ADR Programme;

			
		 	 “Haleon Articles of Association”
	  	 means the articles of association adopted or to be adopted by Haleon that are in the agreed form for the purposes of the
SCIA;

			
		 	 “Haleon Demerger Shares”
	  	 means the Haleon Ordinary Shares to be allotted and issued to the Qualifying GSK Shareholders as GSK shall direct,
credited as fully paid up, in accordance with the Demerger Agreement, together with (where the context so requires) any Haleon Ordinary Shares in issue prior to commencement of the Demerger Completion Steps;

			
		 	 “Haleon Exchange Shares”
	  	 means:
  

(i) the GSK Haleon Exchange Shares;

 

(ii)  the SLP Haleon Exchange Shares; and

 

(iii)  the Pfizer Haleon Exchange Shares,

 
 which, together, immediately following Demerger Completion
and the completion of the Share Exchanges, represent up to approximately 45.53% of the issued Haleon Ordinary Shares (rounded to the nearest whole Haleon Ordinary Share) and 100% of the issued preference shares of Haleon;

			
		 	 “Haleon Group”
	  	 means Haleon and its subsidiaries and subsidiary undertakings from time to time;

			
		 	 “Haleon NVPS”
	  	 means 25,000,000 unlisted redeemable non-voting preference shares of £1.00
each in the share capital of Haleon carrying the rights set out in Haleon’s articles of association (as reproduced in schedule 2 (Haleon NVPS Terms) to the Pfizer Exchange Agreement);

  
 13 

					
	       
	 	 “Haleon Ordinary Shares”
	  	 means ordinary shares in the capital of Haleon having the rights set out in the Haleon Articles of Association from time to
time;

			
		 	 “HMRC”
	  	 means HM Revenue & Customs;

			
		 	 “Indemnified Party”
	  	 has the meaning given to that term in Schedule 1 (Provisions on Claims under the GSK Exchange Indemnities and the
SLP Exchange Indemnities);

			
		 	 “Indemnifying Party”
	  	 has the meaning given to that term in Schedule 1 (Provisions on Claims under the GSK Exchange Indemnities and the
SLP Exchange Indemnities);

			
		 	 “India Condition”
	  	 has the meaning given to that term in the Demerger Agreement;

			
		 	 “Investigation”
	  	 has the meaning given to that term in clause 13.4(B);

			
		 	 “Japan Condition”
	  	 has the meaning given to that term in the Demerger Agreement

			
		 	 “JVCo”
	  	 means GlaxoSmithKline Consumer Healthcare Holdings (No.2) Limited, a company incorporated in England with number 11961650,
having its registered office at 980 Great West Road, Brentford, Middlesex, TW8 9GS;

			
		 	 “JVCo Group”
	  	 means JVCo and its subsidiaries and subsidiary undertakings from time to time;

			
		 	 “Korea Condition”
	  	 has the meaning given to that term in the Demerger Agreement;

			
		 	 “Latest Practicable Date”
	  	 means 30 May 2022 being the last practicable date prior to publication of the Circular;

			
		 	 “Law”
	  	 means any statute, law, rule, regulation, ordinance, code or rule of common law issued, administered or enforced by any
Governmental Entity, or any judicial or administrative interpretation thereof, including the rules of any stock exchange or listing authority;

			
		 	 “Listing Ancillary Agreements”
	  	 means:
  

(i) the Pfizer Relationship Agreement;

 

(ii)  the Orderly Marketing Agreement;

 

(iii)  the Registration Rights Agreement;

 
 (iv) the
Sponsors’ Agreements; and
  

(v)   the Lock-up Deed,

 
 and any document, agreement or arrangement pursuant thereto
or in connection therewith;

  
 14 

					
	       
	 	 “Listing Rules”
	  	 means the rules and regulations made by the FCA (acting in its capacity as the competent authority for the purposes of
FSMA) under FSMA, and contained in the publication of the same name, as amended from time to time (including any successor rules);

			
		 	 “Lock-up Deed”
	  	 means the lock-up deed entered into or to be entered into between GSK, Pfizer, the
SLPs, Citigroup Global Markets Limited and Morgan Stanley & Co. International plc on or around the date of the SCIA;

			
		 	 “London Stock Exchange”
	  	 means London Stock Exchange plc;

			
		 	 “Long Term Access Agreement”
	  	 means the long term access agreement entered into or to be entered into between GSK and Haleon on or around the date of the
SCIA;

			
		 	 “NEBA”
	  	 means the net economic benefit arrangements, comprising the GSK NEB Agreement and the Pfizer NEB Agreement as may be
amended and restated from time to time, including pursuant to the NEBA Amendment Agreement;

			
		 	 “NEBA Amendment Agreement”
	  	 means the amendment and restatement agreement with respect to the GSK NEB Agreement entered into or to be entered into
between GSK, JVCo and Pfizer on or around the date of the SCIA;

			
		 	 “Official List”
	  	 means the Official List maintained by the FCA pursuant to Part 6 of FSMA;

			
		 	 “Orderly Marketing Agreement” 
	  	 means the orderly marketing agreement entered into or to be entered into between GSK, Pfizer and the SLPs on or around the
date of the SCIA;

			
		 	 “Party”
	  	 means a party to this Agreement;

			
		 	 “PFCHHL”
	  	 means PF Consumer Healthcare Holdings LLC, a limited liability company incorporated under the laws of Delaware whose
registered office is at 235 East 42nd Street, New York, New York 10017;

			
		 	 “PFCHHL Interests”
	  	 means all of the common interests in the capital of PFCHHL in issue immediately prior to the completion of the Pfizer Share
Exchange, which comprise all ownership interests of whatever nature in PFCHHL and all of which are held by Anacor as at the date of this Agreement and all of which, from completion of the PFCHHL Transfer until the completion of the Pfizer Share
Exchange, shall be held by Pfizer;

			
		 	 “PFCHHL Transfer”
	  	 means the series of transactions pursuant to which the PFCHHL Interests will be transferred, distributed or otherwise
assigned from Anacor to Pfizer;

  
 15 

					
	       
	 	 “Pfizer”
	  	 means Pfizer Inc., a corporation incorporated under the laws of Delaware whose registered office is at 235 East 42nd
Street, New York, New York 10017;

			
		 	 “Pfizer Exchange Agreement”
	  	 means the exchange agreement between Pfizer, Anacor and Haleon setting out the terms of the Pfizer Share
Exchange;

			
		 	 “Pfizer Group”
	  	 means Pfizer and its subsidiaries and subsidiary undertakings from time to time, excluding the Consumer Healthcare Group
Companies;

			
		 	“Pfizer Group PFCHHL Transferor”	  	 means Anacor or, if the PFCHHL Transfer has completed by the time of Demerger Completion, Pfizer;

			
		 	 “Pfizer Haleon Exchange Shares”
	  	 means the Haleon Ordinary Shares and the Haleon NVPS to be allotted and issued, credited as fully paid up, in accordance
with the Pfizer Exchange Agreement, which immediately following Demerger Completion and the completion of the Share Exchanges, represent respectively 32% of the issued Haleon Ordinary Shares (rounded to the nearest whole Haleon Ordinary Share) and
100% of the issued preference shares of Haleon; 

			
		 	 “Pfizer NEB Agreement”
	  	 means the net economic benefit agreement entered into between Pfizer, GSK and JVCo and dated 31 July 2019, as amended or
supplemented from time to time;

			
		 	 “Pfizer Relationship Agreement”
	  	 means the relationship agreement entered into or to be entered into between Pfizer and Haleon on the Posting
Date;

			
		 	 “Pfizer Share Exchange”
	  	 means the transfer of the PFCHHL Interests from the Pfizer Group PFCHHL Transferor to Haleon in exchange for Haleon issuing
the Pfizer Haleon Exchange Shares to the Pfizer Group PFCHHL Transferor and the Depositary pursuant to and in accordance with the terms of the Pfizer Exchange Agreement;

			
		 	 “Pharmacovigilance Agreement”
	  	 means the pharmacovigilance agreement entered into or to be entered into between GlaxoSmithKline Services Unlimited and
GlaxoSmithKline Consumer Healthcare (Overseas) Limited on or around the date of the SCIA;

			
		 	 “Posting Date”
	  	 means the date of the Demerger Agreement (or such other date as may be determined by GSK and notified to Haleon and Pfizer
as the date for the issue and dispatch of the Circular and the publication of the Prospectus);

  
 16 

					
	       
	 	 “Pre-Separation Dividend”
	  	 means the dividend to be paid by JVCo to GSKCHHL and PFCHHL prior to the Demerger (as provided in clause 17.32(B) of the
Cosmos SHA and as otherwise agreed between the parties to the Cosmos SHA, including pursuant to the Treasury Side Letter);

			
		 	“Pre-Separation GSKCHHL Onward Dividend”	  	 means the dividend to be paid by GSKCHHL to GSK (as holder of the A Shares and B Shares) prior to the Demerger following
the Pre-Separation Dividend and comprising amounts received by GSKCHHL pursuant to the Pre-Separation Dividend;

			
		 	“Pre-Separation PFCHHL Onward Dividend”	  	 means one or more dividend(s), distribution(s), transfer(s) or other similar transaction(s) from PFCHHL to Anacor (or, if
completion of the PFCHHL Transfer has occurred prior to such dividend(s), distribution(s), transfer(s) or other similar transaction(s), Pfizer) prior to the Demerger following the Pre-Separation Dividend and
comprising amounts received by PFCHHL pursuant thereto;

			
		 	 “Proceedings”
	  	 means any proceeding, suit or action arising out of or in connection with this Agreement or the negotiation, existence,
validity or enforceability of this Agreement, whether contractual or non-contractual;

			
		 	 “Prospectus”
	  	 means the prospectus relating to the Admission of the Haleon Admission Shares to be dated the Posting Date;

			
		 	 “Qualifying GSK Shareholders”
	  	 means the GSK Shareholders on the register of members of GSK at the Demerger Record Time;

			
		 	 “Redeemable Shares”
	  	 means the fully paid redeemable preference shares of £1 each in the share capital of Haleon (subscribed by Trexco on
or around the re-registration of Haleon as a public limited company);

			
		 	 “Registration Rights Agreement”
	  	 means the registration rights agreement between Haleon, Pfizer, GSK and each of the SLPs dated on or around the date of the
SCIA;

			
		 	 “Regulatory Conditions”
	  	 means, subject to clause 2.11 of the SCIA, the India Condition, the Japan Condition and the Korea Condition;

			
		 	“Regulatory Information Access and Service Agreement”	  	 means the regulatory information access and service (linked products) agreement entered into or to be entered into between
GlaxoSmithKline Services Unlimited and GlaxoSmithKline Consumer Healthcare (Overseas) Unlimited on or around the date of the SCIA;

			
		 	 “Relevant GSKCHHL Shares”
	  	 means all of the class A ordinary shares of £1.00 each in the capital of GSKCHHL in issue immediately prior to
Demerger Completion;

  
 17 

					
		 	 “SCA Side Letter”
	  	 means the letter agreement between GSKCHHL, Pfizer, PFCHHL, GSK and JVCo dated 22 November 2021;

			
		 	 “SCIA”
	  	 means the Separation Co-operation and Implementation Agreement entered into or to
be entered into between GSK, Pfizer, Anacor, Haleon, JVCo, GSKCHHL and PFCHHL on or around the date of this Agreement;

			
		 	 “SEC”
	  	 means the U.S. Securities and Exchange Commission;

			
	       
	 	“Separation Ancillary Agreements”	  	 means the:
  

(i) SCIA;
  

(ii)  Demerger Agreement;

 

(iii)   Exchange Agreements;

 
 (iv) Cosmos
SAPA Amendment Agreement;
  

(v)   Tax Covenant;

 
 (vi) ATFA;

 

(vii)  Transitional Services Agreement;

 

(viii)  GSK Manufacturing and Supply Agreement;

 
 (ix) Consumer
Manufacturing and Supply Agreement;
  

(x)   GSK Quality Agreement;

 
 (xi) Consumer
Quality Agreement;
  

(xii)  Shared Brands Licences Agreement;

 

(xiii)  Shared Brands Committee Agreement;

 

(xiv) Corporate Brand Licence Agreement;

 
 (xv)   Co-Existence Agreement;
  

(xvi) Long Term Access Agreement;

 

(xvii) Pharmacovigilance
Agreement;

  

  
 18 

					
	       
	 		  	 (xviii)NEBA Amendment Agreement;

 

(xix) Argentina NEBA;

 

(xx)   Brazil ATFA;

 
 (xxi) Deed of
Termination;
  

(xxii) Regulatory Information Access and Service Agreement; and

 
 (xxiii)Guarantee Fee
Arrangements,
  
 and any document, agreement or
arrangement pursuant thereto or in connection therewith;

			
		 	 “Separation Completion”
	  	 means completion of the final step in the Separation Transaction;

			
		 	 “Separation Transaction”
	  	 means the steps comprised in the Demerger, the Exchange Agreements, execution of the Separation Ancillary Agreements and
Admission, pursuant to which, among other things, Haleon will become a listed company holding the Consumer Healthcare Business;

			
		 	 “Service Document”
	  	 means a claim form, application notice, order, judgment or other document relating to any Proceedings;

			
		 	“Shared Brands Committee Agreement”	  	 means the shared brands committee agreement entered into or to be entered into between GlaxoSmithKline Services Unlimited
and GlaxoSmithKline Consumer Healthcare (Overseas) Limited on or around the date of the SCIA;

			
		 	“Shared Brands Licences Agreement”	  	 means the deed of amendment and restatement to amend and restate certain shared brand licence agreements entered into or to
be entered into between certain licensors, certain licensees and certain registered proprietors on or around the date of the SCIA;

			
		 	 “Share Exchanges”
	  	 means the GSK Share Exchange, the Pfizer Share Exchange and the SLP Share Exchange;

			
		 	 “SLP Exchange Agreement”
	  	 means the exchange agreement between the SLPs and Haleon setting out the terms of the SLP Share Exchange;

  
 19 

					
		 	 “SLP Exchange Indemnities”
	  	 means the indemnities given by GSK which are set out in clause 7.3 (GSK Exchange Indemnities and SLP Exchange
Indemnities);

			
	       
	 	 “SLP Haleon Exchange Shares”
	  	 means the Haleon Ordinary Shares to be allotted and issued, credited as fully paid up, in accordance with the SLP
Exchange Agreement, which immediately following Demerger Completion and the completion of the Share Exchanges, represent 7.5% of the issued Haleon Ordinary Shares (rounded to the nearest whole Haleon Ordinary Share);

			
		 	 “SLPs”
	  	 means:
  

(i) GSK (No. 1) Scottish Limited Partnership, a private fund limited partnership registered in
Scotland with registration number SL035527 and whose principal place of business is at 50 Lothian Road, Festival Square, Edinburgh, EH3 9WJ;
  

(ii)  GSK (No. 2) Scottish Limited Partnership, a private fund limited partnership
registered in Scotland with registration number SL035526 and whose principal place of business is at 50 Lothian Road, Festival Square, Edinburgh, EH3 9WJ; and
  

(iii)  GSK (No. 3) Scottish Limited Partnership, a private fund limited partnership
registered in Scotland with registration number SL035525 and whose principal place of business is at 50 Lothian Road, Festival Square, Edinburgh, EH3 9WJ,
  

being the Scottish limited partnerships that will each receive shares in Haleon pursuant to the SLP Exchange Agreement, and
“SLP” shall be construed accordingly;

			
		 	 “SLP Share Exchange”
	  	 means the transfer of each SLP’s entire shareholding of C Shares to Haleon in exchange for Haleon issuing the
applicable portion of the SLP Haleon Exchange Shares to each such SLP pursuant to and in accordance with the terms of the SLP Exchange Agreement;

  
 20 

					
	       
	 	 “Sponsors”
	  	 means:
  

(i) Citigroup Global Markets Limited, a company incorporated in England and Wales with
registered number 01763297 whose registered office is Citigroup Centre, Canada Square, Canary Wharf, London E14 5LB;
  

(ii)  Goldman Sachs International, a company incorporated in England and Wales with
registered number 02263951 whose registered office is Plumtree Court, 25 Shoe Lane, London, EC4A 4AU; and
  

(iii)  Merrill Lynch International, a company incorporated in England and Wales with
registered number 02312079 whose registered office is 2 King Edward Street, London, EC1A 1HQ;

			
		 	 “Sponsors’ Agreements”
	  	 means:
  

(i) the sponsors’ agreement between Haleon, JVCo and each of the Sponsors dated on or
around the date of the SCIA; and
  

(ii)  the sponsors’ agreement between GSK and each of the Sponsors dated on or around
the date of the SCIA;

			
		 	 “Steps Plan”
	  	 means the demerger steps plan prepared by Slaughter and May summarising the proposals in relation to the Separation
Transaction, and initialled for identification purposes by or on behalf of each of GSK, Pfizer and Haleon;

			
		 	 “Sterling” and “£”
	  	 means the lawful currency of the United Kingdom;

			
		 	 “subsidiary undertaking”
	  	 means a subsidiary undertaking as defined in section 1162 Companies Act 2006 (and a company shall be treated, for the
purposes only of the membership requirement contained in subsections 1162(2)(b) and (d) respectively, as a member of another company even if its shares in that other company are registered in the name of (A) another person (or its nominee)
whether by way of security or in connection with the taking of security or (B) its nominee);

			
	       
	 	 “Tax”
	  	 means all taxes, and all levies, duties, imposts, charges and withholdings in the nature of tax, including taxes on
gross or net income, profits or gains and taxes on receipts, sales, use, employment, payroll, land, stamp, transfer,

  
 21 

					
		 		  	 occupation, franchise, value added, wealth and personal property, together with all penalties, charges, additions to tax,
and interest relating to any of them, and regardless of whether any such amounts are chargeable or attributable directly or primarily to any other person or are recoverable from any other person;

			
		 	 “Tax Authority”
	  	 means any taxing, revenue or other authority competent to impose any liability to, or to assess or collect, any Tax,
including, without limitation, HMRC and the Internal Revenue Service;

			
		 	 “Tax Covenant”
	  	 means the deed of tax covenant relating to the Separation Transaction, entered into or to be entered into between GSK,
Haleon, GSKCHHL, Pfizer and JVCo on or around the date of the SCIA;

			
		 	 “Transaction Documents”
	  	 means the Demerger Agreement, the SCIA, the Exchange Agreements and the Ancillary Agreements;

			
		 	“Transitional Services Agreement”	  	 means the transitional services agreement entered into or to be entered into between GlaxoSmithKline Services Unlimited,
GlaxoSmithKline LLC, GlaxoSmithKline Consumer Healthcare (Overseas) Limited and GlaxoSmithKline Consumer Healthcare Holdings (US) LLC on or around the date of the SCIA;

			
	       
	 	 “Treasury Side Letter”
	  	 means the letter agreement entered into between GSKCHHL, Pfizer, PFCHHL, GSK and JVCo dated 4 November 2021 pursuant
to which the parties thereto have agreed the interpretation, and confirmed the application, of certain provisions of the Cosmos SHA;

			
		 	 “Trexco”
	  	 means Trexco Limited, a company incorporated in England with number 00461588, having its registered office at 2 Lambs
Passage, London, EC1Y 8BB;

			
		 	 “VAT”
	  	 means:
  

(i) any value added tax imposed by the Value Added Tax Act 1994 and legislation and regulations
supplemental thereto;

  
 22 

					
	       
	 		  	 (ii)  to the extent not included in paragraph (i) above, any Tax
imposed in compliance with the council directive of 28 November 2006 on the common system of value added tax (EC Directive 2006/112); and
  

(iii)  any other Tax of a similar nature to the Taxes referred to in paragraph (i) or
paragraph (ii) above, whether imposed in the UK or a member state of the EU in substitution for, or levied in addition to, the Taxes referred to in paragraph (i) or paragraph (ii) above or imposed elsewhere; and

			
		 	 “Working Hours”
	  	 means 9.30 a.m. to 5.30 p.m. (local time) on a Business Day.

  

	1.2	 In this Agreement, unless otherwise specified: 

 

	 	(A)	 references to clauses, sub clauses, paragraphs, sub paragraphs, and Schedules are to clauses, sub clauses,
paragraphs, sub paragraphs of, and Schedules to, this Agreement; 

  

	 	(B)	 use of any gender includes the other genders and (unless the context otherwise requires) the singular shall
include the plural and vice versa; 

  

	 	(C)	 references to a “company” shall be construed so as to include any corporation or other body
corporate, wherever and however incorporated or established; 

  

	 	(D)	 references to a “person” shall be construed so as to include any individual, firm, company,
corporation or other body corporate, government, state or agency of a state, local or municipal authority or government body or any joint venture, association or partnership (whether or not having separate legal personality); 

 

	 	(E)	 references to a “holding company” or a “subsidiary” shall be construed as
a holding company or subsidiary (as the case may be) as defined in section 1159 of the Companies Act 2006; 

  

	 	(F)	 references to a “body corporate” shall be construed as a body corporate as defined in
section 1173 of the Companies Act 2006; 

  

	 	(G)	 references to a “parent undertaking” shall be construed as a parent undertaking as defined
in section 1162 of the Companies Act 2006; 

  

	 	(H)	 references to a “party” shall be construed so as to include a reference to that
party’s successors and permitted assigns; 

  

	 	(I)	 a reference to any statute or statutory provision or other regulation shall be construed as a reference to
the same as it may have been, or may from time to time be, amended, modified or re enacted and shall include any subordinate legislation made from time to time under that statute or statutory provision, except to the extent that any amendment or
modification made after the date of this Agreement would increase or alter the liability of any Party under this Agreement; 

  
 23 

	 	(J)	 any reference to a “day” (including within the phrase “Business Day”)
shall mean a period of 24 hours running from midnight to midnight; 

  

	 	(K)	 references to times are to London time (unless otherwise stated); 

 

	 	(L)	 references to “include” and “including” shall be deemed to be followed by
the words “without limitation”; 

  

	 	(M)	 reference to “liabilities”, “costs” and/or “expenses ”
incurred by a person shall not include any amount in respect of VAT or any Tax of a similar nature included in such liabilities, costs and/or expenses for which that person or any other member of its Group is entitled to credit or repayment from any
Tax Authority; 

  

	 	(N)	 references to “indemnify” any person against any circumstance shall include indemnifying
and keeping such person harmless from all actions, claims and proceedings from time to time made against such person and all loss, damage, payments, costs or expenses suffered, made or incurred by such person as a consequence of that circumstance
and, unless otherwise specified, any indemnity given in this Agreement shall be deemed to have been given on an after-Tax basis; 

 

	 	(O)	 any indemnity or obligation to pay (the “Payment Obligation”) being given or assumed on an
“after-Tax basis” or expressed to be “calculated on an after-Tax basis” means that the amount payable pursuant to such Payment
Obligation (the “Payment”) shall be calculated in such a manner as will ensure that, after taking into account: 

  

	 	(i)	 any Tax required to be deducted or withheld from the Payment; 

 

	 	(ii)	 the amount and timing of any additional Tax which becomes (or would, but for the use of any credit or other
relief which would otherwise have been available to reduce the Tax liabilities of any member of the Consumer Healthcare Group or the GSK Group, as the case may be, have become) payable as a result of the Payment’s being subject to Tax; and

  

	 	(iii)	 the amount and timing of any Tax benefit which is obtained, to the extent that such Tax benefit is
attributable to the matter giving rise to the Payment Obligation, 

 the recipient of the Payment is in the
same position as that in which it would have been if the matter giving rise to the Payment Obligation had not occurred (or, in the case of a Payment Obligation arising by reference to a matter affecting a person other than the recipient of the
Payment, the recipient of the Payment and that other person are, taken together, in the same position as that in which they would have been had the matter giving rise to the Payment Obligation not occurred), provided that the amount of the Payment
shall not exceed that which it would have been if it had been regarded for all Tax purposes as received solely by the recipient and not any other person; 

  
 24 

	 	(P)	 references to a “liability to Tax” or “Tax payable” (and equivalent terms)
include circumstances where Tax would be (or become) payable but for the use of a Relief (as such term is defined in the Tax Covenant); 

  

	 	(Q)	 a reference to any other document referred to in this Agreement is a reference to that other document as
amended, varied, novated or supplemented (other than in breach of the provisions of this Agreement or that other document) at any time; 

  

	 	(R)	 a reference to any English legal term for any action, remedy, method of judicial proceeding, legal document,
legal status, court, official or any legal concept or thing shall in respect of any jurisdiction other than England be treated as a reference to any analogous term in that jurisdiction; and 

 

	 	(S)	 the rule known as the ejusdem generis rule shall not apply and accordingly: 

 

	 	(i)	 general words introduced by the word “other” shall not be given a restrictive meaning by reason of
the fact that they are preceded by words indicating a particular class of acts, matters or things; and 

  

	 	(ii)	 general words shall not be given a restrictive meaning by reason of the fact that they are followed by
particular examples intended to be embraced by the general words. 

  

	1.3	 In this Agreement, unless otherwise specified: 

 

	 	(A)	 all headings and titles are inserted for convenience only and are to be ignored in the interpretation of
this Agreement; and 

  

	 	(B)	 the Schedules form part of this Agreement and shall have the same force and effect as if expressly set out
in the body of this Agreement, and any reference to this Agreement shall include the Schedules. 

  

	1.4	 In this Agreement, references to members of Pfizer Group’s or members of GSK Group’s holdings of
Haleon Ordinary Shares shall include: (i) Haleon Ordinary Shares held directly in the form of shares; (ii) Haleon Ordinary Shares held by one or more nominees on behalf of members of the Pfizer Group or GSK Group (as applicable); and (iii) Haleon
Ordinary Shares held indirectly as a result of a holding of Haleon ADSs. 

  

	2.	 CONDITION PRECEDENT 

 

	2.1	 The provisions of this Agreement, other than those arising under clause 1 (Interpretation), clause
2 (Condition Precedent), clause 3 (Termination), clause 8 (Confidentiality), clause 13 (Further Assurance) and clause 14 (Notices) to clause 25 (Governing Law and Jurisdiction) (inclusive), shall be conditional
upon completion of the Demerger Completion Steps.  

  

	2.2	 Each of GSK and Haleon shall use all reasonable endeavours to ensure fulfilment of the Condition Precedent,
which may not be waived by either GSK or Haleon. If the Condition Precedent is not satisfied by 5.00 p.m. on 23 February 2023 (or such other time and/or date as GSK may determine, subject to clause 5), this Agreement shall automatically
terminate and neither GSK nor Haleon shall have any claim of any nature whatsoever against the other Party under this Agreement, save in respect of any rights and liability of any Party set forth in the Cosmos SHA. 

  
 25 

	2.3	 Each of GSK and Haleon undertakes to the other to disclose anything which will or may prevent or delay the
Condition Precedent from being satisfied immediately after it comes to the notice of that Party. 

  

	2.4	 The Parties agree and acknowledge that nothing in this Agreement shall: 

 

	 	(A)	 prevent or inhibit compliance with the Cosmos SHA to any extent; or 

 

	 	(B)	 derogate from or qualify to any extent any party’s rights or obligations pursuant to the Cosmos SHA.

  

	2.5	 The Parties agree and acknowledge that they shall comply in all respects with the Cosmos SHA, and shall
procure such compliance by the members of their respective Groups. The Parties further agree and acknowledge that compliance with the Cosmos SHA by GSK, the members of the GSK Group, Pfizer, the members of the Pfizer Group, Haleon and the members of
the Consumer Healthcare Group is permitted and the Parties hereby consent in all respects to such compliance with the Cosmos SHA. For the avoidance of doubt, the Parties agree and acknowledge that this Agreement is without prejudice to GSK’s or
Pfizer’s rights under the Cosmos SHA, the Cosmos SCA, the Treasury Side Letter and the obligations of Pfizer, GSK and the members of the Pfizer Group and the GSK Group pursuant to the terms of the Cosmos SHA, the Cosmos SCA and the Treasury
Side Letter. 

  

	2.6	 Notwithstanding anything to the contrary in this Agreement or the Cosmos SHA, the Cosmos SCA or the Treasury
Side Letter, the Parties agree and acknowledge that in connection with the Demerger, and in accordance with and subject to the SCA Side Letter, (1) the issuance to the Pfizer Group PFCHHL Transferor of the Haleon NVPS pursuant to the Pfizer
Share Exchange and the sale or disposition of the Haleon NVPS by the Pfizer Group PFCHHL Transferor immediately thereafter and (2) the distribution referred to in limb (ii) of the definition of ATB
Re-organisation shall be expressly permitted for all purposes hereunder and thereunder. Notwithstanding anything to the contrary in this Agreement or the other Transaction Documents, the Parties agree and
acknowledge that, in connection with the Separation Transaction, any reference in this Agreement or the other Transaction Documents to the issuance to GSK of GSK Haleon Exchange Shares shall, at the sole discretion of GSK (upon written notice to
Haleon no fewer than five (5) days prior to the date of Demerger Completion), be read to include an issuance of a portion of such GSK Haleon Exchange Shares (as applicable) to a nominee of GSK’s choice to hold such portion of such GSK Haleon
Exchange Shares on behalf of GSK. 

  

	3.	 TERMINATION 

 

	3.1	 Notwithstanding any other provision of this Agreement (but subject to the Cosmos SHA), the Parties hereby
agree and acknowledge that GSK shall have the right in its absolute discretion to abandon the Separation Transaction by providing notice of the same in writing to Haleon and Pfizer at any time prior to Demerger Completion, and upon GSK providing
such notice, this Agreement shall automatically terminate. 

  

	3.2	 The Parties hereby agree and acknowledge that, in the event that this Agreement is terminated pursuant to
clause 3.1: 

  

	 	(A)	 no Party will have any claim against any other Party for compensation, Costs, damages or otherwise except as
otherwise provided in the Cosmos SHA or the SCIA; 

  

	 	(B)	 this Agreement shall be of no further force or effect; and 

 

	 	(C)	 for the avoidance of doubt, the Cosmos SHA shall continue in full force and effect in accordance with its
terms. 

  
 26 

	3.3	 Save as provided in clause 3.1, no Party shall have the right to rescind or unilaterally terminate
this Agreement, whether before or after Completion. 

  

	4.	 TRANSFER AND ISSUE OF SHARES 

 

	4.1	 Subject to: 

  

	 	(A)	 this Agreement not having been terminated pursuant to clause 3.1; and 

 

	 	(B)	 the Demerger Completion Steps having occurred, 

GSK agrees to transfer at Completion, with full title guarantee and free from all security interests, options, claims, or
encumbrances whatsoever (other than transfer restrictions under applicable securities laws), the B Shares to Haleon (the “Transfer”), and Haleon agrees to acquire the B Shares on the same basis. 

 

	4.2	 Prior to the Demerger Completion (but subject thereto), GSK shall procure that the GSKCHHL Board shall
(i) approve the Transfer and the “Transfer” (as defined in the SLP Exchange Agreement) and (ii) resolve that Haleon will be recorded in the register of members of GSKCHHL as the holder of the B Shares and the C Shares as soon as
reasonably practicable following Completion, in each case, subject to the satisfaction of the Condition Precedent set forth in this Agreement and the Conditions Precedent (as defined in the SLP Exchange Agreement) set forth in the SLP Exchange
Agreement, respectively. 

  

	4.3	 As soon as reasonably practicable following Completion, Haleon shall procure that (subject to stamping of
the relevant instrument of transfer or, as applicable, receipt of appropriate confirmation from HMRC that relief has been adjudicated or otherwise that the change in ownership may be duly registered) Haleon is recorded in the register of members of
GSKCHHL as the holder of the B Shares. For the avoidance of doubt, GSK shall ensure (and shall procure that the members of the GSK Group ensure) that GSK shall be the sole holder of the B Shares until Completion, and the SLPs shall be the sole
holders of the C Shares until completion of the SLP Share Exchange, and that GSK shall be the sole holder of the A Shares until the commencement of the Demerger Completion Steps. 

 

	4.4	 In consideration for the transfer of the B Shares from GSK to Haleon, Haleon shall allot and issue to GSK
the GSK Haleon Exchange Shares, being a number of Haleon Ordinary Shares that is equal to (subject only to rounding): 

502,868,434 less the number of Excess GSK Shares. 

 

	4.5	 Haleon shall ensure that the GSK Haleon Exchange Shares to be allotted and issued to GSK pursuant to
clause 4.4 shall be allotted credited as fully paid and free from all liens, charges, security interests, options, claims and encumbrances whatsoever and shall have the rights described in the Haleon Articles of Association.

  

	4.6	 As soon as reasonably practicable following the allotment and issuance of the GSK Haleon Exchange Shares
pursuant to clause 4.4, Haleon shall procure that GSK is recorded in the register of members of Haleon as the holder of such shares. 

  
 27 

	5.	 COMPLETION OBLIGATIONS 

 

	5.1	 Completion of this Agreement will take place at 10.05 a.m. on the first Sunday after Demerger Completion
(which, for the avoidance of doubt, is prior to the time at which Admission is expected to occur), provided that the Condition Precedent has been satisfied by such time, or at such other time as agreed by the Parties, provided that in all cases,
Completion of this Agreement will take place prior to Admission. 

  

	5.2	 At Completion, the following business shall be transacted: 

 

	 	(A)	 GSK shall deliver to Haleon a duly executed transfer of the B Shares in favour of Haleon, together with the
relevant share certificate(s); and 

  

	 	(B)	 Haleon shall procure that GSK is entered into the Haleon register of members in respect of the GSK Haleon
Exchange Shares to be allotted and issued to GSK pursuant to clause 4.4. 

  

	5.3	 To secure the interest of Haleon in the B Shares, GSK irrevocably appoints Haleon, with effect from
Completion, as GSK’s attorney with authority on its behalf and in its name or otherwise in relation to the B Shares to exercise all rights, powers and privileges which are capable of exercise by GSK in the capacity of registered holder of the B
Shares and for such purpose to do all such acts and things and to execute all such deeds and other documents as Haleon shall consider necessary or desirable pending registration of the B Shares in the name of Haleon, in connection with any matter
including, without limitation, all or any of the following: 

  

	 	(A)	 receiving notice of, attending, participating in and directing the exercise of any voting rights attaching
to the B Shares in any general meeting, class meeting of the shareholders of GSKCHHL or other meeting at which such voting rights are capable of being exercised, or signing any resolution or decision as the registered holder of the B Shares;

  

	 	(B)	 approving, completing or otherwise signing or executing and returning any requisition of any meeting,
consent to short notice or proxy form, written resolution, agreement of the members of GSKCHHL or other document capable of being validly signed or executed by the registered holder of the B Shares; 

 

	 	(C)	 dealing with and giving directions as to any monies, securities, benefits, documents, notices or other
communications (in whatever form) arising by right of the B Shares or received in connection with the B Shares from GSKCHHL (including, but not limited to, altering the registered address relating to the B Shares and agreeing terms with GSKCHHL for
receiving any such thing by means of electronic communications); 

  

	 	(D)	 selling, transferring, exchanging or otherwise disposing of the B Shares or any interest in any of them;

  
 28 

	 	(E)	 agreeing to any compromise or arrangement affecting the B Shares and/or using any lawful means to safeguard
any interest and/or enforce any right of the registered holder of the B Shares; and 

  

	 	(F)	 otherwise endorsing, signing, executing, delivering and doing all agreements, deeds, receipts, dividend and
interest warrants, cheques, releases, discharges, instruments and all other documents, deeds and acts whatsoever in the name of GSK insofar as may be done in that capacity, 

in each case, as Haleon in its absolute discretion sees fit. 

 

	5.4	 Any document to be signed or executed under the authority granted pursuant to clause 5.3 may be
signed or otherwise executed by Haleon in GSK’s name or (at Haleon’s option) in Haleon’s name on behalf of GSK. 

  

	5.5	 GSK undertakes with effect from Completion: 

 

	 	(A)	 to hold the B Shares upon trust for Haleon as beneficial owner; 

 

	 	(B)	 to account to Haleon for all dividends, interest, bonuses, in specie or other distributions or payments of
whatever nature paid or made to Haleon in respect of the B Shares in respect of the period following Completion; 

  

	 	(C)	 not to exercise any rights, powers or privileges attaching to the B Shares or exercisable in the capacity of
registered holder of the B Shares or conferred on Haleon by this Agreement without Haleon’s prior written consent; and 

  

	 	(D)	 promptly on receipt to deliver to Haleon any notice, letter or other document of any nature whatsoever
relating to the B Shares which GSK receives after the date of this Agreement. 

  

	5.6	 Subject to clause 5.7 below, Haleon undertakes fully to indemnify GSK and hold it harmless against
all liabilities (including liabilities to Tax), Costs, claims, actions, charges and expenses (if any) arising out of or in consequence of the proper or purported exercise of any power under the power of attorney constituted by clause 5.3.

  

	5.7	 The indemnity in clause 5.6 shall not apply to any liabilities, Costs, claims, actions, charges or
expenses which would not have been incurred but for the negligence or wilful default of GSK.  

  

	5.8	 The power of attorney constituted by clause 5.3 and the undertaking given in clause 5.5 shall
be irrevocable but shall terminate automatically on the date on which Haleon is entered in the register of members of GSKCHHL as the holder of the B Shares. 

  

	6.	 TAX 

The Parties agree that, except where arrangements in respect of Tax are expressly made in this Agreement, any claim or
potential claim in respect of any liability relating to Tax shall be determined and calculated solely in accordance with the Tax Covenant. To the extent that provisions of this Agreement conflict with any provisions of the Tax Covenant, those in the
Tax Covenant shall prevail. 

  
 29 

	7.	 GSK EXCHANGE INDEMNITIES AND SLP EXCHANGE INDEMNITIES 

 

	7.1	 The issue by Haleon of the GSK Haleon Exchange Shares pursuant to clauses 4.4 to 4.5
(inclusive) to GSK on Completion in accordance with this Agreement shall extinguish any obligation whatsoever of Haleon to issue any shares to GSK, any GSK Group Company or any former, present or future GSK Shareholders or holder of other securities
of GSK or any GSK Group Company in consideration of the transfer of the B Shares to Haleon or otherwise in connection with the transactions contemplated by this Agreement, and GSK hereby covenants and undertakes to indemnify and keep indemnified
Haleon (for itself and as trustee for each Consumer Healthcare Group Company) and each Consumer Healthcare Group Company from and against any such obligation, including any liabilities, losses, demands, claims, Costs and damages whatsoever suffered
or arising, directly or indirectly from or in consequence of: 

  

	 	(A)	 any claim by any person that they became a holder of or were otherwise entitled to shares or any other
interest in the capital of GSKCHHL, GSK, or any member of the GSK Group (or other securities they shall claim to be relevant for such purposes) prior to or at Completion and was, by virtue of such holding, entitled to be issued with Haleon Ordinary
Shares or was otherwise (other than by virtue of holding any interest or purported interest in Pfizer, PFCHHL or any member of the Pfizer Group) entitled to be issued with Haleon Ordinary Shares or other shares or securities; and

  

	 	(B)	 any claim by any person that their rights to be entered into the register of members of Haleon in respect of
Haleon Ordinary Shares have not been satisfied as a result of a dispute over the time or otherwise in respect of the sale or transfer to or by them of B Shares (or other securities they shall claim to be relevant for such purpose).

  

	7.2	 The provisions of Schedule 1 (Provisions on Claims under the GSK Exchange Indemnities and the SLP
Exchange Indemnities) shall apply in relation to the making of any claim under the GSK Exchange Indemnities. 

  

	7.3	 The issue by Haleon of the SLP Haleon Exchange Shares pursuant to the SLP Exchange Agreement to the SLPs on
completion of the SLP Share Exchange in accordance with the SLP Exchange Agreement shall extinguish any obligation whatsoever of Haleon to issue any shares to any of the SLPs or any former, present or future partners of any of the SLPs or holders of
any securities of the SLPs in consideration of the transfer of the C Shares to Haleon or otherwise in connection with the transactions contemplated by the SLP Exchange Agreement, and GSK hereby covenants and undertakes to indemnify and keep
indemnified Haleon (for itself and as trustee for each Consumer Healthcare Group Company) and each Consumer Healthcare Group Company from and against any such obligation, including any liabilities, losses, demands, claims, Costs and damages
whatsoever suffered or arising, directly or indirectly from or in consequence of: 

  

	 	(A)	 any claim by any person that they became a holder of or were otherwise entitled to shares or any other
interest in the capital of GSKCHHL, GSK, any SLP or any 

  
 30 

	 	 
member of the GSK Group (or other securities they shall claim to be relevant for such purposes) prior to or at Completion and was, by virtue of such holding, entitled to be issued with Haleon
Ordinary Shares or was otherwise (other than by virtue of holding an interest or purported interest in Pfizer, PFCHHL or any member of the Pfizer Group) entitled to be issued with Haleon Ordinary Shares or other shares or securities; and

  

	 	(B)	 any claim by any person that their rights to be entered into the register of members of Haleon in respect of
Haleon Ordinary Shares have not been satisfied as a result of a dispute over the time or otherwise in respect of the sale or transfer to or by them of C Shares (or other securities they shall claim to be relevant for such purpose).

  

	7.4	 The provisions of Schedule 1 (Provisions on Claims under the GSK Exchange Indemnities and the SLP
Exchange Indemnities) shall apply in relation to the making of any claim under the SLP Exchange Indemnities. 

  

	8.	 CONFIDENTIALITY 

 

	8.1	 Subject to clause 9.3, each Party shall treat as confidential all information obtained as a precursor
to or as a result of negotiating or entering into or performing this Agreement or which relates to: 

  

	 	(A)	 the provisions of this Agreement; 

 

	 	(B)	 the negotiations relating to this Agreement; or 

 

	 	(C)	 the subject matter of this Agreement. 

 

	8.2	 Each Party shall: 

 

	 	(A)	 not disclose any such confidential information to any person other than: 

 

	 	(i)	 any of its directors or employees who need to know such information in order to discharge their duties; and

  

	 	(ii)	 other members of its Group (and/or, in the case of GSK: (a) the trustee of the GSK Pension Scheme; (b) the
trustee of the GSK Pension Fund; (c) the trustee of the SmithKline Beecham Pension Plan; and/or (d) the trustee of the SmithKline Beecham Senior Executive Pension Plan); 

 

	 	(B)	 not use any such confidential information other than for the purpose of: 

 

	 	(i)	 in the case of Haleon, conducting the Consumer Healthcare Business; 

 

	 	(ii)	 in the case of GSK or any member of its Group, managing or monitoring its investment in Haleon; and

  

	 	(iii)	 in connection with the performance of its obligations and the exercise of its rights under this Agreement;
and 

  
 31 

	 	(C)	 procure that any person to whom any such confidential information is disclosed by it complies with the
restrictions contained in this clause 8 as if such person were a party to this Agreement. 

  

	8.3	 Notwithstanding the other provisions of this clause 8, any Party may disclose any such confidential
information: 

  

	 	(A)	 if and to the extent required by Law or for the purpose of any judicial or arbitral proceedings;

  

	 	(B)	 if and to the extent required by any securities exchange or regulatory or Tax or other Governmental Entity
to which that Party or a member of its Group is subject or submits, wherever situated, including (amongst other bodies) the FCA, London Stock Exchange, Panel on Takeovers and Mergers, HMRC, the SEC or the New York Stock Exchange, whether or not the
requirement for information has the force of Law; 

  

	 	(C)	 to a Tax Authority in connection with the disclosing Party’s (or a member of its Group’s) Tax
affairs; 

  

	 	(D)	 to its advisers, auditors, actual or proposed debt financiers and bankers, provided they have a duty to keep
such information confidential; 

  

	 	(E)	 to the extent the information has come into the public domain through no fault of that Party;

  

	 	(F)	 to the extent the Party (or Parties) to which such information relates has (or have) given prior written
consent to the disclosure; 

  

	 	(G)	 to the extent expressly permitted by this Agreement or to the extent it is expressly permitted to do so
pursuant to any Transaction Document; 

  

	 	(H)	 if and to the extent required in connection with any regulatory consent or clearance process required by
applicable Law; or 

  

	 	(I)	 if it was in the possession of a Party or any of its advisers (in either case as evidenced by written
records) without any obligation of secrecy prior to it being received or held. 

  

	8.4	 The restrictions contained in this clause 8 shall continue to apply to each Party without limit in
time. 

  

	8.5	 Notwithstanding the foregoing in this clause 8, to the extent that the Cosmos SAPA, the Cosmos SHA or
any other Transaction Document or any other contract pursuant to which any Party or any member of its Group is bound provides that certain information shall be maintained confidential on a basis that is more protective of such information or for a
longer period of time than provided for in this clause 8, then the applicable provisions contained in the Cosmos SAPA, the Cosmos SHA or such other Transaction Document or contract shall control with respect thereto but only to the extent
such provision is more protective or runs for a longer period of time. 

  
 32 

	9.	 ANNOUNCEMENTS 

 

	9.1	 Subject to clause 9.2, no announcement or other publication concerning the transactions contemplated
by the Transaction Documents or any ancillary matter shall be made by any Party or member of its Group without the prior written approval of the other Party, such approval not to be unreasonably withheld or delayed. 

 

	9.2	 Notwithstanding clause 9.1, any Party or member of its Group may, whenever practicable and
permissible after consultation with the other Party and Pfizer, make an announcement concerning this Agreement, the Transaction Documents, the Separation Transaction or the Consumer Healthcare Business, if and to the extent required by:

  

	 	(A)	 Law or for the purposes of any judicial or arbitral proceedings; or 

 

	 	(B)	 any securities exchange or regulatory or Governmental Entity to which that Party is subject or submits,
wherever situated, including (amongst other bodies) the FCA, London Stock Exchange, Panel on Takeovers and Mergers, HMRC, the SEC or the New York Stock Exchange, whether or not the requirement has the force of Law. 

 

	9.3	 For the avoidance of doubt, nothing in this Agreement shall prohibit any Party or any member of its
respective Group from making any disclosure or public statements regarding its intentions with respect to the GSK Haleon Exchange Shares or Haleon ADSs in respect thereof that it holds in Haleon. 

 

	9.4	 The restrictions contained in this clause 9.3 shall continue to apply to each Party without limit in
time unless otherwise agreed between the Parties. 

  

	10.	 WARRANTIES 

 

	10.1	 Each Party warrants and undertakes to the other Party as at the date of this Agreement that:

  

	 	(A)	 it is validly existing and is a company duly incorporated and registered under the Law of its jurisdiction
of incorporation; 

  

	 	(B)	 it has the legal right and full power and authority to enter into and perform this Agreement, which will
constitute valid and binding obligations on it in accordance with its terms; 

  

	 	(C)	 except as referred to in this Agreement, (including, for the avoidance of doubt, the filings, notices and
approvals associated with the Regulatory Conditions), it: 

  

	 	(i)	 is not required to make any announcement, consultation, notice, report or filing; and 

 

	 	(ii)	 does not require any consent, approval, registration, authorisation or permit, 

in each case with or from any Governmental Entity in connection with the performance of this Agreement. 

  
 33 

	10.2	 GSK warrants and undertakes to Haleon as at the date of this Agreement and at all times until the completion
of the GSK Share Exchange that: 

  

	 	(A)	 it is the sole legal and beneficial owner of the B Shares to be transferred by it to Haleon pursuant to and
in accordance with this Agreement; 

  

	 	(B)	 there is no option, right to acquire, mortgage, charge, pledge, lien or other form of security or
encumbrance or equity on, over or affecting the B Shares to be transferred by it to Haleon pursuant to and in accordance with this Agreement (other than transfer restrictions under applicable securities laws) and there is no agreement or commitment
to give or create any and no claim has been made by any person to be entitled to any; 

  

	 	(C)	 the B Shares to be transferred by it to Haleon pursuant to and in accordance with this Agreement have been
validly issued and allotted and are fully paid up; 

  

	 	(D)	 other than the Transaction Documents, there is no agreement or commitment outstanding which calls for the
allotment, issue or transfer of, or accords to any person the right to call for the allotment, issue or transfer of, any B Shares; 

  

	 	(E)	 none of the B Shares to be transferred by it to Haleon pursuant to and in accordance with this Agreement are
subject to any rights of pre-emption or restrictions on transfer (other than transfer restrictions under applicable securities laws) and there are no circumstances existing which may give rise to a restriction
being placed on such B Shares; and 

  

	 	(F)	 the B Shares to be transferred by GSK to Haleon under this Agreement represent all issued and outstanding B
Shares. 

  

	10.3	 Haleon warrants and undertakes to GSK that the GSK Haleon Exchange Shares to be issued by Haleon under this
Agreement shall be validly issued and allotted and shall be issued fully paid up and free from all liens, charges, security interests, options, claims and encumbrances whatsoever. 

 

	11.	 COSTS AND EXPENSES 

 

	11.1	 Each of GSK and Haleon agree to the apportionment of Costs as set out in clause 19 (Costs and Expenses) of
the SCIA. 

  

	11.2	 In relation to any Costs not addressed by clause 11.1, except as otherwise set out in this Agreement,
the Cosmos SHA, the SCIA or, in respect of Tax matters, the Tax Covenant, each Party shall pay its own Costs incurred in relation to the negotiation, preparation, execution and carrying into effect of this Agreement and all other agreements forming
part of the Separation Transaction. 

  
 34 

	12.	 PAYMENTS 

  

	12.1	 Payments due to be made under this Agreement shall, if not paid within thirty (30) days of the due date, and
except to the extent the liability giving rise to the payment compensates the recipient for late payment by virtue of its extending to interest and penalties, carry interest at a rate of (i) two (2) per cent. above the base lending rate from time to
time of the Bank of England, or (ii) if such base lending rate is less than zero, at two (2) per cent. (the “Agreed Rate”) for the period from the date falling thirty (30) days after the due date to the date of actual payment.

  

	12.2	 Payment due to be made under this Agreement shall be free and clear of all deductions, withholdings, set-offs, or counterclaims whatsoever, except as may be required by Law.  

  

	13.	 FURTHER ASSURANCE 

 

	13.1	 Prior to Separation Completion, GSK and Haleon shall use all reasonable endeavours to procure the entering
into by the respective parties thereto of such further agreements or documents as shall be necessary to give effect to the transactions set out in the Steps Plan, if and to the extent such agreements or documents are envisaged by the Steps Plan as
occurring prior to Separation Completion. 

  

	13.2	 GSK and Haleon shall each procure the due performance of the obligations of the members of their respective
Groups under any agreements entered into or to be entered into by them in connection with the Separation Transaction. 

  

	13.3	 The Parties undertake to co-operate in good faith following
Completion to ensure they and their respective Groups do such acts and things as may reasonably be necessary for the purpose of giving to GSK and Haleon and their respective Groups the full benefit of the provisions of this Agreement and all other
agreements entered into in connection with the Separation Transaction. 

  

	13.4	 Following Completion: 

 

	 	(A)	 the Parties shall use all reasonable endeavours to procure that, and to procure that the members of their
respective Groups use all reasonable endeavours to procure that, any necessary third party execute such documents and do such acts and things as may be reasonably required for the purpose of giving to GSK and Haleon the full benefit of all relevant
provisions of this Agreement; and 

  

	 	(B)	 without prejudice to any other provision of this Agreement and subject to the terms of the Cosmos SAPA, the
Cosmos SHA, the Demerger Agreement and any Ancillary Agreement, GSK and Haleon undertake to use all reasonable endeavours to co-operate and to ensure their respective Groups
co-operate with each other in relation to the conduct of litigation, inquiries from government or regulatory bodies (including, subject to the terms of the Tax Covenant, any Tax Authority), investigations or
other proceedings of a like nature (“Investigation”) where: 

  

	 	(i)	 they have a mutual interest in the Investigation; and 

 

	 	(ii)	 co-operating in such manner would not materially adversely affect
any material interest of either of them. 

  
 35 

	13.5	 Nothing in this Agreement shall require any Party to act in breach of any provision of the Data Protection
Act 2018 (“DPA”) and any equivalent legislation in any other relevant jurisdiction, and each Party shall only be required to fulfil its obligations under this Agreement to the extent permissible under the DPA. Without prejudice to
the foregoing, neither Party shall be required to disclose or make available to the other Party any information the disclosure or making available of which would or might, in the reasonable opinion of the disclosing Party, cause the disclosing Party
to be in breach of any duty of confidentiality (whether arising at common law or by statute) owed to any person other than the Party requesting disclosure or any of its subsidiaries. 

 

	14.	 NOTICES 

  

	14.1	 A notice under this Agreement shall only be effective if it is in writing.
E-mail is permitted. Any notice validly served on one member of any Party’s Group in accordance with this clause 14 shall be deemed to have been served on each member of such Party’s Group.

  

	14.2	 Notices under this Agreement shall be sent to a party at its address and for the attention of the
individuals set out below: 

  

					
	GSK	  		  	
			
	 Address:
	  		  	
			
	 E-mail address:
	  		  	
			
	 For the attention of:
	  		  	
			
	Haleon	  		  	
			
	 Address:
	  		  	
			
	 E-mail address:
	  		  	
			
	 For the attention of:
	  		  	

 provided that a Party may change its notice details on giving notice to the other Party of the
change in accordance with this clause 14. That notice shall only be effective on the date falling five (5) clear Business Days after the notification has been received or such later date as may be specified in the notice. 

 

	14.3	 Any notice given under this Agreement shall be deemed to have been duly given as follows:

  

	 	(A)	 if delivered personally, on delivery; 

 

	 	(B)	 if sent by first class inland post, two (2) clear Business Days after the date of posting;

  

	 	(C)	 if sent by airmail, six (6) clear Business Days after the date of posting; and 

 

	 	(D)	 if sent by e-mail, when despatched. 

  
 36 

	14.4	 Any notice given under this Agreement outside Working Hours in the place to which it is addressed shall be
deemed not to have been given until the start of the next period of Working Hours in such place. 

  

	14.5	 A notice under or in connection with this Agreement shall not be invalid by reason of any mistake or
typographical error or if the contents are incomplete, provided it should have been reasonably clear to the recipient what the correct or missing particulars should have been. 

 

	14.6	 The provisions of this clause 14 shall not apply in relation to the service of Service Documents.

  

	15.	 ENTIRE AGREEMENT 

 

	15.1	 This Agreement, any other Transaction Document and any other agreement or document entered into by each of
the Parties in connection with any such document, including the Cosmos SHA, the Cosmos SAPA and the other agreements and documents entered into in connection therewith (together, the “Cosmos Agreements”), together constitute the
whole and only agreement between the Parties relating to the subject matter of this Agreement, any Transaction Document and any other agreement or document entered into by each of the Parties in connection with any such document.

  

	15.2	 All terms of the Cosmos Agreements shall remain unchanged and in full force and effect and nothing in this
Agreement or in any of the Transaction Documents shall amend, limit or otherwise modify the parties’ respective rights and obligations under the Cosmos Agreements, in each case except as, and only to the extent, expressly provided in this
Agreement or in any of the Transaction Documents. 

  

	15.3	 Each Party acknowledges that in entering into this Agreement, any Transaction Document and any other
agreement or document entered into by each of the Parties in connection with any such document, it is not relying upon any pre contractual statement which is not set out in this Agreement, any Transaction Document, any Cosmos Agreement or any other
agreement or document entered into by each of the Parties in connection with any such document. 

  

	15.4	 Except in the case of fraud, no Party shall have any right of action against any other Party (or their
respective Connected Persons) arising out of or in connection with any pre contractual statement except to the extent that it is repeated in this Agreement or in a Transaction Document, any Cosmos Agreement or in any other agreement or document
entered into by each of the parties in connection with any such document. 

  

	15.5	 Except in the case of fraud and for any liability in respect of a breach of this Agreement or any
Transaction Document or any Cosmos Agreement, no Party (nor any of its Connected Persons) shall owe any duty of care or have any liability in tort or otherwise to the other Party (or its Connected Persons) in relation to the GSK Share Exchange or
any Transaction Document. 

  
 37 

	15.6	 For the purposes of this clause 15, “pre contractual statement” means any draft,
agreement, undertaking, representation, warranty, promise, assurance or arrangement of any nature whatsoever, whether or not in writing, relating to the subject matter of this Agreement or any Transaction Document or in any other agreement or
document entered into in connection with any such document (as the case may be) made or given by any person at any time prior to the date of this Agreement or any Transaction Document, except for those contained in any Transaction Document or any
Cosmos Agreement. 

  

	15.7	 Each Party agrees to the terms of this clause 15 on its own behalf and as agent for each of its
Connected Persons. The provisions of this clause 15 shall not limit, supersede or otherwise affect any limitation of damages or remedies provisions that are expressly set forth in any Transaction Document or any Cosmos Agreement.

  

	16.	 CONTRACTS (RIGHTS OF THIRD PARTIES) ACT 1999 

 

	16.1	 The Parties agree that: 

 

	 	(A)	 certain provisions of this Agreement confer a benefit on members of the Parties’ respective Groups,
their respective Connected Persons and such other third parties (each a “Relevant Third Party”) and, subject to the remaining provisions of this clause 16, are intended to be enforceable by each of the Relevant Third Parties
by virtue of the Contracts (Rights of Third Parties) Act 1999, provided that the Party in the same Group as (or with the relevant connection to) the Relevant Third Party shall have the sole conduct of any action to enforce such right on behalf of
such Relevant Third Party; 

  

	 	(B)	 without prejudice to the obligations of Pfizer and members of the Pfizer Group pursuant to the terms of the
Cosmos SHA, prior to Completion, Pfizer shall be an express third party beneficiary of this Agreement and this Agreement may not be rescinded, varied or modified without Pfizer’s written consent; and 

 

	 	(C)	 notwithstanding the provisions of clause 16.1(A), but subject to clauses 16.1(B) and
19.1, this Agreement may be rescinded or varied in any way and at any time by the Parties to this Agreement without the consent of any Relevant Third Party. 

 

	16.2	 Save as set out in clauses 16.1(A), 16.1(B) and 19.1, a person who is not a Party shall
have no right under the Contracts (Rights of Third Parties) Act 1999 or any other statutory provision to enforce any of its terms. 

  

	17.	 ASSIGNMENT 

No Party shall, without the prior written consent of the other Party and, without prejudice to the obligations of Pfizer and
members of the Pfizer Group pursuant to the terms of the Cosmos SHA, Pfizer: 
  

	 	(A)	 assign or purport to assign all or any part of the benefit of, or its rights or benefits under, this
Agreement (together with any causes of action arising in connection with any of them); 

  

	 	(B)	 make a declaration of trust in respect of or enter into any arrangement whereby it agrees to hold in trust
for any other person all or any part of the benefit of, or its rights or benefits under, this Agreement; 

  
 38 

	 	(C)	 sub-contract or enter into any arrangement whereby another person is
to perform any or all of its obligations under this Agreement; 

  

	 	(D)	 transfer or charge any of its rights or obligations under this Agreement; or 

 

	 	(E)	 grant, declare, create or dispose of any right or interest in, in whole or in part, this Agreement,

 and any purported assignment in contravention of this clause 17 shall be null and void ab
initio. 
  

	18.	 REMEDIES AND WAIVERS 

 

	18.1	 No delay or omission by any Party in exercising any right, power or remedy provided by Law or under this
Agreement shall: 

  

	 	(A)	 affect that right, power or remedy; or 

 

	 	(B)	 operate as a waiver or variation of it. 

 

	18.2	 The single or partial exercise of any right, power or remedy provided by Law or under this Agreement shall
not preclude any other or further exercise of it or the exercise of any other right, power or remedy. 

  

	18.3	 The rights and remedies of each Party under, or pursuant to, this Agreement are cumulative, may be exercised
as often as such party considers appropriate and are in addition to its rights and remedies under general Law. 

  

	18.4	 Notwithstanding any express remedies provided under this Agreement and without prejudice to any other right
or remedy which any Party may have, each Party acknowledges and agrees that damages alone would not be an adequate remedy for any breach by it of the provisions of this Agreement, so that in the event of a breach or anticipated breach of such
provisions, the remedies of injunction, an order for specific performance and/or other equitable remedies would be available. Furthermore, each Party acknowledges and agrees that it will not raise any objection to the application by or on behalf of
the other Party or any member of its Group for any such remedies. 

  

	19.	 VARIATION 

  

	19.1	 No variation of this Agreement shall be valid unless it is in writing and duly executed by or on behalf of
all the Parties to it; provided that, without prejudice to the obligations of Pfizer and members of the Pfizer Group pursuant to the terms of the Cosmos SHA, any such variation shall be subject to the prior written consent of Pfizer.

  

	19.2	 If this Agreement is varied: 

 

	 	(A)	 the variation shall not constitute a general waiver of any provisions of this Agreement;

  
 39 

	 	(B)	 the variation shall not affect any rights, obligations or liabilities under this Agreement that have already
accrued up to the date of variation; and 

  

	 	(C)	 the rights and obligations of the Parties under this Agreement shall remain in full force and effect, except
as, and only to the extent that, they are so varied. 

  

	20.	 NO PARTNERSHIP OR AGENCY 

Nothing in this Agreement (or in any Transaction Document or any other arrangements contemplated hereby or therein) shall
constitute a partnership between the Parties or make any Party the agent of any other Party for any purpose. No Party has any authority or power to bind, to contract in the name of, or to create a liability for another Party in any way or for any
purpose save as specifically set out in this Agreement. 
  

	21.	 INVALIDITY 

 

	21.1	 If at any time any provision (or part of any provision) of this Agreement is or becomes illegal, invalid or
unenforceable in any respect under the Law of any jurisdiction, that shall not affect or impair: 

  

	 	(A)	 the legality, validity or enforceability in that jurisdiction of any other (or the remainder of a) provision
of this Agreement; or 

  

	 	(B)	 the legality, validity or enforceability under the Law of any other jurisdiction of that or any other
provision of this Agreement. 

  

	21.2	 Each of the provisions of this Agreement is severable. 

 

	21.3	 If and to the extent that any provision of this Agreement: 

 

	 	(A)	 is held to be, or becomes, invalid or unenforceable under the Law of any jurisdiction; but

  

	 	(B)	 would be valid, binding and enforceable if some part of the provision were deleted or amended,

 then the provision shall apply with the minimum modifications necessary to make it valid, binding and
enforceable. All other provisions of this Agreement shall remain in force. 
  

	22.	 CONTINUING EFFECT 

Each provision of this Agreement shall continue in full force and effect after Completion, unless such provision has been fully
performed on or before Completion. 
  

	23.	 COUNTERPARTS 

 

	23.1	 This Agreement may be executed in any number of counterparts, and by the Parties on separate counterparts,
but shall not be effective until each Party has executed at least one counterpart. Each counterpart shall constitute an original of this Agreement, but all the counterparts shall together constitute but one and the same instrument.

  
 40 

	23.2	 Delivery of a counterpart of this Agreement by e-mail attachment
shall be an effective mode of delivery. 

  

	24.	 LANGUAGE 

Each notice or communication under or in connection with this Agreement shall be in English. 

 

	25.	 GOVERNING LAW AND JURISDICTION 

 

	25.1	 This Agreement is to be governed by and construed in accordance with English law. Any matter, claim or
dispute arising out of or in connection with this Agreement, whether contractual or non-contractual, is to be governed by and determined in accordance with English law. 

 

	25.2	 The courts of England are to have exclusive jurisdiction to settle any dispute arising out of or in
connection with this Agreement. Any Proceedings shall be brought only in the courts of England. 

  

	25.3	 Each Party waives (and agrees not to raise) any objection, on the ground of forum non conveniens or
on any other ground, to the taking of proceedings in the courts of England. Each Party also agrees that a judgment against it in Proceedings brought in England shall be conclusive and binding upon it and may be enforced in any other jurisdiction.

  

	25.4	 Each Party irrevocably submits and agrees to submit to the jurisdiction of the courts of England.

  

  
 41 

 IN WITNESS of which this document has been executed as a deed on the date which appears
on page 1 above. 
  

					
	 SIGNED as a DEED by
	  	 )
	  	 /s/ Victoria Whyte

	 VICTORIA WHYTE
	  	 )
	  	 (Signature of attorney)

	 as attorney for GSK PLC
	  	 )
	  	 VICTORIA WHYTE as attorney for

	 in the presence of:
	  	 )
	  	 GSK PLC

 

					
	 Witness’s signature:
	  	 /s/ Iain Whyte
	  	
			
	 Name (print):
	  	 Iain Whyte
	  	
			
	 Occupation:
	  	 Househusband
	  	
			
	 Address:
	  	 	  	

 [GSK Exchange Agreement- signature page] 

  
 42 

					
	 SIGNED as a DEED by
	  	 )
	  	 /s/ Amanda Mellor

	AMANDA MELLOR	  	 )
	  	 (Signature of attorney)

	 as attorney for HALEON PLC
	  	 )
	  	 AMANDA MELLOR as attorney for

	 in the presence of:
	  	 )
	  	 HALEON PLC

 

					
	 Witness’s signature:
	  	 /s/ Rosanna Bassett
	  	
			
	 Name (print):
	  	 Rosanna Bassett
	  	
			
	 Occupation:
	  	 Student
	  	
			
	 Address:
	  	 	  	

 [GSK Exchange Agreement- signature page] 

  
 43

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]